This site uses cookies to deliver our services and to show you relevant ads and presentations. By clicking on "Accept", you acknowledge that you have read and understand our Cookie Policy , Privacy Policy , and our Terms of Use.
X

Download Ovarian cancer Introducation PowerPoint Presentation


Login   OR  Register
X


Iframe embed code :



Presentation url :

X

Description :

Available Ovarian cancer Introducation powerpoint presentation for free download which is uploaded by search an active user in belonging ppt presentation Health & Wellness category.

Tags :

Ovarian cancer Introducation

Home / Health & Wellness / Health & Wellness Presentations / Ovarian cancer Introducation PowerPoint Presentation

Ovarian cancer Introducation PowerPoint Presentation

Ppt Presentation Embed Code   Zoom Ppt Presentation

About This Presentation


Description : Available Ovarian cancer Introducation powerpoint presentation for free download which is uploaded b... Read More

Tags : Ovarian cancer Introducation

Published on : Feb 24, 2014
Views : 334 | Downloads : 0


Download Now

Share on Social Media

             

PowerPoint is the world's most popular presentation software which can let you create professional Ovarian cancer Introducation powerpoint presentation easily and in no time. This helps you give your presentation on Ovarian cancer Introducation in a conference, a school lecture, a business proposal, in a webinar and business and professional representations.

The uploader spent his/her valuable time to create this Ovarian cancer Introducation powerpoint presentation slides, to share his/her useful content with the world. This ppt presentation uploaded by onlinesearch in this Health & Wellness category is available for free download,and can be used according to your industries like finance, marketing, education, health and many more.

SlidesFinder.com provides a platform to marketers, presenters and educationists along with being the preferred search engine for professional PowerPoint presentations on the Internet to upload their Ovarian cancer Introducation ppt presentation slides to help them BUILD THEIR CROWD!!

User Presentation
Related Presentation
Free PowerPoint Templates
Slide 1 - Ovarian Cancer in the Genomics Era Christina M. Annunziata, MD, PhD Medical Oncology Branch National Cancer Institute Bethesda, MD
Slide 2 - Ovarian Cancer in the Genomics Era Christina M. Annunziata, MD, PhD Medical Oncology Branch National Cancer Institute Bethesda, MD Ovarian Cancer Stage Description Incidence Survival I Confined to ovaries 20% 90% II Confined to pelvis 5% 65% III Spread IP or nodes 58% 45% IV Distant metastases 17% <5%
Slide 3 - Ovarian Cancer in the Genomics Era Christina M. Annunziata, MD, PhD Medical Oncology Branch National Cancer Institute Bethesda, MD Ovarian Cancer Stage Description Incidence Survival I Confined to ovaries 20% 90% II Confined to pelvis 5% 65% III Spread IP or nodes 58% 45% IV Distant metastases 17% <5% Ovarian Cancer: Prognostic Factors Stage Extent of Cytoreduction Histology and Grade Performance Status p53 Status Vital Organ Function Physiologic Age Platinum+Taxane Primary Therapy Intraperitoneal therapy Information from Second-Look Surgery Genotype BRCA1/2 VEGF Production
Slide 4 - Ovarian Cancer in the Genomics Era Christina M. Annunziata, MD, PhD Medical Oncology Branch National Cancer Institute Bethesda, MD Ovarian Cancer Stage Description Incidence Survival I Confined to ovaries 20% 90% II Confined to pelvis 5% 65% III Spread IP or nodes 58% 45% IV Distant metastases 17% <5% Ovarian Cancer: Prognostic Factors Stage Extent of Cytoreduction Histology and Grade Performance Status p53 Status Vital Organ Function Physiologic Age Platinum+Taxane Primary Therapy Intraperitoneal therapy Information from Second-Look Surgery Genotype BRCA1/2 VEGF Production Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Chemotherapy Clinical Trials
Slide 5 - Ovarian Cancer in the Genomics Era Christina M. Annunziata, MD, PhD Medical Oncology Branch National Cancer Institute Bethesda, MD Ovarian Cancer Stage Description Incidence Survival I Confined to ovaries 20% 90% II Confined to pelvis 5% 65% III Spread IP or nodes 58% 45% IV Distant metastases 17% <5% Ovarian Cancer: Prognostic Factors Stage Extent of Cytoreduction Histology and Grade Performance Status p53 Status Vital Organ Function Physiologic Age Platinum+Taxane Primary Therapy Intraperitoneal therapy Information from Second-Look Surgery Genotype BRCA1/2 VEGF Production Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Chemotherapy Clinical Trials The State of Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Full assessment of abdomen and pelvis Random biopsy of visually negative areas Lymph node dissection (except Stage I) Optimal reductive surgery Chemotherapy Clinical Trials
Slide 6 - Ovarian Cancer in the Genomics Era Christina M. Annunziata, MD, PhD Medical Oncology Branch National Cancer Institute Bethesda, MD Ovarian Cancer Stage Description Incidence Survival I Confined to ovaries 20% 90% II Confined to pelvis 5% 65% III Spread IP or nodes 58% 45% IV Distant metastases 17% <5% Ovarian Cancer: Prognostic Factors Stage Extent of Cytoreduction Histology and Grade Performance Status p53 Status Vital Organ Function Physiologic Age Platinum+Taxane Primary Therapy Intraperitoneal therapy Information from Second-Look Surgery Genotype BRCA1/2 VEGF Production Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Chemotherapy Clinical Trials The State of Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Full assessment of abdomen and pelvis Random biopsy of visually negative areas Lymph node dissection (except Stage I) Optimal reductive surgery Chemotherapy Clinical Trials Surgical staging of ovarian cancer
Slide 7 - Ovarian Cancer in the Genomics Era Christina M. Annunziata, MD, PhD Medical Oncology Branch National Cancer Institute Bethesda, MD Ovarian Cancer Stage Description Incidence Survival I Confined to ovaries 20% 90% II Confined to pelvis 5% 65% III Spread IP or nodes 58% 45% IV Distant metastases 17% <5% Ovarian Cancer: Prognostic Factors Stage Extent of Cytoreduction Histology and Grade Performance Status p53 Status Vital Organ Function Physiologic Age Platinum+Taxane Primary Therapy Intraperitoneal therapy Information from Second-Look Surgery Genotype BRCA1/2 VEGF Production Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Chemotherapy Clinical Trials The State of Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Full assessment of abdomen and pelvis Random biopsy of visually negative areas Lymph node dissection (except Stage I) Optimal reductive surgery Chemotherapy Clinical Trials Surgical staging of ovarian cancer The State of Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Stage I, II - Complete removal of all disease Stage III, IV - Residual disease < 1 cm Chemotherapy Clinical Trials
Slide 8 - Ovarian Cancer in the Genomics Era Christina M. Annunziata, MD, PhD Medical Oncology Branch National Cancer Institute Bethesda, MD Ovarian Cancer Stage Description Incidence Survival I Confined to ovaries 20% 90% II Confined to pelvis 5% 65% III Spread IP or nodes 58% 45% IV Distant metastases 17% <5% Ovarian Cancer: Prognostic Factors Stage Extent of Cytoreduction Histology and Grade Performance Status p53 Status Vital Organ Function Physiologic Age Platinum+Taxane Primary Therapy Intraperitoneal therapy Information from Second-Look Surgery Genotype BRCA1/2 VEGF Production Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Chemotherapy Clinical Trials The State of Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Full assessment of abdomen and pelvis Random biopsy of visually negative areas Lymph node dissection (except Stage I) Optimal reductive surgery Chemotherapy Clinical Trials Surgical staging of ovarian cancer The State of Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Stage I, II - Complete removal of all disease Stage III, IV - Residual disease < 1 cm Chemotherapy Clinical Trials Optimal Cytoreduction 0 cm 0-1 cm 1-2 cm >2 cm Time since initial surgery (years) Proportion surviving
Slide 9 - Ovarian Cancer in the Genomics Era Christina M. Annunziata, MD, PhD Medical Oncology Branch National Cancer Institute Bethesda, MD Ovarian Cancer Stage Description Incidence Survival I Confined to ovaries 20% 90% II Confined to pelvis 5% 65% III Spread IP or nodes 58% 45% IV Distant metastases 17% <5% Ovarian Cancer: Prognostic Factors Stage Extent of Cytoreduction Histology and Grade Performance Status p53 Status Vital Organ Function Physiologic Age Platinum+Taxane Primary Therapy Intraperitoneal therapy Information from Second-Look Surgery Genotype BRCA1/2 VEGF Production Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Chemotherapy Clinical Trials The State of Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Full assessment of abdomen and pelvis Random biopsy of visually negative areas Lymph node dissection (except Stage I) Optimal reductive surgery Chemotherapy Clinical Trials Surgical staging of ovarian cancer The State of Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Stage I, II - Complete removal of all disease Stage III, IV - Residual disease < 1 cm Chemotherapy Clinical Trials Optimal Cytoreduction 0 cm 0-1 cm 1-2 cm >2 cm Time since initial surgery (years) Proportion surviving The State of Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Chemotherapy Platinum = cisplatin or carboplatin AND Taxane = paclitaxel or docetaxel Intraperitoneal if Stage III, optimal reduction Clinical Trials
Slide 10 - Ovarian Cancer in the Genomics Era Christina M. Annunziata, MD, PhD Medical Oncology Branch National Cancer Institute Bethesda, MD Ovarian Cancer Stage Description Incidence Survival I Confined to ovaries 20% 90% II Confined to pelvis 5% 65% III Spread IP or nodes 58% 45% IV Distant metastases 17% <5% Ovarian Cancer: Prognostic Factors Stage Extent of Cytoreduction Histology and Grade Performance Status p53 Status Vital Organ Function Physiologic Age Platinum+Taxane Primary Therapy Intraperitoneal therapy Information from Second-Look Surgery Genotype BRCA1/2 VEGF Production Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Chemotherapy Clinical Trials The State of Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Full assessment of abdomen and pelvis Random biopsy of visually negative areas Lymph node dissection (except Stage I) Optimal reductive surgery Chemotherapy Clinical Trials Surgical staging of ovarian cancer The State of Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Stage I, II - Complete removal of all disease Stage III, IV - Residual disease < 1 cm Chemotherapy Clinical Trials Optimal Cytoreduction 0 cm 0-1 cm 1-2 cm >2 cm Time since initial surgery (years) Proportion surviving The State of Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Chemotherapy Platinum = cisplatin or carboplatin AND Taxane = paclitaxel or docetaxel Intraperitoneal if Stage III, optimal reduction Clinical Trials 1960 1970 1980 1990 2000 CISPLATIN/ALKYLATOR COMBINATIONS INTRA- PERITONEAL PACLITAXEL/ CARBOPLATIN ALKYLATORS CISPLATIN 5 YR SURVIVAL ADVANCED DISEASE 40% 35% 15% 5% 0 1960 1970 1980 1990 2000 Timeline of Treatment and Outcome for Advanced Ovarian Cancer
Slide 11 - Ovarian Cancer in the Genomics Era Christina M. Annunziata, MD, PhD Medical Oncology Branch National Cancer Institute Bethesda, MD Ovarian Cancer Stage Description Incidence Survival I Confined to ovaries 20% 90% II Confined to pelvis 5% 65% III Spread IP or nodes 58% 45% IV Distant metastases 17% <5% Ovarian Cancer: Prognostic Factors Stage Extent of Cytoreduction Histology and Grade Performance Status p53 Status Vital Organ Function Physiologic Age Platinum+Taxane Primary Therapy Intraperitoneal therapy Information from Second-Look Surgery Genotype BRCA1/2 VEGF Production Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Chemotherapy Clinical Trials The State of Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Full assessment of abdomen and pelvis Random biopsy of visually negative areas Lymph node dissection (except Stage I) Optimal reductive surgery Chemotherapy Clinical Trials Surgical staging of ovarian cancer The State of Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Stage I, II - Complete removal of all disease Stage III, IV - Residual disease < 1 cm Chemotherapy Clinical Trials Optimal Cytoreduction 0 cm 0-1 cm 1-2 cm >2 cm Time since initial surgery (years) Proportion surviving The State of Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Chemotherapy Platinum = cisplatin or carboplatin AND Taxane = paclitaxel or docetaxel Intraperitoneal if Stage III, optimal reduction Clinical Trials 1960 1970 1980 1990 2000 CISPLATIN/ALKYLATOR COMBINATIONS INTRA- PERITONEAL PACLITAXEL/ CARBOPLATIN ALKYLATORS CISPLATIN 5 YR SURVIVAL ADVANCED DISEASE 40% 35% 15% 5% 0 1960 1970 1980 1990 2000 Timeline of Treatment and Outcome for Advanced Ovarian Cancer Representative Chemotherapy Agents Platinum Paclitaxel Topotecan Gemcitabine Doxil Target: DNA b-tubulin Topo-I RN-reductase, Nucleotide pool Topo-II Mechanism:DNA adduct formation TubulinAggregation Stabilize DNA-TopoDNA synth DNA Schedule:Independent Dependent(toxicity)Dependent(efficacy) Dependent Phosporylation Prolonged clearance Resistance:GSH, tolerance, retention MDR-MRP, tubulin mutations Topo-I, BCRP RN-reductase MDR-MRP Topo-II Platinum Interaction:N/A Platelet Sparing ---- Enhanced Toxicity ----
Slide 12 - Ovarian Cancer in the Genomics Era Christina M. Annunziata, MD, PhD Medical Oncology Branch National Cancer Institute Bethesda, MD Ovarian Cancer Stage Description Incidence Survival I Confined to ovaries 20% 90% II Confined to pelvis 5% 65% III Spread IP or nodes 58% 45% IV Distant metastases 17% <5% Ovarian Cancer: Prognostic Factors Stage Extent of Cytoreduction Histology and Grade Performance Status p53 Status Vital Organ Function Physiologic Age Platinum+Taxane Primary Therapy Intraperitoneal therapy Information from Second-Look Surgery Genotype BRCA1/2 VEGF Production Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Chemotherapy Clinical Trials The State of Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Full assessment of abdomen and pelvis Random biopsy of visually negative areas Lymph node dissection (except Stage I) Optimal reductive surgery Chemotherapy Clinical Trials Surgical staging of ovarian cancer The State of Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Stage I, II - Complete removal of all disease Stage III, IV - Residual disease < 1 cm Chemotherapy Clinical Trials Optimal Cytoreduction 0 cm 0-1 cm 1-2 cm >2 cm Time since initial surgery (years) Proportion surviving The State of Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Chemotherapy Platinum = cisplatin or carboplatin AND Taxane = paclitaxel or docetaxel Intraperitoneal if Stage III, optimal reduction Clinical Trials 1960 1970 1980 1990 2000 CISPLATIN/ALKYLATOR COMBINATIONS INTRA- PERITONEAL PACLITAXEL/ CARBOPLATIN ALKYLATORS CISPLATIN 5 YR SURVIVAL ADVANCED DISEASE 40% 35% 15% 5% 0 1960 1970 1980 1990 2000 Timeline of Treatment and Outcome for Advanced Ovarian Cancer Representative Chemotherapy Agents Platinum Paclitaxel Topotecan Gemcitabine Doxil Target: DNA b-tubulin Topo-I RN-reductase, Nucleotide pool Topo-II Mechanism:DNA adduct formation TubulinAggregation Stabilize DNA-TopoDNA synth DNA Schedule:Independent Dependent(toxicity)Dependent(efficacy) Dependent Phosporylation Prolonged clearance Resistance:GSH, tolerance, retention MDR-MRP, tubulin mutations Topo-I, BCRP RN-reductase MDR-MRP Topo-II Platinum Interaction:N/A Platelet Sparing ---- Enhanced Toxicity ---- GOG 172: The new Standard of Care Epithelial Ovarian Cancer, Optimal Stage III, No prior therapy, Well balanced arms 1. Intravenous therapy, Cisplatin 75 mg/m2 Paclitaxel 135 mg/m2 (24 h), 83% completed 6 cycles 2. Intraperitoneal therapy, Cisplatin 100 mg/m2 IP d1 Paclitaxel 135 mg/m2 (24 h) IV d1 Paclitaxel 60 mg/m2 IP d8, 42% completed 6 cycles Open: 23-Mar-98 Closed: 29-Jan-01 Accrual: 416 pts (evaluable)
Slide 13 - Ovarian Cancer in the Genomics Era Christina M. Annunziata, MD, PhD Medical Oncology Branch National Cancer Institute Bethesda, MD Ovarian Cancer Stage Description Incidence Survival I Confined to ovaries 20% 90% II Confined to pelvis 5% 65% III Spread IP or nodes 58% 45% IV Distant metastases 17% <5% Ovarian Cancer: Prognostic Factors Stage Extent of Cytoreduction Histology and Grade Performance Status p53 Status Vital Organ Function Physiologic Age Platinum+Taxane Primary Therapy Intraperitoneal therapy Information from Second-Look Surgery Genotype BRCA1/2 VEGF Production Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Chemotherapy Clinical Trials The State of Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Full assessment of abdomen and pelvis Random biopsy of visually negative areas Lymph node dissection (except Stage I) Optimal reductive surgery Chemotherapy Clinical Trials Surgical staging of ovarian cancer The State of Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Stage I, II - Complete removal of all disease Stage III, IV - Residual disease < 1 cm Chemotherapy Clinical Trials Optimal Cytoreduction 0 cm 0-1 cm 1-2 cm >2 cm Time since initial surgery (years) Proportion surviving The State of Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Chemotherapy Platinum = cisplatin or carboplatin AND Taxane = paclitaxel or docetaxel Intraperitoneal if Stage III, optimal reduction Clinical Trials 1960 1970 1980 1990 2000 CISPLATIN/ALKYLATOR COMBINATIONS INTRA- PERITONEAL PACLITAXEL/ CARBOPLATIN ALKYLATORS CISPLATIN 5 YR SURVIVAL ADVANCED DISEASE 40% 35% 15% 5% 0 1960 1970 1980 1990 2000 Timeline of Treatment and Outcome for Advanced Ovarian Cancer Representative Chemotherapy Agents Platinum Paclitaxel Topotecan Gemcitabine Doxil Target: DNA b-tubulin Topo-I RN-reductase, Nucleotide pool Topo-II Mechanism:DNA adduct formation TubulinAggregation Stabilize DNA-TopoDNA synth DNA Schedule:Independent Dependent(toxicity)Dependent(efficacy) Dependent Phosporylation Prolonged clearance Resistance:GSH, tolerance, retention MDR-MRP, tubulin mutations Topo-I, BCRP RN-reductase MDR-MRP Topo-II Platinum Interaction:N/A Platelet Sparing ---- Enhanced Toxicity ---- GOG 172: The new Standard of Care Epithelial Ovarian Cancer, Optimal Stage III, No prior therapy, Well balanced arms 1. Intravenous therapy, Cisplatin 75 mg/m2 Paclitaxel 135 mg/m2 (24 h), 83% completed 6 cycles 2. Intraperitoneal therapy, Cisplatin 100 mg/m2 IP d1 Paclitaxel 135 mg/m2 (24 h) IV d1 Paclitaxel 60 mg/m2 IP d8, 42% completed 6 cycles Open: 23-Mar-98 Closed: 29-Jan-01 Accrual: 416 pts (evaluable) GOG 172: The new Standard of Care Median survival = 49.7 mo Median survival = 65.6 mo
Slide 14 - Ovarian Cancer in the Genomics Era Christina M. Annunziata, MD, PhD Medical Oncology Branch National Cancer Institute Bethesda, MD Ovarian Cancer Stage Description Incidence Survival I Confined to ovaries 20% 90% II Confined to pelvis 5% 65% III Spread IP or nodes 58% 45% IV Distant metastases 17% <5% Ovarian Cancer: Prognostic Factors Stage Extent of Cytoreduction Histology and Grade Performance Status p53 Status Vital Organ Function Physiologic Age Platinum+Taxane Primary Therapy Intraperitoneal therapy Information from Second-Look Surgery Genotype BRCA1/2 VEGF Production Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Chemotherapy Clinical Trials The State of Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Full assessment of abdomen and pelvis Random biopsy of visually negative areas Lymph node dissection (except Stage I) Optimal reductive surgery Chemotherapy Clinical Trials Surgical staging of ovarian cancer The State of Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Stage I, II - Complete removal of all disease Stage III, IV - Residual disease < 1 cm Chemotherapy Clinical Trials Optimal Cytoreduction 0 cm 0-1 cm 1-2 cm >2 cm Time since initial surgery (years) Proportion surviving The State of Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Chemotherapy Platinum = cisplatin or carboplatin AND Taxane = paclitaxel or docetaxel Intraperitoneal if Stage III, optimal reduction Clinical Trials 1960 1970 1980 1990 2000 CISPLATIN/ALKYLATOR COMBINATIONS INTRA- PERITONEAL PACLITAXEL/ CARBOPLATIN ALKYLATORS CISPLATIN 5 YR SURVIVAL ADVANCED DISEASE 40% 35% 15% 5% 0 1960 1970 1980 1990 2000 Timeline of Treatment and Outcome for Advanced Ovarian Cancer Representative Chemotherapy Agents Platinum Paclitaxel Topotecan Gemcitabine Doxil Target: DNA b-tubulin Topo-I RN-reductase, Nucleotide pool Topo-II Mechanism:DNA adduct formation TubulinAggregation Stabilize DNA-TopoDNA synth DNA Schedule:Independent Dependent(toxicity)Dependent(efficacy) Dependent Phosporylation Prolonged clearance Resistance:GSH, tolerance, retention MDR-MRP, tubulin mutations Topo-I, BCRP RN-reductase MDR-MRP Topo-II Platinum Interaction:N/A Platelet Sparing ---- Enhanced Toxicity ---- GOG 172: The new Standard of Care Epithelial Ovarian Cancer, Optimal Stage III, No prior therapy, Well balanced arms 1. Intravenous therapy, Cisplatin 75 mg/m2 Paclitaxel 135 mg/m2 (24 h), 83% completed 6 cycles 2. Intraperitoneal therapy, Cisplatin 100 mg/m2 IP d1 Paclitaxel 135 mg/m2 (24 h) IV d1 Paclitaxel 60 mg/m2 IP d8, 42% completed 6 cycles Open: 23-Mar-98 Closed: 29-Jan-01 Accrual: 416 pts (evaluable) GOG 172: The new Standard of Care Median survival = 49.7 mo Median survival = 65.6 mo Ovarian Cancer in the Genomics Era Preclinical studies
Slide 15 - Ovarian Cancer in the Genomics Era Christina M. Annunziata, MD, PhD Medical Oncology Branch National Cancer Institute Bethesda, MD Ovarian Cancer Stage Description Incidence Survival I Confined to ovaries 20% 90% II Confined to pelvis 5% 65% III Spread IP or nodes 58% 45% IV Distant metastases 17% <5% Ovarian Cancer: Prognostic Factors Stage Extent of Cytoreduction Histology and Grade Performance Status p53 Status Vital Organ Function Physiologic Age Platinum+Taxane Primary Therapy Intraperitoneal therapy Information from Second-Look Surgery Genotype BRCA1/2 VEGF Production Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Chemotherapy Clinical Trials The State of Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Full assessment of abdomen and pelvis Random biopsy of visually negative areas Lymph node dissection (except Stage I) Optimal reductive surgery Chemotherapy Clinical Trials Surgical staging of ovarian cancer The State of Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Stage I, II - Complete removal of all disease Stage III, IV - Residual disease < 1 cm Chemotherapy Clinical Trials Optimal Cytoreduction 0 cm 0-1 cm 1-2 cm >2 cm Time since initial surgery (years) Proportion surviving The State of Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Chemotherapy Platinum = cisplatin or carboplatin AND Taxane = paclitaxel or docetaxel Intraperitoneal if Stage III, optimal reduction Clinical Trials 1960 1970 1980 1990 2000 CISPLATIN/ALKYLATOR COMBINATIONS INTRA- PERITONEAL PACLITAXEL/ CARBOPLATIN ALKYLATORS CISPLATIN 5 YR SURVIVAL ADVANCED DISEASE 40% 35% 15% 5% 0 1960 1970 1980 1990 2000 Timeline of Treatment and Outcome for Advanced Ovarian Cancer Representative Chemotherapy Agents Platinum Paclitaxel Topotecan Gemcitabine Doxil Target: DNA b-tubulin Topo-I RN-reductase, Nucleotide pool Topo-II Mechanism:DNA adduct formation TubulinAggregation Stabilize DNA-TopoDNA synth DNA Schedule:Independent Dependent(toxicity)Dependent(efficacy) Dependent Phosporylation Prolonged clearance Resistance:GSH, tolerance, retention MDR-MRP, tubulin mutations Topo-I, BCRP RN-reductase MDR-MRP Topo-II Platinum Interaction:N/A Platelet Sparing ---- Enhanced Toxicity ---- GOG 172: The new Standard of Care Epithelial Ovarian Cancer, Optimal Stage III, No prior therapy, Well balanced arms 1. Intravenous therapy, Cisplatin 75 mg/m2 Paclitaxel 135 mg/m2 (24 h), 83% completed 6 cycles 2. Intraperitoneal therapy, Cisplatin 100 mg/m2 IP d1 Paclitaxel 135 mg/m2 (24 h) IV d1 Paclitaxel 60 mg/m2 IP d8, 42% completed 6 cycles Open: 23-Mar-98 Closed: 29-Jan-01 Accrual: 416 pts (evaluable) GOG 172: The new Standard of Care Median survival = 49.7 mo Median survival = 65.6 mo Ovarian Cancer in the Genomics Era Preclinical studies Translational Oncology Observation Hypothesis Experiment / Trial Result Analysis
Slide 16 - Ovarian Cancer in the Genomics Era Christina M. Annunziata, MD, PhD Medical Oncology Branch National Cancer Institute Bethesda, MD Ovarian Cancer Stage Description Incidence Survival I Confined to ovaries 20% 90% II Confined to pelvis 5% 65% III Spread IP or nodes 58% 45% IV Distant metastases 17% <5% Ovarian Cancer: Prognostic Factors Stage Extent of Cytoreduction Histology and Grade Performance Status p53 Status Vital Organ Function Physiologic Age Platinum+Taxane Primary Therapy Intraperitoneal therapy Information from Second-Look Surgery Genotype BRCA1/2 VEGF Production Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Chemotherapy Clinical Trials The State of Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Full assessment of abdomen and pelvis Random biopsy of visually negative areas Lymph node dissection (except Stage I) Optimal reductive surgery Chemotherapy Clinical Trials Surgical staging of ovarian cancer The State of Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Stage I, II - Complete removal of all disease Stage III, IV - Residual disease < 1 cm Chemotherapy Clinical Trials Optimal Cytoreduction 0 cm 0-1 cm 1-2 cm >2 cm Time since initial surgery (years) Proportion surviving The State of Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Chemotherapy Platinum = cisplatin or carboplatin AND Taxane = paclitaxel or docetaxel Intraperitoneal if Stage III, optimal reduction Clinical Trials 1960 1970 1980 1990 2000 CISPLATIN/ALKYLATOR COMBINATIONS INTRA- PERITONEAL PACLITAXEL/ CARBOPLATIN ALKYLATORS CISPLATIN 5 YR SURVIVAL ADVANCED DISEASE 40% 35% 15% 5% 0 1960 1970 1980 1990 2000 Timeline of Treatment and Outcome for Advanced Ovarian Cancer Representative Chemotherapy Agents Platinum Paclitaxel Topotecan Gemcitabine Doxil Target: DNA b-tubulin Topo-I RN-reductase, Nucleotide pool Topo-II Mechanism:DNA adduct formation TubulinAggregation Stabilize DNA-TopoDNA synth DNA Schedule:Independent Dependent(toxicity)Dependent(efficacy) Dependent Phosporylation Prolonged clearance Resistance:GSH, tolerance, retention MDR-MRP, tubulin mutations Topo-I, BCRP RN-reductase MDR-MRP Topo-II Platinum Interaction:N/A Platelet Sparing ---- Enhanced Toxicity ---- GOG 172: The new Standard of Care Epithelial Ovarian Cancer, Optimal Stage III, No prior therapy, Well balanced arms 1. Intravenous therapy, Cisplatin 75 mg/m2 Paclitaxel 135 mg/m2 (24 h), 83% completed 6 cycles 2. Intraperitoneal therapy, Cisplatin 100 mg/m2 IP d1 Paclitaxel 135 mg/m2 (24 h) IV d1 Paclitaxel 60 mg/m2 IP d8, 42% completed 6 cycles Open: 23-Mar-98 Closed: 29-Jan-01 Accrual: 416 pts (evaluable) GOG 172: The new Standard of Care Median survival = 49.7 mo Median survival = 65.6 mo Ovarian Cancer in the Genomics Era Preclinical studies Translational Oncology Observation Hypothesis Experiment / Trial Result Analysis Integrated genomic analyses of ovarian carcinoma The Cancer Genome Atlas Research Network* Nature 474: 609-615
Slide 17 - Ovarian Cancer in the Genomics Era Christina M. Annunziata, MD, PhD Medical Oncology Branch National Cancer Institute Bethesda, MD Ovarian Cancer Stage Description Incidence Survival I Confined to ovaries 20% 90% II Confined to pelvis 5% 65% III Spread IP or nodes 58% 45% IV Distant metastases 17% <5% Ovarian Cancer: Prognostic Factors Stage Extent of Cytoreduction Histology and Grade Performance Status p53 Status Vital Organ Function Physiologic Age Platinum+Taxane Primary Therapy Intraperitoneal therapy Information from Second-Look Surgery Genotype BRCA1/2 VEGF Production Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Chemotherapy Clinical Trials The State of Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Full assessment of abdomen and pelvis Random biopsy of visually negative areas Lymph node dissection (except Stage I) Optimal reductive surgery Chemotherapy Clinical Trials Surgical staging of ovarian cancer The State of Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Stage I, II - Complete removal of all disease Stage III, IV - Residual disease < 1 cm Chemotherapy Clinical Trials Optimal Cytoreduction 0 cm 0-1 cm 1-2 cm >2 cm Time since initial surgery (years) Proportion surviving The State of Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Chemotherapy Platinum = cisplatin or carboplatin AND Taxane = paclitaxel or docetaxel Intraperitoneal if Stage III, optimal reduction Clinical Trials 1960 1970 1980 1990 2000 CISPLATIN/ALKYLATOR COMBINATIONS INTRA- PERITONEAL PACLITAXEL/ CARBOPLATIN ALKYLATORS CISPLATIN 5 YR SURVIVAL ADVANCED DISEASE 40% 35% 15% 5% 0 1960 1970 1980 1990 2000 Timeline of Treatment and Outcome for Advanced Ovarian Cancer Representative Chemotherapy Agents Platinum Paclitaxel Topotecan Gemcitabine Doxil Target: DNA b-tubulin Topo-I RN-reductase, Nucleotide pool Topo-II Mechanism:DNA adduct formation TubulinAggregation Stabilize DNA-TopoDNA synth DNA Schedule:Independent Dependent(toxicity)Dependent(efficacy) Dependent Phosporylation Prolonged clearance Resistance:GSH, tolerance, retention MDR-MRP, tubulin mutations Topo-I, BCRP RN-reductase MDR-MRP Topo-II Platinum Interaction:N/A Platelet Sparing ---- Enhanced Toxicity ---- GOG 172: The new Standard of Care Epithelial Ovarian Cancer, Optimal Stage III, No prior therapy, Well balanced arms 1. Intravenous therapy, Cisplatin 75 mg/m2 Paclitaxel 135 mg/m2 (24 h), 83% completed 6 cycles 2. Intraperitoneal therapy, Cisplatin 100 mg/m2 IP d1 Paclitaxel 135 mg/m2 (24 h) IV d1 Paclitaxel 60 mg/m2 IP d8, 42% completed 6 cycles Open: 23-Mar-98 Closed: 29-Jan-01 Accrual: 416 pts (evaluable) GOG 172: The new Standard of Care Median survival = 49.7 mo Median survival = 65.6 mo Ovarian Cancer in the Genomics Era Preclinical studies Translational Oncology Observation Hypothesis Experiment / Trial Result Analysis Integrated genomic analyses of ovarian carcinoma The Cancer Genome Atlas Research Network* Nature 474: 609-615 Background The Cancer Genome Atlas (TCGA) Clinically annotated HGS-OvCa samples Identify molecular abnormalities that influence pathophysiology, affect outcome and constitute therapeutic targets. Microarray analyses: 489 HGS-OvCa tumours, mRNA expression, microRNA (miRNA) expression, DNA copy number and DNA promoter methylation for and Whole exome DNA sequence: 316 samples.
Slide 18 - Ovarian Cancer in the Genomics Era Christina M. Annunziata, MD, PhD Medical Oncology Branch National Cancer Institute Bethesda, MD Ovarian Cancer Stage Description Incidence Survival I Confined to ovaries 20% 90% II Confined to pelvis 5% 65% III Spread IP or nodes 58% 45% IV Distant metastases 17% <5% Ovarian Cancer: Prognostic Factors Stage Extent of Cytoreduction Histology and Grade Performance Status p53 Status Vital Organ Function Physiologic Age Platinum+Taxane Primary Therapy Intraperitoneal therapy Information from Second-Look Surgery Genotype BRCA1/2 VEGF Production Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Chemotherapy Clinical Trials The State of Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Full assessment of abdomen and pelvis Random biopsy of visually negative areas Lymph node dissection (except Stage I) Optimal reductive surgery Chemotherapy Clinical Trials Surgical staging of ovarian cancer The State of Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Stage I, II - Complete removal of all disease Stage III, IV - Residual disease < 1 cm Chemotherapy Clinical Trials Optimal Cytoreduction 0 cm 0-1 cm 1-2 cm >2 cm Time since initial surgery (years) Proportion surviving The State of Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Chemotherapy Platinum = cisplatin or carboplatin AND Taxane = paclitaxel or docetaxel Intraperitoneal if Stage III, optimal reduction Clinical Trials 1960 1970 1980 1990 2000 CISPLATIN/ALKYLATOR COMBINATIONS INTRA- PERITONEAL PACLITAXEL/ CARBOPLATIN ALKYLATORS CISPLATIN 5 YR SURVIVAL ADVANCED DISEASE 40% 35% 15% 5% 0 1960 1970 1980 1990 2000 Timeline of Treatment and Outcome for Advanced Ovarian Cancer Representative Chemotherapy Agents Platinum Paclitaxel Topotecan Gemcitabine Doxil Target: DNA b-tubulin Topo-I RN-reductase, Nucleotide pool Topo-II Mechanism:DNA adduct formation TubulinAggregation Stabilize DNA-TopoDNA synth DNA Schedule:Independent Dependent(toxicity)Dependent(efficacy) Dependent Phosporylation Prolonged clearance Resistance:GSH, tolerance, retention MDR-MRP, tubulin mutations Topo-I, BCRP RN-reductase MDR-MRP Topo-II Platinum Interaction:N/A Platelet Sparing ---- Enhanced Toxicity ---- GOG 172: The new Standard of Care Epithelial Ovarian Cancer, Optimal Stage III, No prior therapy, Well balanced arms 1. Intravenous therapy, Cisplatin 75 mg/m2 Paclitaxel 135 mg/m2 (24 h), 83% completed 6 cycles 2. Intraperitoneal therapy, Cisplatin 100 mg/m2 IP d1 Paclitaxel 135 mg/m2 (24 h) IV d1 Paclitaxel 60 mg/m2 IP d8, 42% completed 6 cycles Open: 23-Mar-98 Closed: 29-Jan-01 Accrual: 416 pts (evaluable) GOG 172: The new Standard of Care Median survival = 49.7 mo Median survival = 65.6 mo Ovarian Cancer in the Genomics Era Preclinical studies Translational Oncology Observation Hypothesis Experiment / Trial Result Analysis Integrated genomic analyses of ovarian carcinoma The Cancer Genome Atlas Research Network* Nature 474: 609-615 Background The Cancer Genome Atlas (TCGA) Clinically annotated HGS-OvCa samples Identify molecular abnormalities that influence pathophysiology, affect outcome and constitute therapeutic targets. Microarray analyses: 489 HGS-OvCa tumours, mRNA expression, microRNA (miRNA) expression, DNA copy number and DNA promoter methylation for and Whole exome DNA sequence: 316 samples. Methods Sample inclusion criteria Newly diagnosed patients ovarian serous adenocarcinoma no prior treatment regardless of surgical stage or histologic grade Each frozen tumor specimen had to have a companion normal tissue specimen, which could be adjacent normal tissue, peripheral lymphocytes, or previously extracted germline DNA.
Slide 19 - Ovarian Cancer in the Genomics Era Christina M. Annunziata, MD, PhD Medical Oncology Branch National Cancer Institute Bethesda, MD Ovarian Cancer Stage Description Incidence Survival I Confined to ovaries 20% 90% II Confined to pelvis 5% 65% III Spread IP or nodes 58% 45% IV Distant metastases 17% <5% Ovarian Cancer: Prognostic Factors Stage Extent of Cytoreduction Histology and Grade Performance Status p53 Status Vital Organ Function Physiologic Age Platinum+Taxane Primary Therapy Intraperitoneal therapy Information from Second-Look Surgery Genotype BRCA1/2 VEGF Production Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Chemotherapy Clinical Trials The State of Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Full assessment of abdomen and pelvis Random biopsy of visually negative areas Lymph node dissection (except Stage I) Optimal reductive surgery Chemotherapy Clinical Trials Surgical staging of ovarian cancer The State of Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Stage I, II - Complete removal of all disease Stage III, IV - Residual disease < 1 cm Chemotherapy Clinical Trials Optimal Cytoreduction 0 cm 0-1 cm 1-2 cm >2 cm Time since initial surgery (years) Proportion surviving The State of Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Chemotherapy Platinum = cisplatin or carboplatin AND Taxane = paclitaxel or docetaxel Intraperitoneal if Stage III, optimal reduction Clinical Trials 1960 1970 1980 1990 2000 CISPLATIN/ALKYLATOR COMBINATIONS INTRA- PERITONEAL PACLITAXEL/ CARBOPLATIN ALKYLATORS CISPLATIN 5 YR SURVIVAL ADVANCED DISEASE 40% 35% 15% 5% 0 1960 1970 1980 1990 2000 Timeline of Treatment and Outcome for Advanced Ovarian Cancer Representative Chemotherapy Agents Platinum Paclitaxel Topotecan Gemcitabine Doxil Target: DNA b-tubulin Topo-I RN-reductase, Nucleotide pool Topo-II Mechanism:DNA adduct formation TubulinAggregation Stabilize DNA-TopoDNA synth DNA Schedule:Independent Dependent(toxicity)Dependent(efficacy) Dependent Phosporylation Prolonged clearance Resistance:GSH, tolerance, retention MDR-MRP, tubulin mutations Topo-I, BCRP RN-reductase MDR-MRP Topo-II Platinum Interaction:N/A Platelet Sparing ---- Enhanced Toxicity ---- GOG 172: The new Standard of Care Epithelial Ovarian Cancer, Optimal Stage III, No prior therapy, Well balanced arms 1. Intravenous therapy, Cisplatin 75 mg/m2 Paclitaxel 135 mg/m2 (24 h), 83% completed 6 cycles 2. Intraperitoneal therapy, Cisplatin 100 mg/m2 IP d1 Paclitaxel 135 mg/m2 (24 h) IV d1 Paclitaxel 60 mg/m2 IP d8, 42% completed 6 cycles Open: 23-Mar-98 Closed: 29-Jan-01 Accrual: 416 pts (evaluable) GOG 172: The new Standard of Care Median survival = 49.7 mo Median survival = 65.6 mo Ovarian Cancer in the Genomics Era Preclinical studies Translational Oncology Observation Hypothesis Experiment / Trial Result Analysis Integrated genomic analyses of ovarian carcinoma The Cancer Genome Atlas Research Network* Nature 474: 609-615 Background The Cancer Genome Atlas (TCGA) Clinically annotated HGS-OvCa samples Identify molecular abnormalities that influence pathophysiology, affect outcome and constitute therapeutic targets. Microarray analyses: 489 HGS-OvCa tumours, mRNA expression, microRNA (miRNA) expression, DNA copy number and DNA promoter methylation for and Whole exome DNA sequence: 316 samples. Methods Sample inclusion criteria Newly diagnosed patients ovarian serous adenocarcinoma no prior treatment regardless of surgical stage or histologic grade Each frozen tumor specimen had to have a companion normal tissue specimen, which could be adjacent normal tissue, peripheral lymphocytes, or previously extracted germline DNA. Methods Clinical data collection Clinical data can be accessed and downloaded from the TCGA Data Portal Demographics, histopathologic information treatment details outcome parameters
Slide 20 - Ovarian Cancer in the Genomics Era Christina M. Annunziata, MD, PhD Medical Oncology Branch National Cancer Institute Bethesda, MD Ovarian Cancer Stage Description Incidence Survival I Confined to ovaries 20% 90% II Confined to pelvis 5% 65% III Spread IP or nodes 58% 45% IV Distant metastases 17% <5% Ovarian Cancer: Prognostic Factors Stage Extent of Cytoreduction Histology and Grade Performance Status p53 Status Vital Organ Function Physiologic Age Platinum+Taxane Primary Therapy Intraperitoneal therapy Information from Second-Look Surgery Genotype BRCA1/2 VEGF Production Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Chemotherapy Clinical Trials The State of Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Full assessment of abdomen and pelvis Random biopsy of visually negative areas Lymph node dissection (except Stage I) Optimal reductive surgery Chemotherapy Clinical Trials Surgical staging of ovarian cancer The State of Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Stage I, II - Complete removal of all disease Stage III, IV - Residual disease < 1 cm Chemotherapy Clinical Trials Optimal Cytoreduction 0 cm 0-1 cm 1-2 cm >2 cm Time since initial surgery (years) Proportion surviving The State of Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Chemotherapy Platinum = cisplatin or carboplatin AND Taxane = paclitaxel or docetaxel Intraperitoneal if Stage III, optimal reduction Clinical Trials 1960 1970 1980 1990 2000 CISPLATIN/ALKYLATOR COMBINATIONS INTRA- PERITONEAL PACLITAXEL/ CARBOPLATIN ALKYLATORS CISPLATIN 5 YR SURVIVAL ADVANCED DISEASE 40% 35% 15% 5% 0 1960 1970 1980 1990 2000 Timeline of Treatment and Outcome for Advanced Ovarian Cancer Representative Chemotherapy Agents Platinum Paclitaxel Topotecan Gemcitabine Doxil Target: DNA b-tubulin Topo-I RN-reductase, Nucleotide pool Topo-II Mechanism:DNA adduct formation TubulinAggregation Stabilize DNA-TopoDNA synth DNA Schedule:Independent Dependent(toxicity)Dependent(efficacy) Dependent Phosporylation Prolonged clearance Resistance:GSH, tolerance, retention MDR-MRP, tubulin mutations Topo-I, BCRP RN-reductase MDR-MRP Topo-II Platinum Interaction:N/A Platelet Sparing ---- Enhanced Toxicity ---- GOG 172: The new Standard of Care Epithelial Ovarian Cancer, Optimal Stage III, No prior therapy, Well balanced arms 1. Intravenous therapy, Cisplatin 75 mg/m2 Paclitaxel 135 mg/m2 (24 h), 83% completed 6 cycles 2. Intraperitoneal therapy, Cisplatin 100 mg/m2 IP d1 Paclitaxel 135 mg/m2 (24 h) IV d1 Paclitaxel 60 mg/m2 IP d8, 42% completed 6 cycles Open: 23-Mar-98 Closed: 29-Jan-01 Accrual: 416 pts (evaluable) GOG 172: The new Standard of Care Median survival = 49.7 mo Median survival = 65.6 mo Ovarian Cancer in the Genomics Era Preclinical studies Translational Oncology Observation Hypothesis Experiment / Trial Result Analysis Integrated genomic analyses of ovarian carcinoma The Cancer Genome Atlas Research Network* Nature 474: 609-615 Background The Cancer Genome Atlas (TCGA) Clinically annotated HGS-OvCa samples Identify molecular abnormalities that influence pathophysiology, affect outcome and constitute therapeutic targets. Microarray analyses: 489 HGS-OvCa tumours, mRNA expression, microRNA (miRNA) expression, DNA copy number and DNA promoter methylation for and Whole exome DNA sequence: 316 samples. Methods Sample inclusion criteria Newly diagnosed patients ovarian serous adenocarcinoma no prior treatment regardless of surgical stage or histologic grade Each frozen tumor specimen had to have a companion normal tissue specimen, which could be adjacent normal tissue, peripheral lymphocytes, or previously extracted germline DNA. Methods Clinical data collection Clinical data can be accessed and downloaded from the TCGA Data Portal Demographics, histopathologic information treatment details outcome parameters Methods
Slide 21 - Ovarian Cancer in the Genomics Era Christina M. Annunziata, MD, PhD Medical Oncology Branch National Cancer Institute Bethesda, MD Ovarian Cancer Stage Description Incidence Survival I Confined to ovaries 20% 90% II Confined to pelvis 5% 65% III Spread IP or nodes 58% 45% IV Distant metastases 17% <5% Ovarian Cancer: Prognostic Factors Stage Extent of Cytoreduction Histology and Grade Performance Status p53 Status Vital Organ Function Physiologic Age Platinum+Taxane Primary Therapy Intraperitoneal therapy Information from Second-Look Surgery Genotype BRCA1/2 VEGF Production Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Chemotherapy Clinical Trials The State of Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Full assessment of abdomen and pelvis Random biopsy of visually negative areas Lymph node dissection (except Stage I) Optimal reductive surgery Chemotherapy Clinical Trials Surgical staging of ovarian cancer The State of Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Stage I, II - Complete removal of all disease Stage III, IV - Residual disease < 1 cm Chemotherapy Clinical Trials Optimal Cytoreduction 0 cm 0-1 cm 1-2 cm >2 cm Time since initial surgery (years) Proportion surviving The State of Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Chemotherapy Platinum = cisplatin or carboplatin AND Taxane = paclitaxel or docetaxel Intraperitoneal if Stage III, optimal reduction Clinical Trials 1960 1970 1980 1990 2000 CISPLATIN/ALKYLATOR COMBINATIONS INTRA- PERITONEAL PACLITAXEL/ CARBOPLATIN ALKYLATORS CISPLATIN 5 YR SURVIVAL ADVANCED DISEASE 40% 35% 15% 5% 0 1960 1970 1980 1990 2000 Timeline of Treatment and Outcome for Advanced Ovarian Cancer Representative Chemotherapy Agents Platinum Paclitaxel Topotecan Gemcitabine Doxil Target: DNA b-tubulin Topo-I RN-reductase, Nucleotide pool Topo-II Mechanism:DNA adduct formation TubulinAggregation Stabilize DNA-TopoDNA synth DNA Schedule:Independent Dependent(toxicity)Dependent(efficacy) Dependent Phosporylation Prolonged clearance Resistance:GSH, tolerance, retention MDR-MRP, tubulin mutations Topo-I, BCRP RN-reductase MDR-MRP Topo-II Platinum Interaction:N/A Platelet Sparing ---- Enhanced Toxicity ---- GOG 172: The new Standard of Care Epithelial Ovarian Cancer, Optimal Stage III, No prior therapy, Well balanced arms 1. Intravenous therapy, Cisplatin 75 mg/m2 Paclitaxel 135 mg/m2 (24 h), 83% completed 6 cycles 2. Intraperitoneal therapy, Cisplatin 100 mg/m2 IP d1 Paclitaxel 135 mg/m2 (24 h) IV d1 Paclitaxel 60 mg/m2 IP d8, 42% completed 6 cycles Open: 23-Mar-98 Closed: 29-Jan-01 Accrual: 416 pts (evaluable) GOG 172: The new Standard of Care Median survival = 49.7 mo Median survival = 65.6 mo Ovarian Cancer in the Genomics Era Preclinical studies Translational Oncology Observation Hypothesis Experiment / Trial Result Analysis Integrated genomic analyses of ovarian carcinoma The Cancer Genome Atlas Research Network* Nature 474: 609-615 Background The Cancer Genome Atlas (TCGA) Clinically annotated HGS-OvCa samples Identify molecular abnormalities that influence pathophysiology, affect outcome and constitute therapeutic targets. Microarray analyses: 489 HGS-OvCa tumours, mRNA expression, microRNA (miRNA) expression, DNA copy number and DNA promoter methylation for and Whole exome DNA sequence: 316 samples. Methods Sample inclusion criteria Newly diagnosed patients ovarian serous adenocarcinoma no prior treatment regardless of surgical stage or histologic grade Each frozen tumor specimen had to have a companion normal tissue specimen, which could be adjacent normal tissue, peripheral lymphocytes, or previously extracted germline DNA. Methods Clinical data collection Clinical data can be accessed and downloaded from the TCGA Data Portal Demographics, histopathologic information treatment details outcome parameters Methods Mutated genes in HGS-OvCa
Slide 22 - Ovarian Cancer in the Genomics Era Christina M. Annunziata, MD, PhD Medical Oncology Branch National Cancer Institute Bethesda, MD Ovarian Cancer Stage Description Incidence Survival I Confined to ovaries 20% 90% II Confined to pelvis 5% 65% III Spread IP or nodes 58% 45% IV Distant metastases 17% <5% Ovarian Cancer: Prognostic Factors Stage Extent of Cytoreduction Histology and Grade Performance Status p53 Status Vital Organ Function Physiologic Age Platinum+Taxane Primary Therapy Intraperitoneal therapy Information from Second-Look Surgery Genotype BRCA1/2 VEGF Production Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Chemotherapy Clinical Trials The State of Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Full assessment of abdomen and pelvis Random biopsy of visually negative areas Lymph node dissection (except Stage I) Optimal reductive surgery Chemotherapy Clinical Trials Surgical staging of ovarian cancer The State of Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Stage I, II - Complete removal of all disease Stage III, IV - Residual disease < 1 cm Chemotherapy Clinical Trials Optimal Cytoreduction 0 cm 0-1 cm 1-2 cm >2 cm Time since initial surgery (years) Proportion surviving The State of Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Chemotherapy Platinum = cisplatin or carboplatin AND Taxane = paclitaxel or docetaxel Intraperitoneal if Stage III, optimal reduction Clinical Trials 1960 1970 1980 1990 2000 CISPLATIN/ALKYLATOR COMBINATIONS INTRA- PERITONEAL PACLITAXEL/ CARBOPLATIN ALKYLATORS CISPLATIN 5 YR SURVIVAL ADVANCED DISEASE 40% 35% 15% 5% 0 1960 1970 1980 1990 2000 Timeline of Treatment and Outcome for Advanced Ovarian Cancer Representative Chemotherapy Agents Platinum Paclitaxel Topotecan Gemcitabine Doxil Target: DNA b-tubulin Topo-I RN-reductase, Nucleotide pool Topo-II Mechanism:DNA adduct formation TubulinAggregation Stabilize DNA-TopoDNA synth DNA Schedule:Independent Dependent(toxicity)Dependent(efficacy) Dependent Phosporylation Prolonged clearance Resistance:GSH, tolerance, retention MDR-MRP, tubulin mutations Topo-I, BCRP RN-reductase MDR-MRP Topo-II Platinum Interaction:N/A Platelet Sparing ---- Enhanced Toxicity ---- GOG 172: The new Standard of Care Epithelial Ovarian Cancer, Optimal Stage III, No prior therapy, Well balanced arms 1. Intravenous therapy, Cisplatin 75 mg/m2 Paclitaxel 135 mg/m2 (24 h), 83% completed 6 cycles 2. Intraperitoneal therapy, Cisplatin 100 mg/m2 IP d1 Paclitaxel 135 mg/m2 (24 h) IV d1 Paclitaxel 60 mg/m2 IP d8, 42% completed 6 cycles Open: 23-Mar-98 Closed: 29-Jan-01 Accrual: 416 pts (evaluable) GOG 172: The new Standard of Care Median survival = 49.7 mo Median survival = 65.6 mo Ovarian Cancer in the Genomics Era Preclinical studies Translational Oncology Observation Hypothesis Experiment / Trial Result Analysis Integrated genomic analyses of ovarian carcinoma The Cancer Genome Atlas Research Network* Nature 474: 609-615 Background The Cancer Genome Atlas (TCGA) Clinically annotated HGS-OvCa samples Identify molecular abnormalities that influence pathophysiology, affect outcome and constitute therapeutic targets. Microarray analyses: 489 HGS-OvCa tumours, mRNA expression, microRNA (miRNA) expression, DNA copy number and DNA promoter methylation for and Whole exome DNA sequence: 316 samples. Methods Sample inclusion criteria Newly diagnosed patients ovarian serous adenocarcinoma no prior treatment regardless of surgical stage or histologic grade Each frozen tumor specimen had to have a companion normal tissue specimen, which could be adjacent normal tissue, peripheral lymphocytes, or previously extracted germline DNA. Methods Clinical data collection Clinical data can be accessed and downloaded from the TCGA Data Portal Demographics, histopathologic information treatment details outcome parameters Methods Mutated genes in HGS-OvCa Genome copy number abnormality Copy number profiles of 489 HGS-OvCa, compared with profiles of 197 glioblastoma multiforme (GBM) tumours. Copy number increases (red) and decreases (blue) are plotted as a function of distance along the normal genome (vertical axis, divided into chromosomes).
Slide 23 - Ovarian Cancer in the Genomics Era Christina M. Annunziata, MD, PhD Medical Oncology Branch National Cancer Institute Bethesda, MD Ovarian Cancer Stage Description Incidence Survival I Confined to ovaries 20% 90% II Confined to pelvis 5% 65% III Spread IP or nodes 58% 45% IV Distant metastases 17% <5% Ovarian Cancer: Prognostic Factors Stage Extent of Cytoreduction Histology and Grade Performance Status p53 Status Vital Organ Function Physiologic Age Platinum+Taxane Primary Therapy Intraperitoneal therapy Information from Second-Look Surgery Genotype BRCA1/2 VEGF Production Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Chemotherapy Clinical Trials The State of Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Full assessment of abdomen and pelvis Random biopsy of visually negative areas Lymph node dissection (except Stage I) Optimal reductive surgery Chemotherapy Clinical Trials Surgical staging of ovarian cancer The State of Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Stage I, II - Complete removal of all disease Stage III, IV - Residual disease < 1 cm Chemotherapy Clinical Trials Optimal Cytoreduction 0 cm 0-1 cm 1-2 cm >2 cm Time since initial surgery (years) Proportion surviving The State of Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Chemotherapy Platinum = cisplatin or carboplatin AND Taxane = paclitaxel or docetaxel Intraperitoneal if Stage III, optimal reduction Clinical Trials 1960 1970 1980 1990 2000 CISPLATIN/ALKYLATOR COMBINATIONS INTRA- PERITONEAL PACLITAXEL/ CARBOPLATIN ALKYLATORS CISPLATIN 5 YR SURVIVAL ADVANCED DISEASE 40% 35% 15% 5% 0 1960 1970 1980 1990 2000 Timeline of Treatment and Outcome for Advanced Ovarian Cancer Representative Chemotherapy Agents Platinum Paclitaxel Topotecan Gemcitabine Doxil Target: DNA b-tubulin Topo-I RN-reductase, Nucleotide pool Topo-II Mechanism:DNA adduct formation TubulinAggregation Stabilize DNA-TopoDNA synth DNA Schedule:Independent Dependent(toxicity)Dependent(efficacy) Dependent Phosporylation Prolonged clearance Resistance:GSH, tolerance, retention MDR-MRP, tubulin mutations Topo-I, BCRP RN-reductase MDR-MRP Topo-II Platinum Interaction:N/A Platelet Sparing ---- Enhanced Toxicity ---- GOG 172: The new Standard of Care Epithelial Ovarian Cancer, Optimal Stage III, No prior therapy, Well balanced arms 1. Intravenous therapy, Cisplatin 75 mg/m2 Paclitaxel 135 mg/m2 (24 h), 83% completed 6 cycles 2. Intraperitoneal therapy, Cisplatin 100 mg/m2 IP d1 Paclitaxel 135 mg/m2 (24 h) IV d1 Paclitaxel 60 mg/m2 IP d8, 42% completed 6 cycles Open: 23-Mar-98 Closed: 29-Jan-01 Accrual: 416 pts (evaluable) GOG 172: The new Standard of Care Median survival = 49.7 mo Median survival = 65.6 mo Ovarian Cancer in the Genomics Era Preclinical studies Translational Oncology Observation Hypothesis Experiment / Trial Result Analysis Integrated genomic analyses of ovarian carcinoma The Cancer Genome Atlas Research Network* Nature 474: 609-615 Background The Cancer Genome Atlas (TCGA) Clinically annotated HGS-OvCa samples Identify molecular abnormalities that influence pathophysiology, affect outcome and constitute therapeutic targets. Microarray analyses: 489 HGS-OvCa tumours, mRNA expression, microRNA (miRNA) expression, DNA copy number and DNA promoter methylation for and Whole exome DNA sequence: 316 samples. Methods Sample inclusion criteria Newly diagnosed patients ovarian serous adenocarcinoma no prior treatment regardless of surgical stage or histologic grade Each frozen tumor specimen had to have a companion normal tissue specimen, which could be adjacent normal tissue, peripheral lymphocytes, or previously extracted germline DNA. Methods Clinical data collection Clinical data can be accessed and downloaded from the TCGA Data Portal Demographics, histopathologic information treatment details outcome parameters Methods Mutated genes in HGS-OvCa Genome copy number abnormality Copy number profiles of 489 HGS-OvCa, compared with profiles of 197 glioblastoma multiforme (GBM) tumours. Copy number increases (red) and decreases (blue) are plotted as a function of distance along the normal genome (vertical axis, divided into chromosomes). Gene and miRNA patterns: Molecular subtype and outcome prediction
Slide 24 - Ovarian Cancer in the Genomics Era Christina M. Annunziata, MD, PhD Medical Oncology Branch National Cancer Institute Bethesda, MD Ovarian Cancer Stage Description Incidence Survival I Confined to ovaries 20% 90% II Confined to pelvis 5% 65% III Spread IP or nodes 58% 45% IV Distant metastases 17% <5% Ovarian Cancer: Prognostic Factors Stage Extent of Cytoreduction Histology and Grade Performance Status p53 Status Vital Organ Function Physiologic Age Platinum+Taxane Primary Therapy Intraperitoneal therapy Information from Second-Look Surgery Genotype BRCA1/2 VEGF Production Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Chemotherapy Clinical Trials The State of Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Full assessment of abdomen and pelvis Random biopsy of visually negative areas Lymph node dissection (except Stage I) Optimal reductive surgery Chemotherapy Clinical Trials Surgical staging of ovarian cancer The State of Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Stage I, II - Complete removal of all disease Stage III, IV - Residual disease < 1 cm Chemotherapy Clinical Trials Optimal Cytoreduction 0 cm 0-1 cm 1-2 cm >2 cm Time since initial surgery (years) Proportion surviving The State of Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Chemotherapy Platinum = cisplatin or carboplatin AND Taxane = paclitaxel or docetaxel Intraperitoneal if Stage III, optimal reduction Clinical Trials 1960 1970 1980 1990 2000 CISPLATIN/ALKYLATOR COMBINATIONS INTRA- PERITONEAL PACLITAXEL/ CARBOPLATIN ALKYLATORS CISPLATIN 5 YR SURVIVAL ADVANCED DISEASE 40% 35% 15% 5% 0 1960 1970 1980 1990 2000 Timeline of Treatment and Outcome for Advanced Ovarian Cancer Representative Chemotherapy Agents Platinum Paclitaxel Topotecan Gemcitabine Doxil Target: DNA b-tubulin Topo-I RN-reductase, Nucleotide pool Topo-II Mechanism:DNA adduct formation TubulinAggregation Stabilize DNA-TopoDNA synth DNA Schedule:Independent Dependent(toxicity)Dependent(efficacy) Dependent Phosporylation Prolonged clearance Resistance:GSH, tolerance, retention MDR-MRP, tubulin mutations Topo-I, BCRP RN-reductase MDR-MRP Topo-II Platinum Interaction:N/A Platelet Sparing ---- Enhanced Toxicity ---- GOG 172: The new Standard of Care Epithelial Ovarian Cancer, Optimal Stage III, No prior therapy, Well balanced arms 1. Intravenous therapy, Cisplatin 75 mg/m2 Paclitaxel 135 mg/m2 (24 h), 83% completed 6 cycles 2. Intraperitoneal therapy, Cisplatin 100 mg/m2 IP d1 Paclitaxel 135 mg/m2 (24 h) IV d1 Paclitaxel 60 mg/m2 IP d8, 42% completed 6 cycles Open: 23-Mar-98 Closed: 29-Jan-01 Accrual: 416 pts (evaluable) GOG 172: The new Standard of Care Median survival = 49.7 mo Median survival = 65.6 mo Ovarian Cancer in the Genomics Era Preclinical studies Translational Oncology Observation Hypothesis Experiment / Trial Result Analysis Integrated genomic analyses of ovarian carcinoma The Cancer Genome Atlas Research Network* Nature 474: 609-615 Background The Cancer Genome Atlas (TCGA) Clinically annotated HGS-OvCa samples Identify molecular abnormalities that influence pathophysiology, affect outcome and constitute therapeutic targets. Microarray analyses: 489 HGS-OvCa tumours, mRNA expression, microRNA (miRNA) expression, DNA copy number and DNA promoter methylation for and Whole exome DNA sequence: 316 samples. Methods Sample inclusion criteria Newly diagnosed patients ovarian serous adenocarcinoma no prior treatment regardless of surgical stage or histologic grade Each frozen tumor specimen had to have a companion normal tissue specimen, which could be adjacent normal tissue, peripheral lymphocytes, or previously extracted germline DNA. Methods Clinical data collection Clinical data can be accessed and downloaded from the TCGA Data Portal Demographics, histopathologic information treatment details outcome parameters Methods Mutated genes in HGS-OvCa Genome copy number abnormality Copy number profiles of 489 HGS-OvCa, compared with profiles of 197 glioblastoma multiforme (GBM) tumours. Copy number increases (red) and decreases (blue) are plotted as a function of distance along the normal genome (vertical axis, divided into chromosomes). Gene and miRNA patterns: Molecular subtype and outcome prediction Altered pathways in HGS-OvCa
Slide 25 - Ovarian Cancer in the Genomics Era Christina M. Annunziata, MD, PhD Medical Oncology Branch National Cancer Institute Bethesda, MD Ovarian Cancer Stage Description Incidence Survival I Confined to ovaries 20% 90% II Confined to pelvis 5% 65% III Spread IP or nodes 58% 45% IV Distant metastases 17% <5% Ovarian Cancer: Prognostic Factors Stage Extent of Cytoreduction Histology and Grade Performance Status p53 Status Vital Organ Function Physiologic Age Platinum+Taxane Primary Therapy Intraperitoneal therapy Information from Second-Look Surgery Genotype BRCA1/2 VEGF Production Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Chemotherapy Clinical Trials The State of Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Full assessment of abdomen and pelvis Random biopsy of visually negative areas Lymph node dissection (except Stage I) Optimal reductive surgery Chemotherapy Clinical Trials Surgical staging of ovarian cancer The State of Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Stage I, II - Complete removal of all disease Stage III, IV - Residual disease < 1 cm Chemotherapy Clinical Trials Optimal Cytoreduction 0 cm 0-1 cm 1-2 cm >2 cm Time since initial surgery (years) Proportion surviving The State of Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Chemotherapy Platinum = cisplatin or carboplatin AND Taxane = paclitaxel or docetaxel Intraperitoneal if Stage III, optimal reduction Clinical Trials 1960 1970 1980 1990 2000 CISPLATIN/ALKYLATOR COMBINATIONS INTRA- PERITONEAL PACLITAXEL/ CARBOPLATIN ALKYLATORS CISPLATIN 5 YR SURVIVAL ADVANCED DISEASE 40% 35% 15% 5% 0 1960 1970 1980 1990 2000 Timeline of Treatment and Outcome for Advanced Ovarian Cancer Representative Chemotherapy Agents Platinum Paclitaxel Topotecan Gemcitabine Doxil Target: DNA b-tubulin Topo-I RN-reductase, Nucleotide pool Topo-II Mechanism:DNA adduct formation TubulinAggregation Stabilize DNA-TopoDNA synth DNA Schedule:Independent Dependent(toxicity)Dependent(efficacy) Dependent Phosporylation Prolonged clearance Resistance:GSH, tolerance, retention MDR-MRP, tubulin mutations Topo-I, BCRP RN-reductase MDR-MRP Topo-II Platinum Interaction:N/A Platelet Sparing ---- Enhanced Toxicity ---- GOG 172: The new Standard of Care Epithelial Ovarian Cancer, Optimal Stage III, No prior therapy, Well balanced arms 1. Intravenous therapy, Cisplatin 75 mg/m2 Paclitaxel 135 mg/m2 (24 h), 83% completed 6 cycles 2. Intraperitoneal therapy, Cisplatin 100 mg/m2 IP d1 Paclitaxel 135 mg/m2 (24 h) IV d1 Paclitaxel 60 mg/m2 IP d8, 42% completed 6 cycles Open: 23-Mar-98 Closed: 29-Jan-01 Accrual: 416 pts (evaluable) GOG 172: The new Standard of Care Median survival = 49.7 mo Median survival = 65.6 mo Ovarian Cancer in the Genomics Era Preclinical studies Translational Oncology Observation Hypothesis Experiment / Trial Result Analysis Integrated genomic analyses of ovarian carcinoma The Cancer Genome Atlas Research Network* Nature 474: 609-615 Background The Cancer Genome Atlas (TCGA) Clinically annotated HGS-OvCa samples Identify molecular abnormalities that influence pathophysiology, affect outcome and constitute therapeutic targets. Microarray analyses: 489 HGS-OvCa tumours, mRNA expression, microRNA (miRNA) expression, DNA copy number and DNA promoter methylation for and Whole exome DNA sequence: 316 samples. Methods Sample inclusion criteria Newly diagnosed patients ovarian serous adenocarcinoma no prior treatment regardless of surgical stage or histologic grade Each frozen tumor specimen had to have a companion normal tissue specimen, which could be adjacent normal tissue, peripheral lymphocytes, or previously extracted germline DNA. Methods Clinical data collection Clinical data can be accessed and downloaded from the TCGA Data Portal Demographics, histopathologic information treatment details outcome parameters Methods Mutated genes in HGS-OvCa Genome copy number abnormality Copy number profiles of 489 HGS-OvCa, compared with profiles of 197 glioblastoma multiforme (GBM) tumours. Copy number increases (red) and decreases (blue) are plotted as a function of distance along the normal genome (vertical axis, divided into chromosomes). Gene and miRNA patterns: Molecular subtype and outcome prediction Altered pathways in HGS-OvCa Altered pathways in HGS-OvCa
Slide 26 - Ovarian Cancer in the Genomics Era Christina M. Annunziata, MD, PhD Medical Oncology Branch National Cancer Institute Bethesda, MD Ovarian Cancer Stage Description Incidence Survival I Confined to ovaries 20% 90% II Confined to pelvis 5% 65% III Spread IP or nodes 58% 45% IV Distant metastases 17% <5% Ovarian Cancer: Prognostic Factors Stage Extent of Cytoreduction Histology and Grade Performance Status p53 Status Vital Organ Function Physiologic Age Platinum+Taxane Primary Therapy Intraperitoneal therapy Information from Second-Look Surgery Genotype BRCA1/2 VEGF Production Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Chemotherapy Clinical Trials The State of Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Full assessment of abdomen and pelvis Random biopsy of visually negative areas Lymph node dissection (except Stage I) Optimal reductive surgery Chemotherapy Clinical Trials Surgical staging of ovarian cancer The State of Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Stage I, II - Complete removal of all disease Stage III, IV - Residual disease < 1 cm Chemotherapy Clinical Trials Optimal Cytoreduction 0 cm 0-1 cm 1-2 cm >2 cm Time since initial surgery (years) Proportion surviving The State of Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Chemotherapy Platinum = cisplatin or carboplatin AND Taxane = paclitaxel or docetaxel Intraperitoneal if Stage III, optimal reduction Clinical Trials 1960 1970 1980 1990 2000 CISPLATIN/ALKYLATOR COMBINATIONS INTRA- PERITONEAL PACLITAXEL/ CARBOPLATIN ALKYLATORS CISPLATIN 5 YR SURVIVAL ADVANCED DISEASE 40% 35% 15% 5% 0 1960 1970 1980 1990 2000 Timeline of Treatment and Outcome for Advanced Ovarian Cancer Representative Chemotherapy Agents Platinum Paclitaxel Topotecan Gemcitabine Doxil Target: DNA b-tubulin Topo-I RN-reductase, Nucleotide pool Topo-II Mechanism:DNA adduct formation TubulinAggregation Stabilize DNA-TopoDNA synth DNA Schedule:Independent Dependent(toxicity)Dependent(efficacy) Dependent Phosporylation Prolonged clearance Resistance:GSH, tolerance, retention MDR-MRP, tubulin mutations Topo-I, BCRP RN-reductase MDR-MRP Topo-II Platinum Interaction:N/A Platelet Sparing ---- Enhanced Toxicity ---- GOG 172: The new Standard of Care Epithelial Ovarian Cancer, Optimal Stage III, No prior therapy, Well balanced arms 1. Intravenous therapy, Cisplatin 75 mg/m2 Paclitaxel 135 mg/m2 (24 h), 83% completed 6 cycles 2. Intraperitoneal therapy, Cisplatin 100 mg/m2 IP d1 Paclitaxel 135 mg/m2 (24 h) IV d1 Paclitaxel 60 mg/m2 IP d8, 42% completed 6 cycles Open: 23-Mar-98 Closed: 29-Jan-01 Accrual: 416 pts (evaluable) GOG 172: The new Standard of Care Median survival = 49.7 mo Median survival = 65.6 mo Ovarian Cancer in the Genomics Era Preclinical studies Translational Oncology Observation Hypothesis Experiment / Trial Result Analysis Integrated genomic analyses of ovarian carcinoma The Cancer Genome Atlas Research Network* Nature 474: 609-615 Background The Cancer Genome Atlas (TCGA) Clinically annotated HGS-OvCa samples Identify molecular abnormalities that influence pathophysiology, affect outcome and constitute therapeutic targets. Microarray analyses: 489 HGS-OvCa tumours, mRNA expression, microRNA (miRNA) expression, DNA copy number and DNA promoter methylation for and Whole exome DNA sequence: 316 samples. Methods Sample inclusion criteria Newly diagnosed patients ovarian serous adenocarcinoma no prior treatment regardless of surgical stage or histologic grade Each frozen tumor specimen had to have a companion normal tissue specimen, which could be adjacent normal tissue, peripheral lymphocytes, or previously extracted germline DNA. Methods Clinical data collection Clinical data can be accessed and downloaded from the TCGA Data Portal Demographics, histopathologic information treatment details outcome parameters Methods Mutated genes in HGS-OvCa Genome copy number abnormality Copy number profiles of 489 HGS-OvCa, compared with profiles of 197 glioblastoma multiforme (GBM) tumours. Copy number increases (red) and decreases (blue) are plotted as a function of distance along the normal genome (vertical axis, divided into chromosomes). Gene and miRNA patterns: Molecular subtype and outcome prediction Altered pathways in HGS-OvCa Altered pathways in HGS-OvCa Altered pathways in HGS-OvCa
Slide 27 - Ovarian Cancer in the Genomics Era Christina M. Annunziata, MD, PhD Medical Oncology Branch National Cancer Institute Bethesda, MD Ovarian Cancer Stage Description Incidence Survival I Confined to ovaries 20% 90% II Confined to pelvis 5% 65% III Spread IP or nodes 58% 45% IV Distant metastases 17% <5% Ovarian Cancer: Prognostic Factors Stage Extent of Cytoreduction Histology and Grade Performance Status p53 Status Vital Organ Function Physiologic Age Platinum+Taxane Primary Therapy Intraperitoneal therapy Information from Second-Look Surgery Genotype BRCA1/2 VEGF Production Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Chemotherapy Clinical Trials The State of Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Full assessment of abdomen and pelvis Random biopsy of visually negative areas Lymph node dissection (except Stage I) Optimal reductive surgery Chemotherapy Clinical Trials Surgical staging of ovarian cancer The State of Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Stage I, II - Complete removal of all disease Stage III, IV - Residual disease < 1 cm Chemotherapy Clinical Trials Optimal Cytoreduction 0 cm 0-1 cm 1-2 cm >2 cm Time since initial surgery (years) Proportion surviving The State of Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Chemotherapy Platinum = cisplatin or carboplatin AND Taxane = paclitaxel or docetaxel Intraperitoneal if Stage III, optimal reduction Clinical Trials 1960 1970 1980 1990 2000 CISPLATIN/ALKYLATOR COMBINATIONS INTRA- PERITONEAL PACLITAXEL/ CARBOPLATIN ALKYLATORS CISPLATIN 5 YR SURVIVAL ADVANCED DISEASE 40% 35% 15% 5% 0 1960 1970 1980 1990 2000 Timeline of Treatment and Outcome for Advanced Ovarian Cancer Representative Chemotherapy Agents Platinum Paclitaxel Topotecan Gemcitabine Doxil Target: DNA b-tubulin Topo-I RN-reductase, Nucleotide pool Topo-II Mechanism:DNA adduct formation TubulinAggregation Stabilize DNA-TopoDNA synth DNA Schedule:Independent Dependent(toxicity)Dependent(efficacy) Dependent Phosporylation Prolonged clearance Resistance:GSH, tolerance, retention MDR-MRP, tubulin mutations Topo-I, BCRP RN-reductase MDR-MRP Topo-II Platinum Interaction:N/A Platelet Sparing ---- Enhanced Toxicity ---- GOG 172: The new Standard of Care Epithelial Ovarian Cancer, Optimal Stage III, No prior therapy, Well balanced arms 1. Intravenous therapy, Cisplatin 75 mg/m2 Paclitaxel 135 mg/m2 (24 h), 83% completed 6 cycles 2. Intraperitoneal therapy, Cisplatin 100 mg/m2 IP d1 Paclitaxel 135 mg/m2 (24 h) IV d1 Paclitaxel 60 mg/m2 IP d8, 42% completed 6 cycles Open: 23-Mar-98 Closed: 29-Jan-01 Accrual: 416 pts (evaluable) GOG 172: The new Standard of Care Median survival = 49.7 mo Median survival = 65.6 mo Ovarian Cancer in the Genomics Era Preclinical studies Translational Oncology Observation Hypothesis Experiment / Trial Result Analysis Integrated genomic analyses of ovarian carcinoma The Cancer Genome Atlas Research Network* Nature 474: 609-615 Background The Cancer Genome Atlas (TCGA) Clinically annotated HGS-OvCa samples Identify molecular abnormalities that influence pathophysiology, affect outcome and constitute therapeutic targets. Microarray analyses: 489 HGS-OvCa tumours, mRNA expression, microRNA (miRNA) expression, DNA copy number and DNA promoter methylation for and Whole exome DNA sequence: 316 samples. Methods Sample inclusion criteria Newly diagnosed patients ovarian serous adenocarcinoma no prior treatment regardless of surgical stage or histologic grade Each frozen tumor specimen had to have a companion normal tissue specimen, which could be adjacent normal tissue, peripheral lymphocytes, or previously extracted germline DNA. Methods Clinical data collection Clinical data can be accessed and downloaded from the TCGA Data Portal Demographics, histopathologic information treatment details outcome parameters Methods Mutated genes in HGS-OvCa Genome copy number abnormality Copy number profiles of 489 HGS-OvCa, compared with profiles of 197 glioblastoma multiforme (GBM) tumours. Copy number increases (red) and decreases (blue) are plotted as a function of distance along the normal genome (vertical axis, divided into chromosomes). Gene and miRNA patterns: Molecular subtype and outcome prediction Altered pathways in HGS-OvCa Altered pathways in HGS-OvCa Altered pathways in HGS-OvCa Altered pathways in HGS-OvCa
Slide 28 - Ovarian Cancer in the Genomics Era Christina M. Annunziata, MD, PhD Medical Oncology Branch National Cancer Institute Bethesda, MD Ovarian Cancer Stage Description Incidence Survival I Confined to ovaries 20% 90% II Confined to pelvis 5% 65% III Spread IP or nodes 58% 45% IV Distant metastases 17% <5% Ovarian Cancer: Prognostic Factors Stage Extent of Cytoreduction Histology and Grade Performance Status p53 Status Vital Organ Function Physiologic Age Platinum+Taxane Primary Therapy Intraperitoneal therapy Information from Second-Look Surgery Genotype BRCA1/2 VEGF Production Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Chemotherapy Clinical Trials The State of Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Full assessment of abdomen and pelvis Random biopsy of visually negative areas Lymph node dissection (except Stage I) Optimal reductive surgery Chemotherapy Clinical Trials Surgical staging of ovarian cancer The State of Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Stage I, II - Complete removal of all disease Stage III, IV - Residual disease < 1 cm Chemotherapy Clinical Trials Optimal Cytoreduction 0 cm 0-1 cm 1-2 cm >2 cm Time since initial surgery (years) Proportion surviving The State of Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Chemotherapy Platinum = cisplatin or carboplatin AND Taxane = paclitaxel or docetaxel Intraperitoneal if Stage III, optimal reduction Clinical Trials 1960 1970 1980 1990 2000 CISPLATIN/ALKYLATOR COMBINATIONS INTRA- PERITONEAL PACLITAXEL/ CARBOPLATIN ALKYLATORS CISPLATIN 5 YR SURVIVAL ADVANCED DISEASE 40% 35% 15% 5% 0 1960 1970 1980 1990 2000 Timeline of Treatment and Outcome for Advanced Ovarian Cancer Representative Chemotherapy Agents Platinum Paclitaxel Topotecan Gemcitabine Doxil Target: DNA b-tubulin Topo-I RN-reductase, Nucleotide pool Topo-II Mechanism:DNA adduct formation TubulinAggregation Stabilize DNA-TopoDNA synth DNA Schedule:Independent Dependent(toxicity)Dependent(efficacy) Dependent Phosporylation Prolonged clearance Resistance:GSH, tolerance, retention MDR-MRP, tubulin mutations Topo-I, BCRP RN-reductase MDR-MRP Topo-II Platinum Interaction:N/A Platelet Sparing ---- Enhanced Toxicity ---- GOG 172: The new Standard of Care Epithelial Ovarian Cancer, Optimal Stage III, No prior therapy, Well balanced arms 1. Intravenous therapy, Cisplatin 75 mg/m2 Paclitaxel 135 mg/m2 (24 h), 83% completed 6 cycles 2. Intraperitoneal therapy, Cisplatin 100 mg/m2 IP d1 Paclitaxel 135 mg/m2 (24 h) IV d1 Paclitaxel 60 mg/m2 IP d8, 42% completed 6 cycles Open: 23-Mar-98 Closed: 29-Jan-01 Accrual: 416 pts (evaluable) GOG 172: The new Standard of Care Median survival = 49.7 mo Median survival = 65.6 mo Ovarian Cancer in the Genomics Era Preclinical studies Translational Oncology Observation Hypothesis Experiment / Trial Result Analysis Integrated genomic analyses of ovarian carcinoma The Cancer Genome Atlas Research Network* Nature 474: 609-615 Background The Cancer Genome Atlas (TCGA) Clinically annotated HGS-OvCa samples Identify molecular abnormalities that influence pathophysiology, affect outcome and constitute therapeutic targets. Microarray analyses: 489 HGS-OvCa tumours, mRNA expression, microRNA (miRNA) expression, DNA copy number and DNA promoter methylation for and Whole exome DNA sequence: 316 samples. Methods Sample inclusion criteria Newly diagnosed patients ovarian serous adenocarcinoma no prior treatment regardless of surgical stage or histologic grade Each frozen tumor specimen had to have a companion normal tissue specimen, which could be adjacent normal tissue, peripheral lymphocytes, or previously extracted germline DNA. Methods Clinical data collection Clinical data can be accessed and downloaded from the TCGA Data Portal Demographics, histopathologic information treatment details outcome parameters Methods Mutated genes in HGS-OvCa Genome copy number abnormality Copy number profiles of 489 HGS-OvCa, compared with profiles of 197 glioblastoma multiforme (GBM) tumours. Copy number increases (red) and decreases (blue) are plotted as a function of distance along the normal genome (vertical axis, divided into chromosomes). Gene and miRNA patterns: Molecular subtype and outcome prediction Altered pathways in HGS-OvCa Altered pathways in HGS-OvCa Altered pathways in HGS-OvCa Altered pathways in HGS-OvCa TCGA findings TCGA: large-scale integrative view of aberrations in HGS-OvCa Mutational spectrum “surprisingly simple” TP53 predominated = 96% BRCA1 and BRCA2 =22% Seven other significantly mutated genes = 2–6% HGS-OvCa is distinct from other histological subtypes Clear-cell: few TP53; recurrent ARID1A, PIK3CA mutations Endometrioid: frequent CTNNB1, ARID1A and PIK3CA; fewer TP53 Mucinous: prevalent KRAS mutations
Slide 29 - Ovarian Cancer in the Genomics Era Christina M. Annunziata, MD, PhD Medical Oncology Branch National Cancer Institute Bethesda, MD Ovarian Cancer Stage Description Incidence Survival I Confined to ovaries 20% 90% II Confined to pelvis 5% 65% III Spread IP or nodes 58% 45% IV Distant metastases 17% <5% Ovarian Cancer: Prognostic Factors Stage Extent of Cytoreduction Histology and Grade Performance Status p53 Status Vital Organ Function Physiologic Age Platinum+Taxane Primary Therapy Intraperitoneal therapy Information from Second-Look Surgery Genotype BRCA1/2 VEGF Production Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Chemotherapy Clinical Trials The State of Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Full assessment of abdomen and pelvis Random biopsy of visually negative areas Lymph node dissection (except Stage I) Optimal reductive surgery Chemotherapy Clinical Trials Surgical staging of ovarian cancer The State of Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Stage I, II - Complete removal of all disease Stage III, IV - Residual disease < 1 cm Chemotherapy Clinical Trials Optimal Cytoreduction 0 cm 0-1 cm 1-2 cm >2 cm Time since initial surgery (years) Proportion surviving The State of Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Chemotherapy Platinum = cisplatin or carboplatin AND Taxane = paclitaxel or docetaxel Intraperitoneal if Stage III, optimal reduction Clinical Trials 1960 1970 1980 1990 2000 CISPLATIN/ALKYLATOR COMBINATIONS INTRA- PERITONEAL PACLITAXEL/ CARBOPLATIN ALKYLATORS CISPLATIN 5 YR SURVIVAL ADVANCED DISEASE 40% 35% 15% 5% 0 1960 1970 1980 1990 2000 Timeline of Treatment and Outcome for Advanced Ovarian Cancer Representative Chemotherapy Agents Platinum Paclitaxel Topotecan Gemcitabine Doxil Target: DNA b-tubulin Topo-I RN-reductase, Nucleotide pool Topo-II Mechanism:DNA adduct formation TubulinAggregation Stabilize DNA-TopoDNA synth DNA Schedule:Independent Dependent(toxicity)Dependent(efficacy) Dependent Phosporylation Prolonged clearance Resistance:GSH, tolerance, retention MDR-MRP, tubulin mutations Topo-I, BCRP RN-reductase MDR-MRP Topo-II Platinum Interaction:N/A Platelet Sparing ---- Enhanced Toxicity ---- GOG 172: The new Standard of Care Epithelial Ovarian Cancer, Optimal Stage III, No prior therapy, Well balanced arms 1. Intravenous therapy, Cisplatin 75 mg/m2 Paclitaxel 135 mg/m2 (24 h), 83% completed 6 cycles 2. Intraperitoneal therapy, Cisplatin 100 mg/m2 IP d1 Paclitaxel 135 mg/m2 (24 h) IV d1 Paclitaxel 60 mg/m2 IP d8, 42% completed 6 cycles Open: 23-Mar-98 Closed: 29-Jan-01 Accrual: 416 pts (evaluable) GOG 172: The new Standard of Care Median survival = 49.7 mo Median survival = 65.6 mo Ovarian Cancer in the Genomics Era Preclinical studies Translational Oncology Observation Hypothesis Experiment / Trial Result Analysis Integrated genomic analyses of ovarian carcinoma The Cancer Genome Atlas Research Network* Nature 474: 609-615 Background The Cancer Genome Atlas (TCGA) Clinically annotated HGS-OvCa samples Identify molecular abnormalities that influence pathophysiology, affect outcome and constitute therapeutic targets. Microarray analyses: 489 HGS-OvCa tumours, mRNA expression, microRNA (miRNA) expression, DNA copy number and DNA promoter methylation for and Whole exome DNA sequence: 316 samples. Methods Sample inclusion criteria Newly diagnosed patients ovarian serous adenocarcinoma no prior treatment regardless of surgical stage or histologic grade Each frozen tumor specimen had to have a companion normal tissue specimen, which could be adjacent normal tissue, peripheral lymphocytes, or previously extracted germline DNA. Methods Clinical data collection Clinical data can be accessed and downloaded from the TCGA Data Portal Demographics, histopathologic information treatment details outcome parameters Methods Mutated genes in HGS-OvCa Genome copy number abnormality Copy number profiles of 489 HGS-OvCa, compared with profiles of 197 glioblastoma multiforme (GBM) tumours. Copy number increases (red) and decreases (blue) are plotted as a function of distance along the normal genome (vertical axis, divided into chromosomes). Gene and miRNA patterns: Molecular subtype and outcome prediction Altered pathways in HGS-OvCa Altered pathways in HGS-OvCa Altered pathways in HGS-OvCa Altered pathways in HGS-OvCa TCGA findings TCGA: large-scale integrative view of aberrations in HGS-OvCa Mutational spectrum “surprisingly simple” TP53 predominated = 96% BRCA1 and BRCA2 =22% Seven other significantly mutated genes = 2–6% HGS-OvCa is distinct from other histological subtypes Clear-cell: few TP53; recurrent ARID1A, PIK3CA mutations Endometrioid: frequent CTNNB1, ARID1A and PIK3CA; fewer TP53 Mucinous: prevalent KRAS mutations TCGA findings “Remarkable degree of genomic disarray” “Striking contrast to previous TCGA findings in glioblastoma” Mutations and promoter methylation in putative DNA repair genes (HR) may explain the high prevalence of SCNAs.
Slide 30 - Ovarian Cancer in the Genomics Era Christina M. Annunziata, MD, PhD Medical Oncology Branch National Cancer Institute Bethesda, MD Ovarian Cancer Stage Description Incidence Survival I Confined to ovaries 20% 90% II Confined to pelvis 5% 65% III Spread IP or nodes 58% 45% IV Distant metastases 17% <5% Ovarian Cancer: Prognostic Factors Stage Extent of Cytoreduction Histology and Grade Performance Status p53 Status Vital Organ Function Physiologic Age Platinum+Taxane Primary Therapy Intraperitoneal therapy Information from Second-Look Surgery Genotype BRCA1/2 VEGF Production Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Chemotherapy Clinical Trials The State of Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Full assessment of abdomen and pelvis Random biopsy of visually negative areas Lymph node dissection (except Stage I) Optimal reductive surgery Chemotherapy Clinical Trials Surgical staging of ovarian cancer The State of Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Stage I, II - Complete removal of all disease Stage III, IV - Residual disease < 1 cm Chemotherapy Clinical Trials Optimal Cytoreduction 0 cm 0-1 cm 1-2 cm >2 cm Time since initial surgery (years) Proportion surviving The State of Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Chemotherapy Platinum = cisplatin or carboplatin AND Taxane = paclitaxel or docetaxel Intraperitoneal if Stage III, optimal reduction Clinical Trials 1960 1970 1980 1990 2000 CISPLATIN/ALKYLATOR COMBINATIONS INTRA- PERITONEAL PACLITAXEL/ CARBOPLATIN ALKYLATORS CISPLATIN 5 YR SURVIVAL ADVANCED DISEASE 40% 35% 15% 5% 0 1960 1970 1980 1990 2000 Timeline of Treatment and Outcome for Advanced Ovarian Cancer Representative Chemotherapy Agents Platinum Paclitaxel Topotecan Gemcitabine Doxil Target: DNA b-tubulin Topo-I RN-reductase, Nucleotide pool Topo-II Mechanism:DNA adduct formation TubulinAggregation Stabilize DNA-TopoDNA synth DNA Schedule:Independent Dependent(toxicity)Dependent(efficacy) Dependent Phosporylation Prolonged clearance Resistance:GSH, tolerance, retention MDR-MRP, tubulin mutations Topo-I, BCRP RN-reductase MDR-MRP Topo-II Platinum Interaction:N/A Platelet Sparing ---- Enhanced Toxicity ---- GOG 172: The new Standard of Care Epithelial Ovarian Cancer, Optimal Stage III, No prior therapy, Well balanced arms 1. Intravenous therapy, Cisplatin 75 mg/m2 Paclitaxel 135 mg/m2 (24 h), 83% completed 6 cycles 2. Intraperitoneal therapy, Cisplatin 100 mg/m2 IP d1 Paclitaxel 135 mg/m2 (24 h) IV d1 Paclitaxel 60 mg/m2 IP d8, 42% completed 6 cycles Open: 23-Mar-98 Closed: 29-Jan-01 Accrual: 416 pts (evaluable) GOG 172: The new Standard of Care Median survival = 49.7 mo Median survival = 65.6 mo Ovarian Cancer in the Genomics Era Preclinical studies Translational Oncology Observation Hypothesis Experiment / Trial Result Analysis Integrated genomic analyses of ovarian carcinoma The Cancer Genome Atlas Research Network* Nature 474: 609-615 Background The Cancer Genome Atlas (TCGA) Clinically annotated HGS-OvCa samples Identify molecular abnormalities that influence pathophysiology, affect outcome and constitute therapeutic targets. Microarray analyses: 489 HGS-OvCa tumours, mRNA expression, microRNA (miRNA) expression, DNA copy number and DNA promoter methylation for and Whole exome DNA sequence: 316 samples. Methods Sample inclusion criteria Newly diagnosed patients ovarian serous adenocarcinoma no prior treatment regardless of surgical stage or histologic grade Each frozen tumor specimen had to have a companion normal tissue specimen, which could be adjacent normal tissue, peripheral lymphocytes, or previously extracted germline DNA. Methods Clinical data collection Clinical data can be accessed and downloaded from the TCGA Data Portal Demographics, histopathologic information treatment details outcome parameters Methods Mutated genes in HGS-OvCa Genome copy number abnormality Copy number profiles of 489 HGS-OvCa, compared with profiles of 197 glioblastoma multiforme (GBM) tumours. Copy number increases (red) and decreases (blue) are plotted as a function of distance along the normal genome (vertical axis, divided into chromosomes). Gene and miRNA patterns: Molecular subtype and outcome prediction Altered pathways in HGS-OvCa Altered pathways in HGS-OvCa Altered pathways in HGS-OvCa Altered pathways in HGS-OvCa TCGA findings TCGA: large-scale integrative view of aberrations in HGS-OvCa Mutational spectrum “surprisingly simple” TP53 predominated = 96% BRCA1 and BRCA2 =22% Seven other significantly mutated genes = 2–6% HGS-OvCa is distinct from other histological subtypes Clear-cell: few TP53; recurrent ARID1A, PIK3CA mutations Endometrioid: frequent CTNNB1, ARID1A and PIK3CA; fewer TP53 Mucinous: prevalent KRAS mutations TCGA findings “Remarkable degree of genomic disarray” “Striking contrast to previous TCGA findings in glioblastoma” Mutations and promoter methylation in putative DNA repair genes (HR) may explain the high prevalence of SCNAs. TCGA – what next? New therapeutic approaches? 50% with HR defects : PARP inhibitors commonly deregulated pathways: RB, RAS/PI3K, FOXM1, NOTCH, provide opportunities for therapeutic treatment Inhibitors exist for 22 genes in regions of recurrent amplification aberrant genes or networks: targeted therapies selected to be effective ...
Slide 31 - Ovarian Cancer in the Genomics Era Christina M. Annunziata, MD, PhD Medical Oncology Branch National Cancer Institute Bethesda, MD Ovarian Cancer Stage Description Incidence Survival I Confined to ovaries 20% 90% II Confined to pelvis 5% 65% III Spread IP or nodes 58% 45% IV Distant metastases 17% <5% Ovarian Cancer: Prognostic Factors Stage Extent of Cytoreduction Histology and Grade Performance Status p53 Status Vital Organ Function Physiologic Age Platinum+Taxane Primary Therapy Intraperitoneal therapy Information from Second-Look Surgery Genotype BRCA1/2 VEGF Production Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Chemotherapy Clinical Trials The State of Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Full assessment of abdomen and pelvis Random biopsy of visually negative areas Lymph node dissection (except Stage I) Optimal reductive surgery Chemotherapy Clinical Trials Surgical staging of ovarian cancer The State of Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Stage I, II - Complete removal of all disease Stage III, IV - Residual disease < 1 cm Chemotherapy Clinical Trials Optimal Cytoreduction 0 cm 0-1 cm 1-2 cm >2 cm Time since initial surgery (years) Proportion surviving The State of Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Chemotherapy Platinum = cisplatin or carboplatin AND Taxane = paclitaxel or docetaxel Intraperitoneal if Stage III, optimal reduction Clinical Trials 1960 1970 1980 1990 2000 CISPLATIN/ALKYLATOR COMBINATIONS INTRA- PERITONEAL PACLITAXEL/ CARBOPLATIN ALKYLATORS CISPLATIN 5 YR SURVIVAL ADVANCED DISEASE 40% 35% 15% 5% 0 1960 1970 1980 1990 2000 Timeline of Treatment and Outcome for Advanced Ovarian Cancer Representative Chemotherapy Agents Platinum Paclitaxel Topotecan Gemcitabine Doxil Target: DNA b-tubulin Topo-I RN-reductase, Nucleotide pool Topo-II Mechanism:DNA adduct formation TubulinAggregation Stabilize DNA-TopoDNA synth DNA Schedule:Independent Dependent(toxicity)Dependent(efficacy) Dependent Phosporylation Prolonged clearance Resistance:GSH, tolerance, retention MDR-MRP, tubulin mutations Topo-I, BCRP RN-reductase MDR-MRP Topo-II Platinum Interaction:N/A Platelet Sparing ---- Enhanced Toxicity ---- GOG 172: The new Standard of Care Epithelial Ovarian Cancer, Optimal Stage III, No prior therapy, Well balanced arms 1. Intravenous therapy, Cisplatin 75 mg/m2 Paclitaxel 135 mg/m2 (24 h), 83% completed 6 cycles 2. Intraperitoneal therapy, Cisplatin 100 mg/m2 IP d1 Paclitaxel 135 mg/m2 (24 h) IV d1 Paclitaxel 60 mg/m2 IP d8, 42% completed 6 cycles Open: 23-Mar-98 Closed: 29-Jan-01 Accrual: 416 pts (evaluable) GOG 172: The new Standard of Care Median survival = 49.7 mo Median survival = 65.6 mo Ovarian Cancer in the Genomics Era Preclinical studies Translational Oncology Observation Hypothesis Experiment / Trial Result Analysis Integrated genomic analyses of ovarian carcinoma The Cancer Genome Atlas Research Network* Nature 474: 609-615 Background The Cancer Genome Atlas (TCGA) Clinically annotated HGS-OvCa samples Identify molecular abnormalities that influence pathophysiology, affect outcome and constitute therapeutic targets. Microarray analyses: 489 HGS-OvCa tumours, mRNA expression, microRNA (miRNA) expression, DNA copy number and DNA promoter methylation for and Whole exome DNA sequence: 316 samples. Methods Sample inclusion criteria Newly diagnosed patients ovarian serous adenocarcinoma no prior treatment regardless of surgical stage or histologic grade Each frozen tumor specimen had to have a companion normal tissue specimen, which could be adjacent normal tissue, peripheral lymphocytes, or previously extracted germline DNA. Methods Clinical data collection Clinical data can be accessed and downloaded from the TCGA Data Portal Demographics, histopathologic information treatment details outcome parameters Methods Mutated genes in HGS-OvCa Genome copy number abnormality Copy number profiles of 489 HGS-OvCa, compared with profiles of 197 glioblastoma multiforme (GBM) tumours. Copy number increases (red) and decreases (blue) are plotted as a function of distance along the normal genome (vertical axis, divided into chromosomes). Gene and miRNA patterns: Molecular subtype and outcome prediction Altered pathways in HGS-OvCa Altered pathways in HGS-OvCa Altered pathways in HGS-OvCa Altered pathways in HGS-OvCa TCGA findings TCGA: large-scale integrative view of aberrations in HGS-OvCa Mutational spectrum “surprisingly simple” TP53 predominated = 96% BRCA1 and BRCA2 =22% Seven other significantly mutated genes = 2–6% HGS-OvCa is distinct from other histological subtypes Clear-cell: few TP53; recurrent ARID1A, PIK3CA mutations Endometrioid: frequent CTNNB1, ARID1A and PIK3CA; fewer TP53 Mucinous: prevalent KRAS mutations TCGA findings “Remarkable degree of genomic disarray” “Striking contrast to previous TCGA findings in glioblastoma” Mutations and promoter methylation in putative DNA repair genes (HR) may explain the high prevalence of SCNAs. TCGA – what next? New therapeutic approaches? 50% with HR defects : PARP inhibitors commonly deregulated pathways: RB, RAS/PI3K, FOXM1, NOTCH, provide opportunities for therapeutic treatment Inhibitors exist for 22 genes in regions of recurrent amplification aberrant genes or networks: targeted therapies selected to be effective ... The State of Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Chemotherapy Clinical Trials: targeted therapies
Slide 32 - Ovarian Cancer in the Genomics Era Christina M. Annunziata, MD, PhD Medical Oncology Branch National Cancer Institute Bethesda, MD Ovarian Cancer Stage Description Incidence Survival I Confined to ovaries 20% 90% II Confined to pelvis 5% 65% III Spread IP or nodes 58% 45% IV Distant metastases 17% <5% Ovarian Cancer: Prognostic Factors Stage Extent of Cytoreduction Histology and Grade Performance Status p53 Status Vital Organ Function Physiologic Age Platinum+Taxane Primary Therapy Intraperitoneal therapy Information from Second-Look Surgery Genotype BRCA1/2 VEGF Production Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Chemotherapy Clinical Trials The State of Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Full assessment of abdomen and pelvis Random biopsy of visually negative areas Lymph node dissection (except Stage I) Optimal reductive surgery Chemotherapy Clinical Trials Surgical staging of ovarian cancer The State of Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Stage I, II - Complete removal of all disease Stage III, IV - Residual disease < 1 cm Chemotherapy Clinical Trials Optimal Cytoreduction 0 cm 0-1 cm 1-2 cm >2 cm Time since initial surgery (years) Proportion surviving The State of Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Chemotherapy Platinum = cisplatin or carboplatin AND Taxane = paclitaxel or docetaxel Intraperitoneal if Stage III, optimal reduction Clinical Trials 1960 1970 1980 1990 2000 CISPLATIN/ALKYLATOR COMBINATIONS INTRA- PERITONEAL PACLITAXEL/ CARBOPLATIN ALKYLATORS CISPLATIN 5 YR SURVIVAL ADVANCED DISEASE 40% 35% 15% 5% 0 1960 1970 1980 1990 2000 Timeline of Treatment and Outcome for Advanced Ovarian Cancer Representative Chemotherapy Agents Platinum Paclitaxel Topotecan Gemcitabine Doxil Target: DNA b-tubulin Topo-I RN-reductase, Nucleotide pool Topo-II Mechanism:DNA adduct formation TubulinAggregation Stabilize DNA-TopoDNA synth DNA Schedule:Independent Dependent(toxicity)Dependent(efficacy) Dependent Phosporylation Prolonged clearance Resistance:GSH, tolerance, retention MDR-MRP, tubulin mutations Topo-I, BCRP RN-reductase MDR-MRP Topo-II Platinum Interaction:N/A Platelet Sparing ---- Enhanced Toxicity ---- GOG 172: The new Standard of Care Epithelial Ovarian Cancer, Optimal Stage III, No prior therapy, Well balanced arms 1. Intravenous therapy, Cisplatin 75 mg/m2 Paclitaxel 135 mg/m2 (24 h), 83% completed 6 cycles 2. Intraperitoneal therapy, Cisplatin 100 mg/m2 IP d1 Paclitaxel 135 mg/m2 (24 h) IV d1 Paclitaxel 60 mg/m2 IP d8, 42% completed 6 cycles Open: 23-Mar-98 Closed: 29-Jan-01 Accrual: 416 pts (evaluable) GOG 172: The new Standard of Care Median survival = 49.7 mo Median survival = 65.6 mo Ovarian Cancer in the Genomics Era Preclinical studies Translational Oncology Observation Hypothesis Experiment / Trial Result Analysis Integrated genomic analyses of ovarian carcinoma The Cancer Genome Atlas Research Network* Nature 474: 609-615 Background The Cancer Genome Atlas (TCGA) Clinically annotated HGS-OvCa samples Identify molecular abnormalities that influence pathophysiology, affect outcome and constitute therapeutic targets. Microarray analyses: 489 HGS-OvCa tumours, mRNA expression, microRNA (miRNA) expression, DNA copy number and DNA promoter methylation for and Whole exome DNA sequence: 316 samples. Methods Sample inclusion criteria Newly diagnosed patients ovarian serous adenocarcinoma no prior treatment regardless of surgical stage or histologic grade Each frozen tumor specimen had to have a companion normal tissue specimen, which could be adjacent normal tissue, peripheral lymphocytes, or previously extracted germline DNA. Methods Clinical data collection Clinical data can be accessed and downloaded from the TCGA Data Portal Demographics, histopathologic information treatment details outcome parameters Methods Mutated genes in HGS-OvCa Genome copy number abnormality Copy number profiles of 489 HGS-OvCa, compared with profiles of 197 glioblastoma multiforme (GBM) tumours. Copy number increases (red) and decreases (blue) are plotted as a function of distance along the normal genome (vertical axis, divided into chromosomes). Gene and miRNA patterns: Molecular subtype and outcome prediction Altered pathways in HGS-OvCa Altered pathways in HGS-OvCa Altered pathways in HGS-OvCa Altered pathways in HGS-OvCa TCGA findings TCGA: large-scale integrative view of aberrations in HGS-OvCa Mutational spectrum “surprisingly simple” TP53 predominated = 96% BRCA1 and BRCA2 =22% Seven other significantly mutated genes = 2–6% HGS-OvCa is distinct from other histological subtypes Clear-cell: few TP53; recurrent ARID1A, PIK3CA mutations Endometrioid: frequent CTNNB1, ARID1A and PIK3CA; fewer TP53 Mucinous: prevalent KRAS mutations TCGA findings “Remarkable degree of genomic disarray” “Striking contrast to previous TCGA findings in glioblastoma” Mutations and promoter methylation in putative DNA repair genes (HR) may explain the high prevalence of SCNAs. TCGA – what next? New therapeutic approaches? 50% with HR defects : PARP inhibitors commonly deregulated pathways: RB, RAS/PI3K, FOXM1, NOTCH, provide opportunities for therapeutic treatment Inhibitors exist for 22 genes in regions of recurrent amplification aberrant genes or networks: targeted therapies selected to be effective ... The State of Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Chemotherapy Clinical Trials: targeted therapies Translational Oncology Observation Hypothesis Experiment / Trial Result Analysis
Slide 33 - Ovarian Cancer in the Genomics Era Christina M. Annunziata, MD, PhD Medical Oncology Branch National Cancer Institute Bethesda, MD Ovarian Cancer Stage Description Incidence Survival I Confined to ovaries 20% 90% II Confined to pelvis 5% 65% III Spread IP or nodes 58% 45% IV Distant metastases 17% <5% Ovarian Cancer: Prognostic Factors Stage Extent of Cytoreduction Histology and Grade Performance Status p53 Status Vital Organ Function Physiologic Age Platinum+Taxane Primary Therapy Intraperitoneal therapy Information from Second-Look Surgery Genotype BRCA1/2 VEGF Production Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Chemotherapy Clinical Trials The State of Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Full assessment of abdomen and pelvis Random biopsy of visually negative areas Lymph node dissection (except Stage I) Optimal reductive surgery Chemotherapy Clinical Trials Surgical staging of ovarian cancer The State of Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Stage I, II - Complete removal of all disease Stage III, IV - Residual disease < 1 cm Chemotherapy Clinical Trials Optimal Cytoreduction 0 cm 0-1 cm 1-2 cm >2 cm Time since initial surgery (years) Proportion surviving The State of Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Chemotherapy Platinum = cisplatin or carboplatin AND Taxane = paclitaxel or docetaxel Intraperitoneal if Stage III, optimal reduction Clinical Trials 1960 1970 1980 1990 2000 CISPLATIN/ALKYLATOR COMBINATIONS INTRA- PERITONEAL PACLITAXEL/ CARBOPLATIN ALKYLATORS CISPLATIN 5 YR SURVIVAL ADVANCED DISEASE 40% 35% 15% 5% 0 1960 1970 1980 1990 2000 Timeline of Treatment and Outcome for Advanced Ovarian Cancer Representative Chemotherapy Agents Platinum Paclitaxel Topotecan Gemcitabine Doxil Target: DNA b-tubulin Topo-I RN-reductase, Nucleotide pool Topo-II Mechanism:DNA adduct formation TubulinAggregation Stabilize DNA-TopoDNA synth DNA Schedule:Independent Dependent(toxicity)Dependent(efficacy) Dependent Phosporylation Prolonged clearance Resistance:GSH, tolerance, retention MDR-MRP, tubulin mutations Topo-I, BCRP RN-reductase MDR-MRP Topo-II Platinum Interaction:N/A Platelet Sparing ---- Enhanced Toxicity ---- GOG 172: The new Standard of Care Epithelial Ovarian Cancer, Optimal Stage III, No prior therapy, Well balanced arms 1. Intravenous therapy, Cisplatin 75 mg/m2 Paclitaxel 135 mg/m2 (24 h), 83% completed 6 cycles 2. Intraperitoneal therapy, Cisplatin 100 mg/m2 IP d1 Paclitaxel 135 mg/m2 (24 h) IV d1 Paclitaxel 60 mg/m2 IP d8, 42% completed 6 cycles Open: 23-Mar-98 Closed: 29-Jan-01 Accrual: 416 pts (evaluable) GOG 172: The new Standard of Care Median survival = 49.7 mo Median survival = 65.6 mo Ovarian Cancer in the Genomics Era Preclinical studies Translational Oncology Observation Hypothesis Experiment / Trial Result Analysis Integrated genomic analyses of ovarian carcinoma The Cancer Genome Atlas Research Network* Nature 474: 609-615 Background The Cancer Genome Atlas (TCGA) Clinically annotated HGS-OvCa samples Identify molecular abnormalities that influence pathophysiology, affect outcome and constitute therapeutic targets. Microarray analyses: 489 HGS-OvCa tumours, mRNA expression, microRNA (miRNA) expression, DNA copy number and DNA promoter methylation for and Whole exome DNA sequence: 316 samples. Methods Sample inclusion criteria Newly diagnosed patients ovarian serous adenocarcinoma no prior treatment regardless of surgical stage or histologic grade Each frozen tumor specimen had to have a companion normal tissue specimen, which could be adjacent normal tissue, peripheral lymphocytes, or previously extracted germline DNA. Methods Clinical data collection Clinical data can be accessed and downloaded from the TCGA Data Portal Demographics, histopathologic information treatment details outcome parameters Methods Mutated genes in HGS-OvCa Genome copy number abnormality Copy number profiles of 489 HGS-OvCa, compared with profiles of 197 glioblastoma multiforme (GBM) tumours. Copy number increases (red) and decreases (blue) are plotted as a function of distance along the normal genome (vertical axis, divided into chromosomes). Gene and miRNA patterns: Molecular subtype and outcome prediction Altered pathways in HGS-OvCa Altered pathways in HGS-OvCa Altered pathways in HGS-OvCa Altered pathways in HGS-OvCa TCGA findings TCGA: large-scale integrative view of aberrations in HGS-OvCa Mutational spectrum “surprisingly simple” TP53 predominated = 96% BRCA1 and BRCA2 =22% Seven other significantly mutated genes = 2–6% HGS-OvCa is distinct from other histological subtypes Clear-cell: few TP53; recurrent ARID1A, PIK3CA mutations Endometrioid: frequent CTNNB1, ARID1A and PIK3CA; fewer TP53 Mucinous: prevalent KRAS mutations TCGA findings “Remarkable degree of genomic disarray” “Striking contrast to previous TCGA findings in glioblastoma” Mutations and promoter methylation in putative DNA repair genes (HR) may explain the high prevalence of SCNAs. TCGA – what next? New therapeutic approaches? 50% with HR defects : PARP inhibitors commonly deregulated pathways: RB, RAS/PI3K, FOXM1, NOTCH, provide opportunities for therapeutic treatment Inhibitors exist for 22 genes in regions of recurrent amplification aberrant genes or networks: targeted therapies selected to be effective ... The State of Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Chemotherapy Clinical Trials: targeted therapies Translational Oncology Observation Hypothesis Experiment / Trial Result Analysis Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced ovarian cancer American Society of Clinical Oncology, 2009 Presenter: M William Audeh From genomic aberration to pathway
Slide 34 - Ovarian Cancer in the Genomics Era Christina M. Annunziata, MD, PhD Medical Oncology Branch National Cancer Institute Bethesda, MD Ovarian Cancer Stage Description Incidence Survival I Confined to ovaries 20% 90% II Confined to pelvis 5% 65% III Spread IP or nodes 58% 45% IV Distant metastases 17% <5% Ovarian Cancer: Prognostic Factors Stage Extent of Cytoreduction Histology and Grade Performance Status p53 Status Vital Organ Function Physiologic Age Platinum+Taxane Primary Therapy Intraperitoneal therapy Information from Second-Look Surgery Genotype BRCA1/2 VEGF Production Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Chemotherapy Clinical Trials The State of Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Full assessment of abdomen and pelvis Random biopsy of visually negative areas Lymph node dissection (except Stage I) Optimal reductive surgery Chemotherapy Clinical Trials Surgical staging of ovarian cancer The State of Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Stage I, II - Complete removal of all disease Stage III, IV - Residual disease < 1 cm Chemotherapy Clinical Trials Optimal Cytoreduction 0 cm 0-1 cm 1-2 cm >2 cm Time since initial surgery (years) Proportion surviving The State of Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Chemotherapy Platinum = cisplatin or carboplatin AND Taxane = paclitaxel or docetaxel Intraperitoneal if Stage III, optimal reduction Clinical Trials 1960 1970 1980 1990 2000 CISPLATIN/ALKYLATOR COMBINATIONS INTRA- PERITONEAL PACLITAXEL/ CARBOPLATIN ALKYLATORS CISPLATIN 5 YR SURVIVAL ADVANCED DISEASE 40% 35% 15% 5% 0 1960 1970 1980 1990 2000 Timeline of Treatment and Outcome for Advanced Ovarian Cancer Representative Chemotherapy Agents Platinum Paclitaxel Topotecan Gemcitabine Doxil Target: DNA b-tubulin Topo-I RN-reductase, Nucleotide pool Topo-II Mechanism:DNA adduct formation TubulinAggregation Stabilize DNA-TopoDNA synth DNA Schedule:Independent Dependent(toxicity)Dependent(efficacy) Dependent Phosporylation Prolonged clearance Resistance:GSH, tolerance, retention MDR-MRP, tubulin mutations Topo-I, BCRP RN-reductase MDR-MRP Topo-II Platinum Interaction:N/A Platelet Sparing ---- Enhanced Toxicity ---- GOG 172: The new Standard of Care Epithelial Ovarian Cancer, Optimal Stage III, No prior therapy, Well balanced arms 1. Intravenous therapy, Cisplatin 75 mg/m2 Paclitaxel 135 mg/m2 (24 h), 83% completed 6 cycles 2. Intraperitoneal therapy, Cisplatin 100 mg/m2 IP d1 Paclitaxel 135 mg/m2 (24 h) IV d1 Paclitaxel 60 mg/m2 IP d8, 42% completed 6 cycles Open: 23-Mar-98 Closed: 29-Jan-01 Accrual: 416 pts (evaluable) GOG 172: The new Standard of Care Median survival = 49.7 mo Median survival = 65.6 mo Ovarian Cancer in the Genomics Era Preclinical studies Translational Oncology Observation Hypothesis Experiment / Trial Result Analysis Integrated genomic analyses of ovarian carcinoma The Cancer Genome Atlas Research Network* Nature 474: 609-615 Background The Cancer Genome Atlas (TCGA) Clinically annotated HGS-OvCa samples Identify molecular abnormalities that influence pathophysiology, affect outcome and constitute therapeutic targets. Microarray analyses: 489 HGS-OvCa tumours, mRNA expression, microRNA (miRNA) expression, DNA copy number and DNA promoter methylation for and Whole exome DNA sequence: 316 samples. Methods Sample inclusion criteria Newly diagnosed patients ovarian serous adenocarcinoma no prior treatment regardless of surgical stage or histologic grade Each frozen tumor specimen had to have a companion normal tissue specimen, which could be adjacent normal tissue, peripheral lymphocytes, or previously extracted germline DNA. Methods Clinical data collection Clinical data can be accessed and downloaded from the TCGA Data Portal Demographics, histopathologic information treatment details outcome parameters Methods Mutated genes in HGS-OvCa Genome copy number abnormality Copy number profiles of 489 HGS-OvCa, compared with profiles of 197 glioblastoma multiforme (GBM) tumours. Copy number increases (red) and decreases (blue) are plotted as a function of distance along the normal genome (vertical axis, divided into chromosomes). Gene and miRNA patterns: Molecular subtype and outcome prediction Altered pathways in HGS-OvCa Altered pathways in HGS-OvCa Altered pathways in HGS-OvCa Altered pathways in HGS-OvCa TCGA findings TCGA: large-scale integrative view of aberrations in HGS-OvCa Mutational spectrum “surprisingly simple” TP53 predominated = 96% BRCA1 and BRCA2 =22% Seven other significantly mutated genes = 2–6% HGS-OvCa is distinct from other histological subtypes Clear-cell: few TP53; recurrent ARID1A, PIK3CA mutations Endometrioid: frequent CTNNB1, ARID1A and PIK3CA; fewer TP53 Mucinous: prevalent KRAS mutations TCGA findings “Remarkable degree of genomic disarray” “Striking contrast to previous TCGA findings in glioblastoma” Mutations and promoter methylation in putative DNA repair genes (HR) may explain the high prevalence of SCNAs. TCGA – what next? New therapeutic approaches? 50% with HR defects : PARP inhibitors commonly deregulated pathways: RB, RAS/PI3K, FOXM1, NOTCH, provide opportunities for therapeutic treatment Inhibitors exist for 22 genes in regions of recurrent amplification aberrant genes or networks: targeted therapies selected to be effective ... The State of Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Chemotherapy Clinical Trials: targeted therapies Translational Oncology Observation Hypothesis Experiment / Trial Result Analysis Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced ovarian cancer American Society of Clinical Oncology, 2009 Presenter: M William Audeh From genomic aberration to pathway PARP PARP inhibition: BRCA-mutant cancers
Slide 35 - Ovarian Cancer in the Genomics Era Christina M. Annunziata, MD, PhD Medical Oncology Branch National Cancer Institute Bethesda, MD Ovarian Cancer Stage Description Incidence Survival I Confined to ovaries 20% 90% II Confined to pelvis 5% 65% III Spread IP or nodes 58% 45% IV Distant metastases 17% <5% Ovarian Cancer: Prognostic Factors Stage Extent of Cytoreduction Histology and Grade Performance Status p53 Status Vital Organ Function Physiologic Age Platinum+Taxane Primary Therapy Intraperitoneal therapy Information from Second-Look Surgery Genotype BRCA1/2 VEGF Production Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Chemotherapy Clinical Trials The State of Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Full assessment of abdomen and pelvis Random biopsy of visually negative areas Lymph node dissection (except Stage I) Optimal reductive surgery Chemotherapy Clinical Trials Surgical staging of ovarian cancer The State of Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Stage I, II - Complete removal of all disease Stage III, IV - Residual disease < 1 cm Chemotherapy Clinical Trials Optimal Cytoreduction 0 cm 0-1 cm 1-2 cm >2 cm Time since initial surgery (years) Proportion surviving The State of Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Chemotherapy Platinum = cisplatin or carboplatin AND Taxane = paclitaxel or docetaxel Intraperitoneal if Stage III, optimal reduction Clinical Trials 1960 1970 1980 1990 2000 CISPLATIN/ALKYLATOR COMBINATIONS INTRA- PERITONEAL PACLITAXEL/ CARBOPLATIN ALKYLATORS CISPLATIN 5 YR SURVIVAL ADVANCED DISEASE 40% 35% 15% 5% 0 1960 1970 1980 1990 2000 Timeline of Treatment and Outcome for Advanced Ovarian Cancer Representative Chemotherapy Agents Platinum Paclitaxel Topotecan Gemcitabine Doxil Target: DNA b-tubulin Topo-I RN-reductase, Nucleotide pool Topo-II Mechanism:DNA adduct formation TubulinAggregation Stabilize DNA-TopoDNA synth DNA Schedule:Independent Dependent(toxicity)Dependent(efficacy) Dependent Phosporylation Prolonged clearance Resistance:GSH, tolerance, retention MDR-MRP, tubulin mutations Topo-I, BCRP RN-reductase MDR-MRP Topo-II Platinum Interaction:N/A Platelet Sparing ---- Enhanced Toxicity ---- GOG 172: The new Standard of Care Epithelial Ovarian Cancer, Optimal Stage III, No prior therapy, Well balanced arms 1. Intravenous therapy, Cisplatin 75 mg/m2 Paclitaxel 135 mg/m2 (24 h), 83% completed 6 cycles 2. Intraperitoneal therapy, Cisplatin 100 mg/m2 IP d1 Paclitaxel 135 mg/m2 (24 h) IV d1 Paclitaxel 60 mg/m2 IP d8, 42% completed 6 cycles Open: 23-Mar-98 Closed: 29-Jan-01 Accrual: 416 pts (evaluable) GOG 172: The new Standard of Care Median survival = 49.7 mo Median survival = 65.6 mo Ovarian Cancer in the Genomics Era Preclinical studies Translational Oncology Observation Hypothesis Experiment / Trial Result Analysis Integrated genomic analyses of ovarian carcinoma The Cancer Genome Atlas Research Network* Nature 474: 609-615 Background The Cancer Genome Atlas (TCGA) Clinically annotated HGS-OvCa samples Identify molecular abnormalities that influence pathophysiology, affect outcome and constitute therapeutic targets. Microarray analyses: 489 HGS-OvCa tumours, mRNA expression, microRNA (miRNA) expression, DNA copy number and DNA promoter methylation for and Whole exome DNA sequence: 316 samples. Methods Sample inclusion criteria Newly diagnosed patients ovarian serous adenocarcinoma no prior treatment regardless of surgical stage or histologic grade Each frozen tumor specimen had to have a companion normal tissue specimen, which could be adjacent normal tissue, peripheral lymphocytes, or previously extracted germline DNA. Methods Clinical data collection Clinical data can be accessed and downloaded from the TCGA Data Portal Demographics, histopathologic information treatment details outcome parameters Methods Mutated genes in HGS-OvCa Genome copy number abnormality Copy number profiles of 489 HGS-OvCa, compared with profiles of 197 glioblastoma multiforme (GBM) tumours. Copy number increases (red) and decreases (blue) are plotted as a function of distance along the normal genome (vertical axis, divided into chromosomes). Gene and miRNA patterns: Molecular subtype and outcome prediction Altered pathways in HGS-OvCa Altered pathways in HGS-OvCa Altered pathways in HGS-OvCa Altered pathways in HGS-OvCa TCGA findings TCGA: large-scale integrative view of aberrations in HGS-OvCa Mutational spectrum “surprisingly simple” TP53 predominated = 96% BRCA1 and BRCA2 =22% Seven other significantly mutated genes = 2–6% HGS-OvCa is distinct from other histological subtypes Clear-cell: few TP53; recurrent ARID1A, PIK3CA mutations Endometrioid: frequent CTNNB1, ARID1A and PIK3CA; fewer TP53 Mucinous: prevalent KRAS mutations TCGA findings “Remarkable degree of genomic disarray” “Striking contrast to previous TCGA findings in glioblastoma” Mutations and promoter methylation in putative DNA repair genes (HR) may explain the high prevalence of SCNAs. TCGA – what next? New therapeutic approaches? 50% with HR defects : PARP inhibitors commonly deregulated pathways: RB, RAS/PI3K, FOXM1, NOTCH, provide opportunities for therapeutic treatment Inhibitors exist for 22 genes in regions of recurrent amplification aberrant genes or networks: targeted therapies selected to be effective ... The State of Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Chemotherapy Clinical Trials: targeted therapies Translational Oncology Observation Hypothesis Experiment / Trial Result Analysis Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced ovarian cancer American Society of Clinical Oncology, 2009 Presenter: M William Audeh From genomic aberration to pathway PARP PARP inhibition: BRCA-mutant cancers Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced ovarian cancer Olaparib (AZD2281) novel, orally active PARP inhibitor synthetic lethality in homozygous BRCA-mut cells The primary aim of this study was to test the efficacy of olaparib in confirmed BRCA1/BRCA2 carriers with advanced refractory ovarian cancer
Slide 36 - Ovarian Cancer in the Genomics Era Christina M. Annunziata, MD, PhD Medical Oncology Branch National Cancer Institute Bethesda, MD Ovarian Cancer Stage Description Incidence Survival I Confined to ovaries 20% 90% II Confined to pelvis 5% 65% III Spread IP or nodes 58% 45% IV Distant metastases 17% <5% Ovarian Cancer: Prognostic Factors Stage Extent of Cytoreduction Histology and Grade Performance Status p53 Status Vital Organ Function Physiologic Age Platinum+Taxane Primary Therapy Intraperitoneal therapy Information from Second-Look Surgery Genotype BRCA1/2 VEGF Production Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Chemotherapy Clinical Trials The State of Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Full assessment of abdomen and pelvis Random biopsy of visually negative areas Lymph node dissection (except Stage I) Optimal reductive surgery Chemotherapy Clinical Trials Surgical staging of ovarian cancer The State of Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Stage I, II - Complete removal of all disease Stage III, IV - Residual disease < 1 cm Chemotherapy Clinical Trials Optimal Cytoreduction 0 cm 0-1 cm 1-2 cm >2 cm Time since initial surgery (years) Proportion surviving The State of Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Chemotherapy Platinum = cisplatin or carboplatin AND Taxane = paclitaxel or docetaxel Intraperitoneal if Stage III, optimal reduction Clinical Trials 1960 1970 1980 1990 2000 CISPLATIN/ALKYLATOR COMBINATIONS INTRA- PERITONEAL PACLITAXEL/ CARBOPLATIN ALKYLATORS CISPLATIN 5 YR SURVIVAL ADVANCED DISEASE 40% 35% 15% 5% 0 1960 1970 1980 1990 2000 Timeline of Treatment and Outcome for Advanced Ovarian Cancer Representative Chemotherapy Agents Platinum Paclitaxel Topotecan Gemcitabine Doxil Target: DNA b-tubulin Topo-I RN-reductase, Nucleotide pool Topo-II Mechanism:DNA adduct formation TubulinAggregation Stabilize DNA-TopoDNA synth DNA Schedule:Independent Dependent(toxicity)Dependent(efficacy) Dependent Phosporylation Prolonged clearance Resistance:GSH, tolerance, retention MDR-MRP, tubulin mutations Topo-I, BCRP RN-reductase MDR-MRP Topo-II Platinum Interaction:N/A Platelet Sparing ---- Enhanced Toxicity ---- GOG 172: The new Standard of Care Epithelial Ovarian Cancer, Optimal Stage III, No prior therapy, Well balanced arms 1. Intravenous therapy, Cisplatin 75 mg/m2 Paclitaxel 135 mg/m2 (24 h), 83% completed 6 cycles 2. Intraperitoneal therapy, Cisplatin 100 mg/m2 IP d1 Paclitaxel 135 mg/m2 (24 h) IV d1 Paclitaxel 60 mg/m2 IP d8, 42% completed 6 cycles Open: 23-Mar-98 Closed: 29-Jan-01 Accrual: 416 pts (evaluable) GOG 172: The new Standard of Care Median survival = 49.7 mo Median survival = 65.6 mo Ovarian Cancer in the Genomics Era Preclinical studies Translational Oncology Observation Hypothesis Experiment / Trial Result Analysis Integrated genomic analyses of ovarian carcinoma The Cancer Genome Atlas Research Network* Nature 474: 609-615 Background The Cancer Genome Atlas (TCGA) Clinically annotated HGS-OvCa samples Identify molecular abnormalities that influence pathophysiology, affect outcome and constitute therapeutic targets. Microarray analyses: 489 HGS-OvCa tumours, mRNA expression, microRNA (miRNA) expression, DNA copy number and DNA promoter methylation for and Whole exome DNA sequence: 316 samples. Methods Sample inclusion criteria Newly diagnosed patients ovarian serous adenocarcinoma no prior treatment regardless of surgical stage or histologic grade Each frozen tumor specimen had to have a companion normal tissue specimen, which could be adjacent normal tissue, peripheral lymphocytes, or previously extracted germline DNA. Methods Clinical data collection Clinical data can be accessed and downloaded from the TCGA Data Portal Demographics, histopathologic information treatment details outcome parameters Methods Mutated genes in HGS-OvCa Genome copy number abnormality Copy number profiles of 489 HGS-OvCa, compared with profiles of 197 glioblastoma multiforme (GBM) tumours. Copy number increases (red) and decreases (blue) are plotted as a function of distance along the normal genome (vertical axis, divided into chromosomes). Gene and miRNA patterns: Molecular subtype and outcome prediction Altered pathways in HGS-OvCa Altered pathways in HGS-OvCa Altered pathways in HGS-OvCa Altered pathways in HGS-OvCa TCGA findings TCGA: large-scale integrative view of aberrations in HGS-OvCa Mutational spectrum “surprisingly simple” TP53 predominated = 96% BRCA1 and BRCA2 =22% Seven other significantly mutated genes = 2–6% HGS-OvCa is distinct from other histological subtypes Clear-cell: few TP53; recurrent ARID1A, PIK3CA mutations Endometrioid: frequent CTNNB1, ARID1A and PIK3CA; fewer TP53 Mucinous: prevalent KRAS mutations TCGA findings “Remarkable degree of genomic disarray” “Striking contrast to previous TCGA findings in glioblastoma” Mutations and promoter methylation in putative DNA repair genes (HR) may explain the high prevalence of SCNAs. TCGA – what next? New therapeutic approaches? 50% with HR defects : PARP inhibitors commonly deregulated pathways: RB, RAS/PI3K, FOXM1, NOTCH, provide opportunities for therapeutic treatment Inhibitors exist for 22 genes in regions of recurrent amplification aberrant genes or networks: targeted therapies selected to be effective ... The State of Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Chemotherapy Clinical Trials: targeted therapies Translational Oncology Observation Hypothesis Experiment / Trial Result Analysis Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced ovarian cancer American Society of Clinical Oncology, 2009 Presenter: M William Audeh From genomic aberration to pathway PARP PARP inhibition: BRCA-mutant cancers Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced ovarian cancer Olaparib (AZD2281) novel, orally active PARP inhibitor synthetic lethality in homozygous BRCA-mut cells The primary aim of this study was to test the efficacy of olaparib in confirmed BRCA1/BRCA2 carriers with advanced refractory ovarian cancer Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced ovarian cancer Results: 57 enrolled pts 39 BRCA1 deficient and 18 BRCA2 deficient 33 evaluable at 400 mg bid and 24 at 100 mg bid ORR was 33% at 400 mg bd; 12.5% at 100 mg bd Clinical benefit rate: ORR and/or confirmed ≥50% decline in CA125 57.6% at 400 mg bd and 16.7% at 100 mg bd Median PFS: 5.8 mo (med duration 9.6 mo) Toxicity grade 1/2 nausea (44%); fatigue (35%); anemia (14%) Grade 3 toxicity occurred infrequently, and comprised primarily nausea (7%) and leukopenia (5%).
Slide 37 - Ovarian Cancer in the Genomics Era Christina M. Annunziata, MD, PhD Medical Oncology Branch National Cancer Institute Bethesda, MD Ovarian Cancer Stage Description Incidence Survival I Confined to ovaries 20% 90% II Confined to pelvis 5% 65% III Spread IP or nodes 58% 45% IV Distant metastases 17% <5% Ovarian Cancer: Prognostic Factors Stage Extent of Cytoreduction Histology and Grade Performance Status p53 Status Vital Organ Function Physiologic Age Platinum+Taxane Primary Therapy Intraperitoneal therapy Information from Second-Look Surgery Genotype BRCA1/2 VEGF Production Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Chemotherapy Clinical Trials The State of Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Full assessment of abdomen and pelvis Random biopsy of visually negative areas Lymph node dissection (except Stage I) Optimal reductive surgery Chemotherapy Clinical Trials Surgical staging of ovarian cancer The State of Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Stage I, II - Complete removal of all disease Stage III, IV - Residual disease < 1 cm Chemotherapy Clinical Trials Optimal Cytoreduction 0 cm 0-1 cm 1-2 cm >2 cm Time since initial surgery (years) Proportion surviving The State of Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Chemotherapy Platinum = cisplatin or carboplatin AND Taxane = paclitaxel or docetaxel Intraperitoneal if Stage III, optimal reduction Clinical Trials 1960 1970 1980 1990 2000 CISPLATIN/ALKYLATOR COMBINATIONS INTRA- PERITONEAL PACLITAXEL/ CARBOPLATIN ALKYLATORS CISPLATIN 5 YR SURVIVAL ADVANCED DISEASE 40% 35% 15% 5% 0 1960 1970 1980 1990 2000 Timeline of Treatment and Outcome for Advanced Ovarian Cancer Representative Chemotherapy Agents Platinum Paclitaxel Topotecan Gemcitabine Doxil Target: DNA b-tubulin Topo-I RN-reductase, Nucleotide pool Topo-II Mechanism:DNA adduct formation TubulinAggregation Stabilize DNA-TopoDNA synth DNA Schedule:Independent Dependent(toxicity)Dependent(efficacy) Dependent Phosporylation Prolonged clearance Resistance:GSH, tolerance, retention MDR-MRP, tubulin mutations Topo-I, BCRP RN-reductase MDR-MRP Topo-II Platinum Interaction:N/A Platelet Sparing ---- Enhanced Toxicity ---- GOG 172: The new Standard of Care Epithelial Ovarian Cancer, Optimal Stage III, No prior therapy, Well balanced arms 1. Intravenous therapy, Cisplatin 75 mg/m2 Paclitaxel 135 mg/m2 (24 h), 83% completed 6 cycles 2. Intraperitoneal therapy, Cisplatin 100 mg/m2 IP d1 Paclitaxel 135 mg/m2 (24 h) IV d1 Paclitaxel 60 mg/m2 IP d8, 42% completed 6 cycles Open: 23-Mar-98 Closed: 29-Jan-01 Accrual: 416 pts (evaluable) GOG 172: The new Standard of Care Median survival = 49.7 mo Median survival = 65.6 mo Ovarian Cancer in the Genomics Era Preclinical studies Translational Oncology Observation Hypothesis Experiment / Trial Result Analysis Integrated genomic analyses of ovarian carcinoma The Cancer Genome Atlas Research Network* Nature 474: 609-615 Background The Cancer Genome Atlas (TCGA) Clinically annotated HGS-OvCa samples Identify molecular abnormalities that influence pathophysiology, affect outcome and constitute therapeutic targets. Microarray analyses: 489 HGS-OvCa tumours, mRNA expression, microRNA (miRNA) expression, DNA copy number and DNA promoter methylation for and Whole exome DNA sequence: 316 samples. Methods Sample inclusion criteria Newly diagnosed patients ovarian serous adenocarcinoma no prior treatment regardless of surgical stage or histologic grade Each frozen tumor specimen had to have a companion normal tissue specimen, which could be adjacent normal tissue, peripheral lymphocytes, or previously extracted germline DNA. Methods Clinical data collection Clinical data can be accessed and downloaded from the TCGA Data Portal Demographics, histopathologic information treatment details outcome parameters Methods Mutated genes in HGS-OvCa Genome copy number abnormality Copy number profiles of 489 HGS-OvCa, compared with profiles of 197 glioblastoma multiforme (GBM) tumours. Copy number increases (red) and decreases (blue) are plotted as a function of distance along the normal genome (vertical axis, divided into chromosomes). Gene and miRNA patterns: Molecular subtype and outcome prediction Altered pathways in HGS-OvCa Altered pathways in HGS-OvCa Altered pathways in HGS-OvCa Altered pathways in HGS-OvCa TCGA findings TCGA: large-scale integrative view of aberrations in HGS-OvCa Mutational spectrum “surprisingly simple” TP53 predominated = 96% BRCA1 and BRCA2 =22% Seven other significantly mutated genes = 2–6% HGS-OvCa is distinct from other histological subtypes Clear-cell: few TP53; recurrent ARID1A, PIK3CA mutations Endometrioid: frequent CTNNB1, ARID1A and PIK3CA; fewer TP53 Mucinous: prevalent KRAS mutations TCGA findings “Remarkable degree of genomic disarray” “Striking contrast to previous TCGA findings in glioblastoma” Mutations and promoter methylation in putative DNA repair genes (HR) may explain the high prevalence of SCNAs. TCGA – what next? New therapeutic approaches? 50% with HR defects : PARP inhibitors commonly deregulated pathways: RB, RAS/PI3K, FOXM1, NOTCH, provide opportunities for therapeutic treatment Inhibitors exist for 22 genes in regions of recurrent amplification aberrant genes or networks: targeted therapies selected to be effective ... The State of Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Chemotherapy Clinical Trials: targeted therapies Translational Oncology Observation Hypothesis Experiment / Trial Result Analysis Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced ovarian cancer American Society of Clinical Oncology, 2009 Presenter: M William Audeh From genomic aberration to pathway PARP PARP inhibition: BRCA-mutant cancers Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced ovarian cancer Olaparib (AZD2281) novel, orally active PARP inhibitor synthetic lethality in homozygous BRCA-mut cells The primary aim of this study was to test the efficacy of olaparib in confirmed BRCA1/BRCA2 carriers with advanced refractory ovarian cancer Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced ovarian cancer Results: 57 enrolled pts 39 BRCA1 deficient and 18 BRCA2 deficient 33 evaluable at 400 mg bid and 24 at 100 mg bid ORR was 33% at 400 mg bd; 12.5% at 100 mg bd Clinical benefit rate: ORR and/or confirmed ≥50% decline in CA125 57.6% at 400 mg bd and 16.7% at 100 mg bd Median PFS: 5.8 mo (med duration 9.6 mo) Toxicity grade 1/2 nausea (44%); fatigue (35%); anemia (14%) Grade 3 toxicity occurred infrequently, and comprised primarily nausea (7%) and leukopenia (5%). Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced ovarian cancer Audeh, et al. Lancet 376:245 – 251 (2010)
Slide 38 - Ovarian Cancer in the Genomics Era Christina M. Annunziata, MD, PhD Medical Oncology Branch National Cancer Institute Bethesda, MD Ovarian Cancer Stage Description Incidence Survival I Confined to ovaries 20% 90% II Confined to pelvis 5% 65% III Spread IP or nodes 58% 45% IV Distant metastases 17% <5% Ovarian Cancer: Prognostic Factors Stage Extent of Cytoreduction Histology and Grade Performance Status p53 Status Vital Organ Function Physiologic Age Platinum+Taxane Primary Therapy Intraperitoneal therapy Information from Second-Look Surgery Genotype BRCA1/2 VEGF Production Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Chemotherapy Clinical Trials The State of Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Full assessment of abdomen and pelvis Random biopsy of visually negative areas Lymph node dissection (except Stage I) Optimal reductive surgery Chemotherapy Clinical Trials Surgical staging of ovarian cancer The State of Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Stage I, II - Complete removal of all disease Stage III, IV - Residual disease < 1 cm Chemotherapy Clinical Trials Optimal Cytoreduction 0 cm 0-1 cm 1-2 cm >2 cm Time since initial surgery (years) Proportion surviving The State of Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Chemotherapy Platinum = cisplatin or carboplatin AND Taxane = paclitaxel or docetaxel Intraperitoneal if Stage III, optimal reduction Clinical Trials 1960 1970 1980 1990 2000 CISPLATIN/ALKYLATOR COMBINATIONS INTRA- PERITONEAL PACLITAXEL/ CARBOPLATIN ALKYLATORS CISPLATIN 5 YR SURVIVAL ADVANCED DISEASE 40% 35% 15% 5% 0 1960 1970 1980 1990 2000 Timeline of Treatment and Outcome for Advanced Ovarian Cancer Representative Chemotherapy Agents Platinum Paclitaxel Topotecan Gemcitabine Doxil Target: DNA b-tubulin Topo-I RN-reductase, Nucleotide pool Topo-II Mechanism:DNA adduct formation TubulinAggregation Stabilize DNA-TopoDNA synth DNA Schedule:Independent Dependent(toxicity)Dependent(efficacy) Dependent Phosporylation Prolonged clearance Resistance:GSH, tolerance, retention MDR-MRP, tubulin mutations Topo-I, BCRP RN-reductase MDR-MRP Topo-II Platinum Interaction:N/A Platelet Sparing ---- Enhanced Toxicity ---- GOG 172: The new Standard of Care Epithelial Ovarian Cancer, Optimal Stage III, No prior therapy, Well balanced arms 1. Intravenous therapy, Cisplatin 75 mg/m2 Paclitaxel 135 mg/m2 (24 h), 83% completed 6 cycles 2. Intraperitoneal therapy, Cisplatin 100 mg/m2 IP d1 Paclitaxel 135 mg/m2 (24 h) IV d1 Paclitaxel 60 mg/m2 IP d8, 42% completed 6 cycles Open: 23-Mar-98 Closed: 29-Jan-01 Accrual: 416 pts (evaluable) GOG 172: The new Standard of Care Median survival = 49.7 mo Median survival = 65.6 mo Ovarian Cancer in the Genomics Era Preclinical studies Translational Oncology Observation Hypothesis Experiment / Trial Result Analysis Integrated genomic analyses of ovarian carcinoma The Cancer Genome Atlas Research Network* Nature 474: 609-615 Background The Cancer Genome Atlas (TCGA) Clinically annotated HGS-OvCa samples Identify molecular abnormalities that influence pathophysiology, affect outcome and constitute therapeutic targets. Microarray analyses: 489 HGS-OvCa tumours, mRNA expression, microRNA (miRNA) expression, DNA copy number and DNA promoter methylation for and Whole exome DNA sequence: 316 samples. Methods Sample inclusion criteria Newly diagnosed patients ovarian serous adenocarcinoma no prior treatment regardless of surgical stage or histologic grade Each frozen tumor specimen had to have a companion normal tissue specimen, which could be adjacent normal tissue, peripheral lymphocytes, or previously extracted germline DNA. Methods Clinical data collection Clinical data can be accessed and downloaded from the TCGA Data Portal Demographics, histopathologic information treatment details outcome parameters Methods Mutated genes in HGS-OvCa Genome copy number abnormality Copy number profiles of 489 HGS-OvCa, compared with profiles of 197 glioblastoma multiforme (GBM) tumours. Copy number increases (red) and decreases (blue) are plotted as a function of distance along the normal genome (vertical axis, divided into chromosomes). Gene and miRNA patterns: Molecular subtype and outcome prediction Altered pathways in HGS-OvCa Altered pathways in HGS-OvCa Altered pathways in HGS-OvCa Altered pathways in HGS-OvCa TCGA findings TCGA: large-scale integrative view of aberrations in HGS-OvCa Mutational spectrum “surprisingly simple” TP53 predominated = 96% BRCA1 and BRCA2 =22% Seven other significantly mutated genes = 2–6% HGS-OvCa is distinct from other histological subtypes Clear-cell: few TP53; recurrent ARID1A, PIK3CA mutations Endometrioid: frequent CTNNB1, ARID1A and PIK3CA; fewer TP53 Mucinous: prevalent KRAS mutations TCGA findings “Remarkable degree of genomic disarray” “Striking contrast to previous TCGA findings in glioblastoma” Mutations and promoter methylation in putative DNA repair genes (HR) may explain the high prevalence of SCNAs. TCGA – what next? New therapeutic approaches? 50% with HR defects : PARP inhibitors commonly deregulated pathways: RB, RAS/PI3K, FOXM1, NOTCH, provide opportunities for therapeutic treatment Inhibitors exist for 22 genes in regions of recurrent amplification aberrant genes or networks: targeted therapies selected to be effective ... The State of Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Chemotherapy Clinical Trials: targeted therapies Translational Oncology Observation Hypothesis Experiment / Trial Result Analysis Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced ovarian cancer American Society of Clinical Oncology, 2009 Presenter: M William Audeh From genomic aberration to pathway PARP PARP inhibition: BRCA-mutant cancers Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced ovarian cancer Olaparib (AZD2281) novel, orally active PARP inhibitor synthetic lethality in homozygous BRCA-mut cells The primary aim of this study was to test the efficacy of olaparib in confirmed BRCA1/BRCA2 carriers with advanced refractory ovarian cancer Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced ovarian cancer Results: 57 enrolled pts 39 BRCA1 deficient and 18 BRCA2 deficient 33 evaluable at 400 mg bid and 24 at 100 mg bid ORR was 33% at 400 mg bd; 12.5% at 100 mg bd Clinical benefit rate: ORR and/or confirmed ≥50% decline in CA125 57.6% at 400 mg bd and 16.7% at 100 mg bd Median PFS: 5.8 mo (med duration 9.6 mo) Toxicity grade 1/2 nausea (44%); fatigue (35%); anemia (14%) Grade 3 toxicity occurred infrequently, and comprised primarily nausea (7%) and leukopenia (5%). Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced ovarian cancer Audeh, et al. Lancet 376:245 – 251 (2010) Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced ovarian cancer
Slide 39 - Ovarian Cancer in the Genomics Era Christina M. Annunziata, MD, PhD Medical Oncology Branch National Cancer Institute Bethesda, MD Ovarian Cancer Stage Description Incidence Survival I Confined to ovaries 20% 90% II Confined to pelvis 5% 65% III Spread IP or nodes 58% 45% IV Distant metastases 17% <5% Ovarian Cancer: Prognostic Factors Stage Extent of Cytoreduction Histology and Grade Performance Status p53 Status Vital Organ Function Physiologic Age Platinum+Taxane Primary Therapy Intraperitoneal therapy Information from Second-Look Surgery Genotype BRCA1/2 VEGF Production Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Chemotherapy Clinical Trials The State of Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Full assessment of abdomen and pelvis Random biopsy of visually negative areas Lymph node dissection (except Stage I) Optimal reductive surgery Chemotherapy Clinical Trials Surgical staging of ovarian cancer The State of Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Stage I, II - Complete removal of all disease Stage III, IV - Residual disease < 1 cm Chemotherapy Clinical Trials Optimal Cytoreduction 0 cm 0-1 cm 1-2 cm >2 cm Time since initial surgery (years) Proportion surviving The State of Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Chemotherapy Platinum = cisplatin or carboplatin AND Taxane = paclitaxel or docetaxel Intraperitoneal if Stage III, optimal reduction Clinical Trials 1960 1970 1980 1990 2000 CISPLATIN/ALKYLATOR COMBINATIONS INTRA- PERITONEAL PACLITAXEL/ CARBOPLATIN ALKYLATORS CISPLATIN 5 YR SURVIVAL ADVANCED DISEASE 40% 35% 15% 5% 0 1960 1970 1980 1990 2000 Timeline of Treatment and Outcome for Advanced Ovarian Cancer Representative Chemotherapy Agents Platinum Paclitaxel Topotecan Gemcitabine Doxil Target: DNA b-tubulin Topo-I RN-reductase, Nucleotide pool Topo-II Mechanism:DNA adduct formation TubulinAggregation Stabilize DNA-TopoDNA synth DNA Schedule:Independent Dependent(toxicity)Dependent(efficacy) Dependent Phosporylation Prolonged clearance Resistance:GSH, tolerance, retention MDR-MRP, tubulin mutations Topo-I, BCRP RN-reductase MDR-MRP Topo-II Platinum Interaction:N/A Platelet Sparing ---- Enhanced Toxicity ---- GOG 172: The new Standard of Care Epithelial Ovarian Cancer, Optimal Stage III, No prior therapy, Well balanced arms 1. Intravenous therapy, Cisplatin 75 mg/m2 Paclitaxel 135 mg/m2 (24 h), 83% completed 6 cycles 2. Intraperitoneal therapy, Cisplatin 100 mg/m2 IP d1 Paclitaxel 135 mg/m2 (24 h) IV d1 Paclitaxel 60 mg/m2 IP d8, 42% completed 6 cycles Open: 23-Mar-98 Closed: 29-Jan-01 Accrual: 416 pts (evaluable) GOG 172: The new Standard of Care Median survival = 49.7 mo Median survival = 65.6 mo Ovarian Cancer in the Genomics Era Preclinical studies Translational Oncology Observation Hypothesis Experiment / Trial Result Analysis Integrated genomic analyses of ovarian carcinoma The Cancer Genome Atlas Research Network* Nature 474: 609-615 Background The Cancer Genome Atlas (TCGA) Clinically annotated HGS-OvCa samples Identify molecular abnormalities that influence pathophysiology, affect outcome and constitute therapeutic targets. Microarray analyses: 489 HGS-OvCa tumours, mRNA expression, microRNA (miRNA) expression, DNA copy number and DNA promoter methylation for and Whole exome DNA sequence: 316 samples. Methods Sample inclusion criteria Newly diagnosed patients ovarian serous adenocarcinoma no prior treatment regardless of surgical stage or histologic grade Each frozen tumor specimen had to have a companion normal tissue specimen, which could be adjacent normal tissue, peripheral lymphocytes, or previously extracted germline DNA. Methods Clinical data collection Clinical data can be accessed and downloaded from the TCGA Data Portal Demographics, histopathologic information treatment details outcome parameters Methods Mutated genes in HGS-OvCa Genome copy number abnormality Copy number profiles of 489 HGS-OvCa, compared with profiles of 197 glioblastoma multiforme (GBM) tumours. Copy number increases (red) and decreases (blue) are plotted as a function of distance along the normal genome (vertical axis, divided into chromosomes). Gene and miRNA patterns: Molecular subtype and outcome prediction Altered pathways in HGS-OvCa Altered pathways in HGS-OvCa Altered pathways in HGS-OvCa Altered pathways in HGS-OvCa TCGA findings TCGA: large-scale integrative view of aberrations in HGS-OvCa Mutational spectrum “surprisingly simple” TP53 predominated = 96% BRCA1 and BRCA2 =22% Seven other significantly mutated genes = 2–6% HGS-OvCa is distinct from other histological subtypes Clear-cell: few TP53; recurrent ARID1A, PIK3CA mutations Endometrioid: frequent CTNNB1, ARID1A and PIK3CA; fewer TP53 Mucinous: prevalent KRAS mutations TCGA findings “Remarkable degree of genomic disarray” “Striking contrast to previous TCGA findings in glioblastoma” Mutations and promoter methylation in putative DNA repair genes (HR) may explain the high prevalence of SCNAs. TCGA – what next? New therapeutic approaches? 50% with HR defects : PARP inhibitors commonly deregulated pathways: RB, RAS/PI3K, FOXM1, NOTCH, provide opportunities for therapeutic treatment Inhibitors exist for 22 genes in regions of recurrent amplification aberrant genes or networks: targeted therapies selected to be effective ... The State of Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Chemotherapy Clinical Trials: targeted therapies Translational Oncology Observation Hypothesis Experiment / Trial Result Analysis Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced ovarian cancer American Society of Clinical Oncology, 2009 Presenter: M William Audeh From genomic aberration to pathway PARP PARP inhibition: BRCA-mutant cancers Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced ovarian cancer Olaparib (AZD2281) novel, orally active PARP inhibitor synthetic lethality in homozygous BRCA-mut cells The primary aim of this study was to test the efficacy of olaparib in confirmed BRCA1/BRCA2 carriers with advanced refractory ovarian cancer Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced ovarian cancer Results: 57 enrolled pts 39 BRCA1 deficient and 18 BRCA2 deficient 33 evaluable at 400 mg bid and 24 at 100 mg bid ORR was 33% at 400 mg bd; 12.5% at 100 mg bd Clinical benefit rate: ORR and/or confirmed ≥50% decline in CA125 57.6% at 400 mg bd and 16.7% at 100 mg bd Median PFS: 5.8 mo (med duration 9.6 mo) Toxicity grade 1/2 nausea (44%); fatigue (35%); anemia (14%) Grade 3 toxicity occurred infrequently, and comprised primarily nausea (7%) and leukopenia (5%). Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced ovarian cancer Audeh, et al. Lancet 376:245 – 251 (2010) Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced ovarian cancer Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced ovarian cancer Conclusions: Oral olaparib is well tolerated and highly active in advanced, chemotherapy-refractory BRCA-deficient ovarian cancer Greater activity seen at the higher dose Toxicity in BRCA1/2 carriers was similar to that seen in non-carriers “Positive proof of the concept of the activity and tolerability of genetically defined targeted therapy with olaparib in BRCA-deficient ovarian cancers.”
Slide 40 - Ovarian Cancer in the Genomics Era Christina M. Annunziata, MD, PhD Medical Oncology Branch National Cancer Institute Bethesda, MD Ovarian Cancer Stage Description Incidence Survival I Confined to ovaries 20% 90% II Confined to pelvis 5% 65% III Spread IP or nodes 58% 45% IV Distant metastases 17% <5% Ovarian Cancer: Prognostic Factors Stage Extent of Cytoreduction Histology and Grade Performance Status p53 Status Vital Organ Function Physiologic Age Platinum+Taxane Primary Therapy Intraperitoneal therapy Information from Second-Look Surgery Genotype BRCA1/2 VEGF Production Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Chemotherapy Clinical Trials The State of Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Full assessment of abdomen and pelvis Random biopsy of visually negative areas Lymph node dissection (except Stage I) Optimal reductive surgery Chemotherapy Clinical Trials Surgical staging of ovarian cancer The State of Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Stage I, II - Complete removal of all disease Stage III, IV - Residual disease < 1 cm Chemotherapy Clinical Trials Optimal Cytoreduction 0 cm 0-1 cm 1-2 cm >2 cm Time since initial surgery (years) Proportion surviving The State of Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Chemotherapy Platinum = cisplatin or carboplatin AND Taxane = paclitaxel or docetaxel Intraperitoneal if Stage III, optimal reduction Clinical Trials 1960 1970 1980 1990 2000 CISPLATIN/ALKYLATOR COMBINATIONS INTRA- PERITONEAL PACLITAXEL/ CARBOPLATIN ALKYLATORS CISPLATIN 5 YR SURVIVAL ADVANCED DISEASE 40% 35% 15% 5% 0 1960 1970 1980 1990 2000 Timeline of Treatment and Outcome for Advanced Ovarian Cancer Representative Chemotherapy Agents Platinum Paclitaxel Topotecan Gemcitabine Doxil Target: DNA b-tubulin Topo-I RN-reductase, Nucleotide pool Topo-II Mechanism:DNA adduct formation TubulinAggregation Stabilize DNA-TopoDNA synth DNA Schedule:Independent Dependent(toxicity)Dependent(efficacy) Dependent Phosporylation Prolonged clearance Resistance:GSH, tolerance, retention MDR-MRP, tubulin mutations Topo-I, BCRP RN-reductase MDR-MRP Topo-II Platinum Interaction:N/A Platelet Sparing ---- Enhanced Toxicity ---- GOG 172: The new Standard of Care Epithelial Ovarian Cancer, Optimal Stage III, No prior therapy, Well balanced arms 1. Intravenous therapy, Cisplatin 75 mg/m2 Paclitaxel 135 mg/m2 (24 h), 83% completed 6 cycles 2. Intraperitoneal therapy, Cisplatin 100 mg/m2 IP d1 Paclitaxel 135 mg/m2 (24 h) IV d1 Paclitaxel 60 mg/m2 IP d8, 42% completed 6 cycles Open: 23-Mar-98 Closed: 29-Jan-01 Accrual: 416 pts (evaluable) GOG 172: The new Standard of Care Median survival = 49.7 mo Median survival = 65.6 mo Ovarian Cancer in the Genomics Era Preclinical studies Translational Oncology Observation Hypothesis Experiment / Trial Result Analysis Integrated genomic analyses of ovarian carcinoma The Cancer Genome Atlas Research Network* Nature 474: 609-615 Background The Cancer Genome Atlas (TCGA) Clinically annotated HGS-OvCa samples Identify molecular abnormalities that influence pathophysiology, affect outcome and constitute therapeutic targets. Microarray analyses: 489 HGS-OvCa tumours, mRNA expression, microRNA (miRNA) expression, DNA copy number and DNA promoter methylation for and Whole exome DNA sequence: 316 samples. Methods Sample inclusion criteria Newly diagnosed patients ovarian serous adenocarcinoma no prior treatment regardless of surgical stage or histologic grade Each frozen tumor specimen had to have a companion normal tissue specimen, which could be adjacent normal tissue, peripheral lymphocytes, or previously extracted germline DNA. Methods Clinical data collection Clinical data can be accessed and downloaded from the TCGA Data Portal Demographics, histopathologic information treatment details outcome parameters Methods Mutated genes in HGS-OvCa Genome copy number abnormality Copy number profiles of 489 HGS-OvCa, compared with profiles of 197 glioblastoma multiforme (GBM) tumours. Copy number increases (red) and decreases (blue) are plotted as a function of distance along the normal genome (vertical axis, divided into chromosomes). Gene and miRNA patterns: Molecular subtype and outcome prediction Altered pathways in HGS-OvCa Altered pathways in HGS-OvCa Altered pathways in HGS-OvCa Altered pathways in HGS-OvCa TCGA findings TCGA: large-scale integrative view of aberrations in HGS-OvCa Mutational spectrum “surprisingly simple” TP53 predominated = 96% BRCA1 and BRCA2 =22% Seven other significantly mutated genes = 2–6% HGS-OvCa is distinct from other histological subtypes Clear-cell: few TP53; recurrent ARID1A, PIK3CA mutations Endometrioid: frequent CTNNB1, ARID1A and PIK3CA; fewer TP53 Mucinous: prevalent KRAS mutations TCGA findings “Remarkable degree of genomic disarray” “Striking contrast to previous TCGA findings in glioblastoma” Mutations and promoter methylation in putative DNA repair genes (HR) may explain the high prevalence of SCNAs. TCGA – what next? New therapeutic approaches? 50% with HR defects : PARP inhibitors commonly deregulated pathways: RB, RAS/PI3K, FOXM1, NOTCH, provide opportunities for therapeutic treatment Inhibitors exist for 22 genes in regions of recurrent amplification aberrant genes or networks: targeted therapies selected to be effective ... The State of Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Chemotherapy Clinical Trials: targeted therapies Translational Oncology Observation Hypothesis Experiment / Trial Result Analysis Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced ovarian cancer American Society of Clinical Oncology, 2009 Presenter: M William Audeh From genomic aberration to pathway PARP PARP inhibition: BRCA-mutant cancers Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced ovarian cancer Olaparib (AZD2281) novel, orally active PARP inhibitor synthetic lethality in homozygous BRCA-mut cells The primary aim of this study was to test the efficacy of olaparib in confirmed BRCA1/BRCA2 carriers with advanced refractory ovarian cancer Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced ovarian cancer Results: 57 enrolled pts 39 BRCA1 deficient and 18 BRCA2 deficient 33 evaluable at 400 mg bid and 24 at 100 mg bid ORR was 33% at 400 mg bd; 12.5% at 100 mg bd Clinical benefit rate: ORR and/or confirmed ≥50% decline in CA125 57.6% at 400 mg bd and 16.7% at 100 mg bd Median PFS: 5.8 mo (med duration 9.6 mo) Toxicity grade 1/2 nausea (44%); fatigue (35%); anemia (14%) Grade 3 toxicity occurred infrequently, and comprised primarily nausea (7%) and leukopenia (5%). Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced ovarian cancer Audeh, et al. Lancet 376:245 – 251 (2010) Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced ovarian cancer Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced ovarian cancer Conclusions: Oral olaparib is well tolerated and highly active in advanced, chemotherapy-refractory BRCA-deficient ovarian cancer Greater activity seen at the higher dose Toxicity in BRCA1/2 carriers was similar to that seen in non-carriers “Positive proof of the concept of the activity and tolerability of genetically defined targeted therapy with olaparib in BRCA-deficient ovarian cancers.” NF-B: Deregulation and Targeting A Genomic approach to Ovarian Cancer
Slide 41 - Ovarian Cancer in the Genomics Era Christina M. Annunziata, MD, PhD Medical Oncology Branch National Cancer Institute Bethesda, MD Ovarian Cancer Stage Description Incidence Survival I Confined to ovaries 20% 90% II Confined to pelvis 5% 65% III Spread IP or nodes 58% 45% IV Distant metastases 17% <5% Ovarian Cancer: Prognostic Factors Stage Extent of Cytoreduction Histology and Grade Performance Status p53 Status Vital Organ Function Physiologic Age Platinum+Taxane Primary Therapy Intraperitoneal therapy Information from Second-Look Surgery Genotype BRCA1/2 VEGF Production Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Chemotherapy Clinical Trials The State of Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Full assessment of abdomen and pelvis Random biopsy of visually negative areas Lymph node dissection (except Stage I) Optimal reductive surgery Chemotherapy Clinical Trials Surgical staging of ovarian cancer The State of Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Stage I, II - Complete removal of all disease Stage III, IV - Residual disease < 1 cm Chemotherapy Clinical Trials Optimal Cytoreduction 0 cm 0-1 cm 1-2 cm >2 cm Time since initial surgery (years) Proportion surviving The State of Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Chemotherapy Platinum = cisplatin or carboplatin AND Taxane = paclitaxel or docetaxel Intraperitoneal if Stage III, optimal reduction Clinical Trials 1960 1970 1980 1990 2000 CISPLATIN/ALKYLATOR COMBINATIONS INTRA- PERITONEAL PACLITAXEL/ CARBOPLATIN ALKYLATORS CISPLATIN 5 YR SURVIVAL ADVANCED DISEASE 40% 35% 15% 5% 0 1960 1970 1980 1990 2000 Timeline of Treatment and Outcome for Advanced Ovarian Cancer Representative Chemotherapy Agents Platinum Paclitaxel Topotecan Gemcitabine Doxil Target: DNA b-tubulin Topo-I RN-reductase, Nucleotide pool Topo-II Mechanism:DNA adduct formation TubulinAggregation Stabilize DNA-TopoDNA synth DNA Schedule:Independent Dependent(toxicity)Dependent(efficacy) Dependent Phosporylation Prolonged clearance Resistance:GSH, tolerance, retention MDR-MRP, tubulin mutations Topo-I, BCRP RN-reductase MDR-MRP Topo-II Platinum Interaction:N/A Platelet Sparing ---- Enhanced Toxicity ---- GOG 172: The new Standard of Care Epithelial Ovarian Cancer, Optimal Stage III, No prior therapy, Well balanced arms 1. Intravenous therapy, Cisplatin 75 mg/m2 Paclitaxel 135 mg/m2 (24 h), 83% completed 6 cycles 2. Intraperitoneal therapy, Cisplatin 100 mg/m2 IP d1 Paclitaxel 135 mg/m2 (24 h) IV d1 Paclitaxel 60 mg/m2 IP d8, 42% completed 6 cycles Open: 23-Mar-98 Closed: 29-Jan-01 Accrual: 416 pts (evaluable) GOG 172: The new Standard of Care Median survival = 49.7 mo Median survival = 65.6 mo Ovarian Cancer in the Genomics Era Preclinical studies Translational Oncology Observation Hypothesis Experiment / Trial Result Analysis Integrated genomic analyses of ovarian carcinoma The Cancer Genome Atlas Research Network* Nature 474: 609-615 Background The Cancer Genome Atlas (TCGA) Clinically annotated HGS-OvCa samples Identify molecular abnormalities that influence pathophysiology, affect outcome and constitute therapeutic targets. Microarray analyses: 489 HGS-OvCa tumours, mRNA expression, microRNA (miRNA) expression, DNA copy number and DNA promoter methylation for and Whole exome DNA sequence: 316 samples. Methods Sample inclusion criteria Newly diagnosed patients ovarian serous adenocarcinoma no prior treatment regardless of surgical stage or histologic grade Each frozen tumor specimen had to have a companion normal tissue specimen, which could be adjacent normal tissue, peripheral lymphocytes, or previously extracted germline DNA. Methods Clinical data collection Clinical data can be accessed and downloaded from the TCGA Data Portal Demographics, histopathologic information treatment details outcome parameters Methods Mutated genes in HGS-OvCa Genome copy number abnormality Copy number profiles of 489 HGS-OvCa, compared with profiles of 197 glioblastoma multiforme (GBM) tumours. Copy number increases (red) and decreases (blue) are plotted as a function of distance along the normal genome (vertical axis, divided into chromosomes). Gene and miRNA patterns: Molecular subtype and outcome prediction Altered pathways in HGS-OvCa Altered pathways in HGS-OvCa Altered pathways in HGS-OvCa Altered pathways in HGS-OvCa TCGA findings TCGA: large-scale integrative view of aberrations in HGS-OvCa Mutational spectrum “surprisingly simple” TP53 predominated = 96% BRCA1 and BRCA2 =22% Seven other significantly mutated genes = 2–6% HGS-OvCa is distinct from other histological subtypes Clear-cell: few TP53; recurrent ARID1A, PIK3CA mutations Endometrioid: frequent CTNNB1, ARID1A and PIK3CA; fewer TP53 Mucinous: prevalent KRAS mutations TCGA findings “Remarkable degree of genomic disarray” “Striking contrast to previous TCGA findings in glioblastoma” Mutations and promoter methylation in putative DNA repair genes (HR) may explain the high prevalence of SCNAs. TCGA – what next? New therapeutic approaches? 50% with HR defects : PARP inhibitors commonly deregulated pathways: RB, RAS/PI3K, FOXM1, NOTCH, provide opportunities for therapeutic treatment Inhibitors exist for 22 genes in regions of recurrent amplification aberrant genes or networks: targeted therapies selected to be effective ... The State of Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Chemotherapy Clinical Trials: targeted therapies Translational Oncology Observation Hypothesis Experiment / Trial Result Analysis Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced ovarian cancer American Society of Clinical Oncology, 2009 Presenter: M William Audeh From genomic aberration to pathway PARP PARP inhibition: BRCA-mutant cancers Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced ovarian cancer Olaparib (AZD2281) novel, orally active PARP inhibitor synthetic lethality in homozygous BRCA-mut cells The primary aim of this study was to test the efficacy of olaparib in confirmed BRCA1/BRCA2 carriers with advanced refractory ovarian cancer Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced ovarian cancer Results: 57 enrolled pts 39 BRCA1 deficient and 18 BRCA2 deficient 33 evaluable at 400 mg bid and 24 at 100 mg bid ORR was 33% at 400 mg bd; 12.5% at 100 mg bd Clinical benefit rate: ORR and/or confirmed ≥50% decline in CA125 57.6% at 400 mg bd and 16.7% at 100 mg bd Median PFS: 5.8 mo (med duration 9.6 mo) Toxicity grade 1/2 nausea (44%); fatigue (35%); anemia (14%) Grade 3 toxicity occurred infrequently, and comprised primarily nausea (7%) and leukopenia (5%). Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced ovarian cancer Audeh, et al. Lancet 376:245 – 251 (2010) Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced ovarian cancer Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced ovarian cancer Conclusions: Oral olaparib is well tolerated and highly active in advanced, chemotherapy-refractory BRCA-deficient ovarian cancer Greater activity seen at the higher dose Toxicity in BRCA1/2 carriers was similar to that seen in non-carriers “Positive proof of the concept of the activity and tolerability of genetically defined targeted therapy with olaparib in BRCA-deficient ovarian cancers.” NF-B: Deregulation and Targeting A Genomic approach to Ovarian Cancer Schematic of NF-B signaling
Slide 42 - Ovarian Cancer in the Genomics Era Christina M. Annunziata, MD, PhD Medical Oncology Branch National Cancer Institute Bethesda, MD Ovarian Cancer Stage Description Incidence Survival I Confined to ovaries 20% 90% II Confined to pelvis 5% 65% III Spread IP or nodes 58% 45% IV Distant metastases 17% <5% Ovarian Cancer: Prognostic Factors Stage Extent of Cytoreduction Histology and Grade Performance Status p53 Status Vital Organ Function Physiologic Age Platinum+Taxane Primary Therapy Intraperitoneal therapy Information from Second-Look Surgery Genotype BRCA1/2 VEGF Production Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Chemotherapy Clinical Trials The State of Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Full assessment of abdomen and pelvis Random biopsy of visually negative areas Lymph node dissection (except Stage I) Optimal reductive surgery Chemotherapy Clinical Trials Surgical staging of ovarian cancer The State of Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Stage I, II - Complete removal of all disease Stage III, IV - Residual disease < 1 cm Chemotherapy Clinical Trials Optimal Cytoreduction 0 cm 0-1 cm 1-2 cm >2 cm Time since initial surgery (years) Proportion surviving The State of Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Chemotherapy Platinum = cisplatin or carboplatin AND Taxane = paclitaxel or docetaxel Intraperitoneal if Stage III, optimal reduction Clinical Trials 1960 1970 1980 1990 2000 CISPLATIN/ALKYLATOR COMBINATIONS INTRA- PERITONEAL PACLITAXEL/ CARBOPLATIN ALKYLATORS CISPLATIN 5 YR SURVIVAL ADVANCED DISEASE 40% 35% 15% 5% 0 1960 1970 1980 1990 2000 Timeline of Treatment and Outcome for Advanced Ovarian Cancer Representative Chemotherapy Agents Platinum Paclitaxel Topotecan Gemcitabine Doxil Target: DNA b-tubulin Topo-I RN-reductase, Nucleotide pool Topo-II Mechanism:DNA adduct formation TubulinAggregation Stabilize DNA-TopoDNA synth DNA Schedule:Independent Dependent(toxicity)Dependent(efficacy) Dependent Phosporylation Prolonged clearance Resistance:GSH, tolerance, retention MDR-MRP, tubulin mutations Topo-I, BCRP RN-reductase MDR-MRP Topo-II Platinum Interaction:N/A Platelet Sparing ---- Enhanced Toxicity ---- GOG 172: The new Standard of Care Epithelial Ovarian Cancer, Optimal Stage III, No prior therapy, Well balanced arms 1. Intravenous therapy, Cisplatin 75 mg/m2 Paclitaxel 135 mg/m2 (24 h), 83% completed 6 cycles 2. Intraperitoneal therapy, Cisplatin 100 mg/m2 IP d1 Paclitaxel 135 mg/m2 (24 h) IV d1 Paclitaxel 60 mg/m2 IP d8, 42% completed 6 cycles Open: 23-Mar-98 Closed: 29-Jan-01 Accrual: 416 pts (evaluable) GOG 172: The new Standard of Care Median survival = 49.7 mo Median survival = 65.6 mo Ovarian Cancer in the Genomics Era Preclinical studies Translational Oncology Observation Hypothesis Experiment / Trial Result Analysis Integrated genomic analyses of ovarian carcinoma The Cancer Genome Atlas Research Network* Nature 474: 609-615 Background The Cancer Genome Atlas (TCGA) Clinically annotated HGS-OvCa samples Identify molecular abnormalities that influence pathophysiology, affect outcome and constitute therapeutic targets. Microarray analyses: 489 HGS-OvCa tumours, mRNA expression, microRNA (miRNA) expression, DNA copy number and DNA promoter methylation for and Whole exome DNA sequence: 316 samples. Methods Sample inclusion criteria Newly diagnosed patients ovarian serous adenocarcinoma no prior treatment regardless of surgical stage or histologic grade Each frozen tumor specimen had to have a companion normal tissue specimen, which could be adjacent normal tissue, peripheral lymphocytes, or previously extracted germline DNA. Methods Clinical data collection Clinical data can be accessed and downloaded from the TCGA Data Portal Demographics, histopathologic information treatment details outcome parameters Methods Mutated genes in HGS-OvCa Genome copy number abnormality Copy number profiles of 489 HGS-OvCa, compared with profiles of 197 glioblastoma multiforme (GBM) tumours. Copy number increases (red) and decreases (blue) are plotted as a function of distance along the normal genome (vertical axis, divided into chromosomes). Gene and miRNA patterns: Molecular subtype and outcome prediction Altered pathways in HGS-OvCa Altered pathways in HGS-OvCa Altered pathways in HGS-OvCa Altered pathways in HGS-OvCa TCGA findings TCGA: large-scale integrative view of aberrations in HGS-OvCa Mutational spectrum “surprisingly simple” TP53 predominated = 96% BRCA1 and BRCA2 =22% Seven other significantly mutated genes = 2–6% HGS-OvCa is distinct from other histological subtypes Clear-cell: few TP53; recurrent ARID1A, PIK3CA mutations Endometrioid: frequent CTNNB1, ARID1A and PIK3CA; fewer TP53 Mucinous: prevalent KRAS mutations TCGA findings “Remarkable degree of genomic disarray” “Striking contrast to previous TCGA findings in glioblastoma” Mutations and promoter methylation in putative DNA repair genes (HR) may explain the high prevalence of SCNAs. TCGA – what next? New therapeutic approaches? 50% with HR defects : PARP inhibitors commonly deregulated pathways: RB, RAS/PI3K, FOXM1, NOTCH, provide opportunities for therapeutic treatment Inhibitors exist for 22 genes in regions of recurrent amplification aberrant genes or networks: targeted therapies selected to be effective ... The State of Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Chemotherapy Clinical Trials: targeted therapies Translational Oncology Observation Hypothesis Experiment / Trial Result Analysis Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced ovarian cancer American Society of Clinical Oncology, 2009 Presenter: M William Audeh From genomic aberration to pathway PARP PARP inhibition: BRCA-mutant cancers Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced ovarian cancer Olaparib (AZD2281) novel, orally active PARP inhibitor synthetic lethality in homozygous BRCA-mut cells The primary aim of this study was to test the efficacy of olaparib in confirmed BRCA1/BRCA2 carriers with advanced refractory ovarian cancer Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced ovarian cancer Results: 57 enrolled pts 39 BRCA1 deficient and 18 BRCA2 deficient 33 evaluable at 400 mg bid and 24 at 100 mg bid ORR was 33% at 400 mg bd; 12.5% at 100 mg bd Clinical benefit rate: ORR and/or confirmed ≥50% decline in CA125 57.6% at 400 mg bd and 16.7% at 100 mg bd Median PFS: 5.8 mo (med duration 9.6 mo) Toxicity grade 1/2 nausea (44%); fatigue (35%); anemia (14%) Grade 3 toxicity occurred infrequently, and comprised primarily nausea (7%) and leukopenia (5%). Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced ovarian cancer Audeh, et al. Lancet 376:245 – 251 (2010) Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced ovarian cancer Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced ovarian cancer Conclusions: Oral olaparib is well tolerated and highly active in advanced, chemotherapy-refractory BRCA-deficient ovarian cancer Greater activity seen at the higher dose Toxicity in BRCA1/2 carriers was similar to that seen in non-carriers “Positive proof of the concept of the activity and tolerability of genetically defined targeted therapy with olaparib in BRCA-deficient ovarian cancers.” NF-B: Deregulation and Targeting A Genomic approach to Ovarian Cancer Schematic of NF-B signaling Defining the Ovarian Cancer-specific IKK gene signature using IKK inhibitor and IKK shRNA
Slide 43 - Ovarian Cancer in the Genomics Era Christina M. Annunziata, MD, PhD Medical Oncology Branch National Cancer Institute Bethesda, MD Ovarian Cancer Stage Description Incidence Survival I Confined to ovaries 20% 90% II Confined to pelvis 5% 65% III Spread IP or nodes 58% 45% IV Distant metastases 17% <5% Ovarian Cancer: Prognostic Factors Stage Extent of Cytoreduction Histology and Grade Performance Status p53 Status Vital Organ Function Physiologic Age Platinum+Taxane Primary Therapy Intraperitoneal therapy Information from Second-Look Surgery Genotype BRCA1/2 VEGF Production Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Chemotherapy Clinical Trials The State of Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Full assessment of abdomen and pelvis Random biopsy of visually negative areas Lymph node dissection (except Stage I) Optimal reductive surgery Chemotherapy Clinical Trials Surgical staging of ovarian cancer The State of Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Stage I, II - Complete removal of all disease Stage III, IV - Residual disease < 1 cm Chemotherapy Clinical Trials Optimal Cytoreduction 0 cm 0-1 cm 1-2 cm >2 cm Time since initial surgery (years) Proportion surviving The State of Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Chemotherapy Platinum = cisplatin or carboplatin AND Taxane = paclitaxel or docetaxel Intraperitoneal if Stage III, optimal reduction Clinical Trials 1960 1970 1980 1990 2000 CISPLATIN/ALKYLATOR COMBINATIONS INTRA- PERITONEAL PACLITAXEL/ CARBOPLATIN ALKYLATORS CISPLATIN 5 YR SURVIVAL ADVANCED DISEASE 40% 35% 15% 5% 0 1960 1970 1980 1990 2000 Timeline of Treatment and Outcome for Advanced Ovarian Cancer Representative Chemotherapy Agents Platinum Paclitaxel Topotecan Gemcitabine Doxil Target: DNA b-tubulin Topo-I RN-reductase, Nucleotide pool Topo-II Mechanism:DNA adduct formation TubulinAggregation Stabilize DNA-TopoDNA synth DNA Schedule:Independent Dependent(toxicity)Dependent(efficacy) Dependent Phosporylation Prolonged clearance Resistance:GSH, tolerance, retention MDR-MRP, tubulin mutations Topo-I, BCRP RN-reductase MDR-MRP Topo-II Platinum Interaction:N/A Platelet Sparing ---- Enhanced Toxicity ---- GOG 172: The new Standard of Care Epithelial Ovarian Cancer, Optimal Stage III, No prior therapy, Well balanced arms 1. Intravenous therapy, Cisplatin 75 mg/m2 Paclitaxel 135 mg/m2 (24 h), 83% completed 6 cycles 2. Intraperitoneal therapy, Cisplatin 100 mg/m2 IP d1 Paclitaxel 135 mg/m2 (24 h) IV d1 Paclitaxel 60 mg/m2 IP d8, 42% completed 6 cycles Open: 23-Mar-98 Closed: 29-Jan-01 Accrual: 416 pts (evaluable) GOG 172: The new Standard of Care Median survival = 49.7 mo Median survival = 65.6 mo Ovarian Cancer in the Genomics Era Preclinical studies Translational Oncology Observation Hypothesis Experiment / Trial Result Analysis Integrated genomic analyses of ovarian carcinoma The Cancer Genome Atlas Research Network* Nature 474: 609-615 Background The Cancer Genome Atlas (TCGA) Clinically annotated HGS-OvCa samples Identify molecular abnormalities that influence pathophysiology, affect outcome and constitute therapeutic targets. Microarray analyses: 489 HGS-OvCa tumours, mRNA expression, microRNA (miRNA) expression, DNA copy number and DNA promoter methylation for and Whole exome DNA sequence: 316 samples. Methods Sample inclusion criteria Newly diagnosed patients ovarian serous adenocarcinoma no prior treatment regardless of surgical stage or histologic grade Each frozen tumor specimen had to have a companion normal tissue specimen, which could be adjacent normal tissue, peripheral lymphocytes, or previously extracted germline DNA. Methods Clinical data collection Clinical data can be accessed and downloaded from the TCGA Data Portal Demographics, histopathologic information treatment details outcome parameters Methods Mutated genes in HGS-OvCa Genome copy number abnormality Copy number profiles of 489 HGS-OvCa, compared with profiles of 197 glioblastoma multiforme (GBM) tumours. Copy number increases (red) and decreases (blue) are plotted as a function of distance along the normal genome (vertical axis, divided into chromosomes). Gene and miRNA patterns: Molecular subtype and outcome prediction Altered pathways in HGS-OvCa Altered pathways in HGS-OvCa Altered pathways in HGS-OvCa Altered pathways in HGS-OvCa TCGA findings TCGA: large-scale integrative view of aberrations in HGS-OvCa Mutational spectrum “surprisingly simple” TP53 predominated = 96% BRCA1 and BRCA2 =22% Seven other significantly mutated genes = 2–6% HGS-OvCa is distinct from other histological subtypes Clear-cell: few TP53; recurrent ARID1A, PIK3CA mutations Endometrioid: frequent CTNNB1, ARID1A and PIK3CA; fewer TP53 Mucinous: prevalent KRAS mutations TCGA findings “Remarkable degree of genomic disarray” “Striking contrast to previous TCGA findings in glioblastoma” Mutations and promoter methylation in putative DNA repair genes (HR) may explain the high prevalence of SCNAs. TCGA – what next? New therapeutic approaches? 50% with HR defects : PARP inhibitors commonly deregulated pathways: RB, RAS/PI3K, FOXM1, NOTCH, provide opportunities for therapeutic treatment Inhibitors exist for 22 genes in regions of recurrent amplification aberrant genes or networks: targeted therapies selected to be effective ... The State of Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Chemotherapy Clinical Trials: targeted therapies Translational Oncology Observation Hypothesis Experiment / Trial Result Analysis Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced ovarian cancer American Society of Clinical Oncology, 2009 Presenter: M William Audeh From genomic aberration to pathway PARP PARP inhibition: BRCA-mutant cancers Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced ovarian cancer Olaparib (AZD2281) novel, orally active PARP inhibitor synthetic lethality in homozygous BRCA-mut cells The primary aim of this study was to test the efficacy of olaparib in confirmed BRCA1/BRCA2 carriers with advanced refractory ovarian cancer Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced ovarian cancer Results: 57 enrolled pts 39 BRCA1 deficient and 18 BRCA2 deficient 33 evaluable at 400 mg bid and 24 at 100 mg bid ORR was 33% at 400 mg bd; 12.5% at 100 mg bd Clinical benefit rate: ORR and/or confirmed ≥50% decline in CA125 57.6% at 400 mg bd and 16.7% at 100 mg bd Median PFS: 5.8 mo (med duration 9.6 mo) Toxicity grade 1/2 nausea (44%); fatigue (35%); anemia (14%) Grade 3 toxicity occurred infrequently, and comprised primarily nausea (7%) and leukopenia (5%). Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced ovarian cancer Audeh, et al. Lancet 376:245 – 251 (2010) Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced ovarian cancer Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced ovarian cancer Conclusions: Oral olaparib is well tolerated and highly active in advanced, chemotherapy-refractory BRCA-deficient ovarian cancer Greater activity seen at the higher dose Toxicity in BRCA1/2 carriers was similar to that seen in non-carriers “Positive proof of the concept of the activity and tolerability of genetically defined targeted therapy with olaparib in BRCA-deficient ovarian cancers.” NF-B: Deregulation and Targeting A Genomic approach to Ovarian Cancer Schematic of NF-B signaling Defining the Ovarian Cancer-specific IKK gene signature using IKK inhibitor and IKK shRNA IKK gene signature is coordinately expressed in primary ovarian cancers
Slide 44 - Ovarian Cancer in the Genomics Era Christina M. Annunziata, MD, PhD Medical Oncology Branch National Cancer Institute Bethesda, MD Ovarian Cancer Stage Description Incidence Survival I Confined to ovaries 20% 90% II Confined to pelvis 5% 65% III Spread IP or nodes 58% 45% IV Distant metastases 17% <5% Ovarian Cancer: Prognostic Factors Stage Extent of Cytoreduction Histology and Grade Performance Status p53 Status Vital Organ Function Physiologic Age Platinum+Taxane Primary Therapy Intraperitoneal therapy Information from Second-Look Surgery Genotype BRCA1/2 VEGF Production Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Chemotherapy Clinical Trials The State of Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Full assessment of abdomen and pelvis Random biopsy of visually negative areas Lymph node dissection (except Stage I) Optimal reductive surgery Chemotherapy Clinical Trials Surgical staging of ovarian cancer The State of Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Stage I, II - Complete removal of all disease Stage III, IV - Residual disease < 1 cm Chemotherapy Clinical Trials Optimal Cytoreduction 0 cm 0-1 cm 1-2 cm >2 cm Time since initial surgery (years) Proportion surviving The State of Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Chemotherapy Platinum = cisplatin or carboplatin AND Taxane = paclitaxel or docetaxel Intraperitoneal if Stage III, optimal reduction Clinical Trials 1960 1970 1980 1990 2000 CISPLATIN/ALKYLATOR COMBINATIONS INTRA- PERITONEAL PACLITAXEL/ CARBOPLATIN ALKYLATORS CISPLATIN 5 YR SURVIVAL ADVANCED DISEASE 40% 35% 15% 5% 0 1960 1970 1980 1990 2000 Timeline of Treatment and Outcome for Advanced Ovarian Cancer Representative Chemotherapy Agents Platinum Paclitaxel Topotecan Gemcitabine Doxil Target: DNA b-tubulin Topo-I RN-reductase, Nucleotide pool Topo-II Mechanism:DNA adduct formation TubulinAggregation Stabilize DNA-TopoDNA synth DNA Schedule:Independent Dependent(toxicity)Dependent(efficacy) Dependent Phosporylation Prolonged clearance Resistance:GSH, tolerance, retention MDR-MRP, tubulin mutations Topo-I, BCRP RN-reductase MDR-MRP Topo-II Platinum Interaction:N/A Platelet Sparing ---- Enhanced Toxicity ---- GOG 172: The new Standard of Care Epithelial Ovarian Cancer, Optimal Stage III, No prior therapy, Well balanced arms 1. Intravenous therapy, Cisplatin 75 mg/m2 Paclitaxel 135 mg/m2 (24 h), 83% completed 6 cycles 2. Intraperitoneal therapy, Cisplatin 100 mg/m2 IP d1 Paclitaxel 135 mg/m2 (24 h) IV d1 Paclitaxel 60 mg/m2 IP d8, 42% completed 6 cycles Open: 23-Mar-98 Closed: 29-Jan-01 Accrual: 416 pts (evaluable) GOG 172: The new Standard of Care Median survival = 49.7 mo Median survival = 65.6 mo Ovarian Cancer in the Genomics Era Preclinical studies Translational Oncology Observation Hypothesis Experiment / Trial Result Analysis Integrated genomic analyses of ovarian carcinoma The Cancer Genome Atlas Research Network* Nature 474: 609-615 Background The Cancer Genome Atlas (TCGA) Clinically annotated HGS-OvCa samples Identify molecular abnormalities that influence pathophysiology, affect outcome and constitute therapeutic targets. Microarray analyses: 489 HGS-OvCa tumours, mRNA expression, microRNA (miRNA) expression, DNA copy number and DNA promoter methylation for and Whole exome DNA sequence: 316 samples. Methods Sample inclusion criteria Newly diagnosed patients ovarian serous adenocarcinoma no prior treatment regardless of surgical stage or histologic grade Each frozen tumor specimen had to have a companion normal tissue specimen, which could be adjacent normal tissue, peripheral lymphocytes, or previously extracted germline DNA. Methods Clinical data collection Clinical data can be accessed and downloaded from the TCGA Data Portal Demographics, histopathologic information treatment details outcome parameters Methods Mutated genes in HGS-OvCa Genome copy number abnormality Copy number profiles of 489 HGS-OvCa, compared with profiles of 197 glioblastoma multiforme (GBM) tumours. Copy number increases (red) and decreases (blue) are plotted as a function of distance along the normal genome (vertical axis, divided into chromosomes). Gene and miRNA patterns: Molecular subtype and outcome prediction Altered pathways in HGS-OvCa Altered pathways in HGS-OvCa Altered pathways in HGS-OvCa Altered pathways in HGS-OvCa TCGA findings TCGA: large-scale integrative view of aberrations in HGS-OvCa Mutational spectrum “surprisingly simple” TP53 predominated = 96% BRCA1 and BRCA2 =22% Seven other significantly mutated genes = 2–6% HGS-OvCa is distinct from other histological subtypes Clear-cell: few TP53; recurrent ARID1A, PIK3CA mutations Endometrioid: frequent CTNNB1, ARID1A and PIK3CA; fewer TP53 Mucinous: prevalent KRAS mutations TCGA findings “Remarkable degree of genomic disarray” “Striking contrast to previous TCGA findings in glioblastoma” Mutations and promoter methylation in putative DNA repair genes (HR) may explain the high prevalence of SCNAs. TCGA – what next? New therapeutic approaches? 50% with HR defects : PARP inhibitors commonly deregulated pathways: RB, RAS/PI3K, FOXM1, NOTCH, provide opportunities for therapeutic treatment Inhibitors exist for 22 genes in regions of recurrent amplification aberrant genes or networks: targeted therapies selected to be effective ... The State of Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Chemotherapy Clinical Trials: targeted therapies Translational Oncology Observation Hypothesis Experiment / Trial Result Analysis Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced ovarian cancer American Society of Clinical Oncology, 2009 Presenter: M William Audeh From genomic aberration to pathway PARP PARP inhibition: BRCA-mutant cancers Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced ovarian cancer Olaparib (AZD2281) novel, orally active PARP inhibitor synthetic lethality in homozygous BRCA-mut cells The primary aim of this study was to test the efficacy of olaparib in confirmed BRCA1/BRCA2 carriers with advanced refractory ovarian cancer Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced ovarian cancer Results: 57 enrolled pts 39 BRCA1 deficient and 18 BRCA2 deficient 33 evaluable at 400 mg bid and 24 at 100 mg bid ORR was 33% at 400 mg bd; 12.5% at 100 mg bd Clinical benefit rate: ORR and/or confirmed ≥50% decline in CA125 57.6% at 400 mg bd and 16.7% at 100 mg bd Median PFS: 5.8 mo (med duration 9.6 mo) Toxicity grade 1/2 nausea (44%); fatigue (35%); anemia (14%) Grade 3 toxicity occurred infrequently, and comprised primarily nausea (7%) and leukopenia (5%). Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced ovarian cancer Audeh, et al. Lancet 376:245 – 251 (2010) Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced ovarian cancer Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced ovarian cancer Conclusions: Oral olaparib is well tolerated and highly active in advanced, chemotherapy-refractory BRCA-deficient ovarian cancer Greater activity seen at the higher dose Toxicity in BRCA1/2 carriers was similar to that seen in non-carriers “Positive proof of the concept of the activity and tolerability of genetically defined targeted therapy with olaparib in BRCA-deficient ovarian cancers.” NF-B: Deregulation and Targeting A Genomic approach to Ovarian Cancer Schematic of NF-B signaling Defining the Ovarian Cancer-specific IKK gene signature using IKK inhibitor and IKK shRNA IKK gene signature is coordinately expressed in primary ovarian cancers High IKK activity associates with worse survival in ovarian cancer
Slide 45 - Ovarian Cancer in the Genomics Era Christina M. Annunziata, MD, PhD Medical Oncology Branch National Cancer Institute Bethesda, MD Ovarian Cancer Stage Description Incidence Survival I Confined to ovaries 20% 90% II Confined to pelvis 5% 65% III Spread IP or nodes 58% 45% IV Distant metastases 17% <5% Ovarian Cancer: Prognostic Factors Stage Extent of Cytoreduction Histology and Grade Performance Status p53 Status Vital Organ Function Physiologic Age Platinum+Taxane Primary Therapy Intraperitoneal therapy Information from Second-Look Surgery Genotype BRCA1/2 VEGF Production Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Chemotherapy Clinical Trials The State of Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Full assessment of abdomen and pelvis Random biopsy of visually negative areas Lymph node dissection (except Stage I) Optimal reductive surgery Chemotherapy Clinical Trials Surgical staging of ovarian cancer The State of Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Stage I, II - Complete removal of all disease Stage III, IV - Residual disease < 1 cm Chemotherapy Clinical Trials Optimal Cytoreduction 0 cm 0-1 cm 1-2 cm >2 cm Time since initial surgery (years) Proportion surviving The State of Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Chemotherapy Platinum = cisplatin or carboplatin AND Taxane = paclitaxel or docetaxel Intraperitoneal if Stage III, optimal reduction Clinical Trials 1960 1970 1980 1990 2000 CISPLATIN/ALKYLATOR COMBINATIONS INTRA- PERITONEAL PACLITAXEL/ CARBOPLATIN ALKYLATORS CISPLATIN 5 YR SURVIVAL ADVANCED DISEASE 40% 35% 15% 5% 0 1960 1970 1980 1990 2000 Timeline of Treatment and Outcome for Advanced Ovarian Cancer Representative Chemotherapy Agents Platinum Paclitaxel Topotecan Gemcitabine Doxil Target: DNA b-tubulin Topo-I RN-reductase, Nucleotide pool Topo-II Mechanism:DNA adduct formation TubulinAggregation Stabilize DNA-TopoDNA synth DNA Schedule:Independent Dependent(toxicity)Dependent(efficacy) Dependent Phosporylation Prolonged clearance Resistance:GSH, tolerance, retention MDR-MRP, tubulin mutations Topo-I, BCRP RN-reductase MDR-MRP Topo-II Platinum Interaction:N/A Platelet Sparing ---- Enhanced Toxicity ---- GOG 172: The new Standard of Care Epithelial Ovarian Cancer, Optimal Stage III, No prior therapy, Well balanced arms 1. Intravenous therapy, Cisplatin 75 mg/m2 Paclitaxel 135 mg/m2 (24 h), 83% completed 6 cycles 2. Intraperitoneal therapy, Cisplatin 100 mg/m2 IP d1 Paclitaxel 135 mg/m2 (24 h) IV d1 Paclitaxel 60 mg/m2 IP d8, 42% completed 6 cycles Open: 23-Mar-98 Closed: 29-Jan-01 Accrual: 416 pts (evaluable) GOG 172: The new Standard of Care Median survival = 49.7 mo Median survival = 65.6 mo Ovarian Cancer in the Genomics Era Preclinical studies Translational Oncology Observation Hypothesis Experiment / Trial Result Analysis Integrated genomic analyses of ovarian carcinoma The Cancer Genome Atlas Research Network* Nature 474: 609-615 Background The Cancer Genome Atlas (TCGA) Clinically annotated HGS-OvCa samples Identify molecular abnormalities that influence pathophysiology, affect outcome and constitute therapeutic targets. Microarray analyses: 489 HGS-OvCa tumours, mRNA expression, microRNA (miRNA) expression, DNA copy number and DNA promoter methylation for and Whole exome DNA sequence: 316 samples. Methods Sample inclusion criteria Newly diagnosed patients ovarian serous adenocarcinoma no prior treatment regardless of surgical stage or histologic grade Each frozen tumor specimen had to have a companion normal tissue specimen, which could be adjacent normal tissue, peripheral lymphocytes, or previously extracted germline DNA. Methods Clinical data collection Clinical data can be accessed and downloaded from the TCGA Data Portal Demographics, histopathologic information treatment details outcome parameters Methods Mutated genes in HGS-OvCa Genome copy number abnormality Copy number profiles of 489 HGS-OvCa, compared with profiles of 197 glioblastoma multiforme (GBM) tumours. Copy number increases (red) and decreases (blue) are plotted as a function of distance along the normal genome (vertical axis, divided into chromosomes). Gene and miRNA patterns: Molecular subtype and outcome prediction Altered pathways in HGS-OvCa Altered pathways in HGS-OvCa Altered pathways in HGS-OvCa Altered pathways in HGS-OvCa TCGA findings TCGA: large-scale integrative view of aberrations in HGS-OvCa Mutational spectrum “surprisingly simple” TP53 predominated = 96% BRCA1 and BRCA2 =22% Seven other significantly mutated genes = 2–6% HGS-OvCa is distinct from other histological subtypes Clear-cell: few TP53; recurrent ARID1A, PIK3CA mutations Endometrioid: frequent CTNNB1, ARID1A and PIK3CA; fewer TP53 Mucinous: prevalent KRAS mutations TCGA findings “Remarkable degree of genomic disarray” “Striking contrast to previous TCGA findings in glioblastoma” Mutations and promoter methylation in putative DNA repair genes (HR) may explain the high prevalence of SCNAs. TCGA – what next? New therapeutic approaches? 50% with HR defects : PARP inhibitors commonly deregulated pathways: RB, RAS/PI3K, FOXM1, NOTCH, provide opportunities for therapeutic treatment Inhibitors exist for 22 genes in regions of recurrent amplification aberrant genes or networks: targeted therapies selected to be effective ... The State of Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Chemotherapy Clinical Trials: targeted therapies Translational Oncology Observation Hypothesis Experiment / Trial Result Analysis Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced ovarian cancer American Society of Clinical Oncology, 2009 Presenter: M William Audeh From genomic aberration to pathway PARP PARP inhibition: BRCA-mutant cancers Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced ovarian cancer Olaparib (AZD2281) novel, orally active PARP inhibitor synthetic lethality in homozygous BRCA-mut cells The primary aim of this study was to test the efficacy of olaparib in confirmed BRCA1/BRCA2 carriers with advanced refractory ovarian cancer Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced ovarian cancer Results: 57 enrolled pts 39 BRCA1 deficient and 18 BRCA2 deficient 33 evaluable at 400 mg bid and 24 at 100 mg bid ORR was 33% at 400 mg bd; 12.5% at 100 mg bd Clinical benefit rate: ORR and/or confirmed ≥50% decline in CA125 57.6% at 400 mg bd and 16.7% at 100 mg bd Median PFS: 5.8 mo (med duration 9.6 mo) Toxicity grade 1/2 nausea (44%); fatigue (35%); anemia (14%) Grade 3 toxicity occurred infrequently, and comprised primarily nausea (7%) and leukopenia (5%). Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced ovarian cancer Audeh, et al. Lancet 376:245 – 251 (2010) Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced ovarian cancer Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced ovarian cancer Conclusions: Oral olaparib is well tolerated and highly active in advanced, chemotherapy-refractory BRCA-deficient ovarian cancer Greater activity seen at the higher dose Toxicity in BRCA1/2 carriers was similar to that seen in non-carriers “Positive proof of the concept of the activity and tolerability of genetically defined targeted therapy with olaparib in BRCA-deficient ovarian cancers.” NF-B: Deregulation and Targeting A Genomic approach to Ovarian Cancer Schematic of NF-B signaling Defining the Ovarian Cancer-specific IKK gene signature using IKK inhibitor and IKK shRNA IKK gene signature is coordinately expressed in primary ovarian cancers High IKK activity associates with worse survival in ovarian cancer Intersecting pathways cooperate with NF-κB in ovarian cancer RNAi sensitization screen shRNA library targeting human kinome (500 kinases) Combination with IKK inhibitor (sub-lethal dose)
Slide 46 - Ovarian Cancer in the Genomics Era Christina M. Annunziata, MD, PhD Medical Oncology Branch National Cancer Institute Bethesda, MD Ovarian Cancer Stage Description Incidence Survival I Confined to ovaries 20% 90% II Confined to pelvis 5% 65% III Spread IP or nodes 58% 45% IV Distant metastases 17% <5% Ovarian Cancer: Prognostic Factors Stage Extent of Cytoreduction Histology and Grade Performance Status p53 Status Vital Organ Function Physiologic Age Platinum+Taxane Primary Therapy Intraperitoneal therapy Information from Second-Look Surgery Genotype BRCA1/2 VEGF Production Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Chemotherapy Clinical Trials The State of Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Full assessment of abdomen and pelvis Random biopsy of visually negative areas Lymph node dissection (except Stage I) Optimal reductive surgery Chemotherapy Clinical Trials Surgical staging of ovarian cancer The State of Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Stage I, II - Complete removal of all disease Stage III, IV - Residual disease < 1 cm Chemotherapy Clinical Trials Optimal Cytoreduction 0 cm 0-1 cm 1-2 cm >2 cm Time since initial surgery (years) Proportion surviving The State of Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Chemotherapy Platinum = cisplatin or carboplatin AND Taxane = paclitaxel or docetaxel Intraperitoneal if Stage III, optimal reduction Clinical Trials 1960 1970 1980 1990 2000 CISPLATIN/ALKYLATOR COMBINATIONS INTRA- PERITONEAL PACLITAXEL/ CARBOPLATIN ALKYLATORS CISPLATIN 5 YR SURVIVAL ADVANCED DISEASE 40% 35% 15% 5% 0 1960 1970 1980 1990 2000 Timeline of Treatment and Outcome for Advanced Ovarian Cancer Representative Chemotherapy Agents Platinum Paclitaxel Topotecan Gemcitabine Doxil Target: DNA b-tubulin Topo-I RN-reductase, Nucleotide pool Topo-II Mechanism:DNA adduct formation TubulinAggregation Stabilize DNA-TopoDNA synth DNA Schedule:Independent Dependent(toxicity)Dependent(efficacy) Dependent Phosporylation Prolonged clearance Resistance:GSH, tolerance, retention MDR-MRP, tubulin mutations Topo-I, BCRP RN-reductase MDR-MRP Topo-II Platinum Interaction:N/A Platelet Sparing ---- Enhanced Toxicity ---- GOG 172: The new Standard of Care Epithelial Ovarian Cancer, Optimal Stage III, No prior therapy, Well balanced arms 1. Intravenous therapy, Cisplatin 75 mg/m2 Paclitaxel 135 mg/m2 (24 h), 83% completed 6 cycles 2. Intraperitoneal therapy, Cisplatin 100 mg/m2 IP d1 Paclitaxel 135 mg/m2 (24 h) IV d1 Paclitaxel 60 mg/m2 IP d8, 42% completed 6 cycles Open: 23-Mar-98 Closed: 29-Jan-01 Accrual: 416 pts (evaluable) GOG 172: The new Standard of Care Median survival = 49.7 mo Median survival = 65.6 mo Ovarian Cancer in the Genomics Era Preclinical studies Translational Oncology Observation Hypothesis Experiment / Trial Result Analysis Integrated genomic analyses of ovarian carcinoma The Cancer Genome Atlas Research Network* Nature 474: 609-615 Background The Cancer Genome Atlas (TCGA) Clinically annotated HGS-OvCa samples Identify molecular abnormalities that influence pathophysiology, affect outcome and constitute therapeutic targets. Microarray analyses: 489 HGS-OvCa tumours, mRNA expression, microRNA (miRNA) expression, DNA copy number and DNA promoter methylation for and Whole exome DNA sequence: 316 samples. Methods Sample inclusion criteria Newly diagnosed patients ovarian serous adenocarcinoma no prior treatment regardless of surgical stage or histologic grade Each frozen tumor specimen had to have a companion normal tissue specimen, which could be adjacent normal tissue, peripheral lymphocytes, or previously extracted germline DNA. Methods Clinical data collection Clinical data can be accessed and downloaded from the TCGA Data Portal Demographics, histopathologic information treatment details outcome parameters Methods Mutated genes in HGS-OvCa Genome copy number abnormality Copy number profiles of 489 HGS-OvCa, compared with profiles of 197 glioblastoma multiforme (GBM) tumours. Copy number increases (red) and decreases (blue) are plotted as a function of distance along the normal genome (vertical axis, divided into chromosomes). Gene and miRNA patterns: Molecular subtype and outcome prediction Altered pathways in HGS-OvCa Altered pathways in HGS-OvCa Altered pathways in HGS-OvCa Altered pathways in HGS-OvCa TCGA findings TCGA: large-scale integrative view of aberrations in HGS-OvCa Mutational spectrum “surprisingly simple” TP53 predominated = 96% BRCA1 and BRCA2 =22% Seven other significantly mutated genes = 2–6% HGS-OvCa is distinct from other histological subtypes Clear-cell: few TP53; recurrent ARID1A, PIK3CA mutations Endometrioid: frequent CTNNB1, ARID1A and PIK3CA; fewer TP53 Mucinous: prevalent KRAS mutations TCGA findings “Remarkable degree of genomic disarray” “Striking contrast to previous TCGA findings in glioblastoma” Mutations and promoter methylation in putative DNA repair genes (HR) may explain the high prevalence of SCNAs. TCGA – what next? New therapeutic approaches? 50% with HR defects : PARP inhibitors commonly deregulated pathways: RB, RAS/PI3K, FOXM1, NOTCH, provide opportunities for therapeutic treatment Inhibitors exist for 22 genes in regions of recurrent amplification aberrant genes or networks: targeted therapies selected to be effective ... The State of Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Chemotherapy Clinical Trials: targeted therapies Translational Oncology Observation Hypothesis Experiment / Trial Result Analysis Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced ovarian cancer American Society of Clinical Oncology, 2009 Presenter: M William Audeh From genomic aberration to pathway PARP PARP inhibition: BRCA-mutant cancers Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced ovarian cancer Olaparib (AZD2281) novel, orally active PARP inhibitor synthetic lethality in homozygous BRCA-mut cells The primary aim of this study was to test the efficacy of olaparib in confirmed BRCA1/BRCA2 carriers with advanced refractory ovarian cancer Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced ovarian cancer Results: 57 enrolled pts 39 BRCA1 deficient and 18 BRCA2 deficient 33 evaluable at 400 mg bid and 24 at 100 mg bid ORR was 33% at 400 mg bd; 12.5% at 100 mg bd Clinical benefit rate: ORR and/or confirmed ≥50% decline in CA125 57.6% at 400 mg bd and 16.7% at 100 mg bd Median PFS: 5.8 mo (med duration 9.6 mo) Toxicity grade 1/2 nausea (44%); fatigue (35%); anemia (14%) Grade 3 toxicity occurred infrequently, and comprised primarily nausea (7%) and leukopenia (5%). Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced ovarian cancer Audeh, et al. Lancet 376:245 – 251 (2010) Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced ovarian cancer Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced ovarian cancer Conclusions: Oral olaparib is well tolerated and highly active in advanced, chemotherapy-refractory BRCA-deficient ovarian cancer Greater activity seen at the higher dose Toxicity in BRCA1/2 carriers was similar to that seen in non-carriers “Positive proof of the concept of the activity and tolerability of genetically defined targeted therapy with olaparib in BRCA-deficient ovarian cancers.” NF-B: Deregulation and Targeting A Genomic approach to Ovarian Cancer Schematic of NF-B signaling Defining the Ovarian Cancer-specific IKK gene signature using IKK inhibitor and IKK shRNA IKK gene signature is coordinately expressed in primary ovarian cancers High IKK activity associates with worse survival in ovarian cancer Intersecting pathways cooperate with NF-κB in ovarian cancer RNAi sensitization screen shRNA library targeting human kinome (500 kinases) Combination with IKK inhibitor (sub-lethal dose) Clinical application: How can we leverage caspase 8?
Slide 47 - Ovarian Cancer in the Genomics Era Christina M. Annunziata, MD, PhD Medical Oncology Branch National Cancer Institute Bethesda, MD Ovarian Cancer Stage Description Incidence Survival I Confined to ovaries 20% 90% II Confined to pelvis 5% 65% III Spread IP or nodes 58% 45% IV Distant metastases 17% <5% Ovarian Cancer: Prognostic Factors Stage Extent of Cytoreduction Histology and Grade Performance Status p53 Status Vital Organ Function Physiologic Age Platinum+Taxane Primary Therapy Intraperitoneal therapy Information from Second-Look Surgery Genotype BRCA1/2 VEGF Production Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Chemotherapy Clinical Trials The State of Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Full assessment of abdomen and pelvis Random biopsy of visually negative areas Lymph node dissection (except Stage I) Optimal reductive surgery Chemotherapy Clinical Trials Surgical staging of ovarian cancer The State of Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Stage I, II - Complete removal of all disease Stage III, IV - Residual disease < 1 cm Chemotherapy Clinical Trials Optimal Cytoreduction 0 cm 0-1 cm 1-2 cm >2 cm Time since initial surgery (years) Proportion surviving The State of Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Chemotherapy Platinum = cisplatin or carboplatin AND Taxane = paclitaxel or docetaxel Intraperitoneal if Stage III, optimal reduction Clinical Trials 1960 1970 1980 1990 2000 CISPLATIN/ALKYLATOR COMBINATIONS INTRA- PERITONEAL PACLITAXEL/ CARBOPLATIN ALKYLATORS CISPLATIN 5 YR SURVIVAL ADVANCED DISEASE 40% 35% 15% 5% 0 1960 1970 1980 1990 2000 Timeline of Treatment and Outcome for Advanced Ovarian Cancer Representative Chemotherapy Agents Platinum Paclitaxel Topotecan Gemcitabine Doxil Target: DNA b-tubulin Topo-I RN-reductase, Nucleotide pool Topo-II Mechanism:DNA adduct formation TubulinAggregation Stabilize DNA-TopoDNA synth DNA Schedule:Independent Dependent(toxicity)Dependent(efficacy) Dependent Phosporylation Prolonged clearance Resistance:GSH, tolerance, retention MDR-MRP, tubulin mutations Topo-I, BCRP RN-reductase MDR-MRP Topo-II Platinum Interaction:N/A Platelet Sparing ---- Enhanced Toxicity ---- GOG 172: The new Standard of Care Epithelial Ovarian Cancer, Optimal Stage III, No prior therapy, Well balanced arms 1. Intravenous therapy, Cisplatin 75 mg/m2 Paclitaxel 135 mg/m2 (24 h), 83% completed 6 cycles 2. Intraperitoneal therapy, Cisplatin 100 mg/m2 IP d1 Paclitaxel 135 mg/m2 (24 h) IV d1 Paclitaxel 60 mg/m2 IP d8, 42% completed 6 cycles Open: 23-Mar-98 Closed: 29-Jan-01 Accrual: 416 pts (evaluable) GOG 172: The new Standard of Care Median survival = 49.7 mo Median survival = 65.6 mo Ovarian Cancer in the Genomics Era Preclinical studies Translational Oncology Observation Hypothesis Experiment / Trial Result Analysis Integrated genomic analyses of ovarian carcinoma The Cancer Genome Atlas Research Network* Nature 474: 609-615 Background The Cancer Genome Atlas (TCGA) Clinically annotated HGS-OvCa samples Identify molecular abnormalities that influence pathophysiology, affect outcome and constitute therapeutic targets. Microarray analyses: 489 HGS-OvCa tumours, mRNA expression, microRNA (miRNA) expression, DNA copy number and DNA promoter methylation for and Whole exome DNA sequence: 316 samples. Methods Sample inclusion criteria Newly diagnosed patients ovarian serous adenocarcinoma no prior treatment regardless of surgical stage or histologic grade Each frozen tumor specimen had to have a companion normal tissue specimen, which could be adjacent normal tissue, peripheral lymphocytes, or previously extracted germline DNA. Methods Clinical data collection Clinical data can be accessed and downloaded from the TCGA Data Portal Demographics, histopathologic information treatment details outcome parameters Methods Mutated genes in HGS-OvCa Genome copy number abnormality Copy number profiles of 489 HGS-OvCa, compared with profiles of 197 glioblastoma multiforme (GBM) tumours. Copy number increases (red) and decreases (blue) are plotted as a function of distance along the normal genome (vertical axis, divided into chromosomes). Gene and miRNA patterns: Molecular subtype and outcome prediction Altered pathways in HGS-OvCa Altered pathways in HGS-OvCa Altered pathways in HGS-OvCa Altered pathways in HGS-OvCa TCGA findings TCGA: large-scale integrative view of aberrations in HGS-OvCa Mutational spectrum “surprisingly simple” TP53 predominated = 96% BRCA1 and BRCA2 =22% Seven other significantly mutated genes = 2–6% HGS-OvCa is distinct from other histological subtypes Clear-cell: few TP53; recurrent ARID1A, PIK3CA mutations Endometrioid: frequent CTNNB1, ARID1A and PIK3CA; fewer TP53 Mucinous: prevalent KRAS mutations TCGA findings “Remarkable degree of genomic disarray” “Striking contrast to previous TCGA findings in glioblastoma” Mutations and promoter methylation in putative DNA repair genes (HR) may explain the high prevalence of SCNAs. TCGA – what next? New therapeutic approaches? 50% with HR defects : PARP inhibitors commonly deregulated pathways: RB, RAS/PI3K, FOXM1, NOTCH, provide opportunities for therapeutic treatment Inhibitors exist for 22 genes in regions of recurrent amplification aberrant genes or networks: targeted therapies selected to be effective ... The State of Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Chemotherapy Clinical Trials: targeted therapies Translational Oncology Observation Hypothesis Experiment / Trial Result Analysis Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced ovarian cancer American Society of Clinical Oncology, 2009 Presenter: M William Audeh From genomic aberration to pathway PARP PARP inhibition: BRCA-mutant cancers Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced ovarian cancer Olaparib (AZD2281) novel, orally active PARP inhibitor synthetic lethality in homozygous BRCA-mut cells The primary aim of this study was to test the efficacy of olaparib in confirmed BRCA1/BRCA2 carriers with advanced refractory ovarian cancer Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced ovarian cancer Results: 57 enrolled pts 39 BRCA1 deficient and 18 BRCA2 deficient 33 evaluable at 400 mg bid and 24 at 100 mg bid ORR was 33% at 400 mg bd; 12.5% at 100 mg bd Clinical benefit rate: ORR and/or confirmed ≥50% decline in CA125 57.6% at 400 mg bd and 16.7% at 100 mg bd Median PFS: 5.8 mo (med duration 9.6 mo) Toxicity grade 1/2 nausea (44%); fatigue (35%); anemia (14%) Grade 3 toxicity occurred infrequently, and comprised primarily nausea (7%) and leukopenia (5%). Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced ovarian cancer Audeh, et al. Lancet 376:245 – 251 (2010) Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced ovarian cancer Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced ovarian cancer Conclusions: Oral olaparib is well tolerated and highly active in advanced, chemotherapy-refractory BRCA-deficient ovarian cancer Greater activity seen at the higher dose Toxicity in BRCA1/2 carriers was similar to that seen in non-carriers “Positive proof of the concept of the activity and tolerability of genetically defined targeted therapy with olaparib in BRCA-deficient ovarian cancers.” NF-B: Deregulation and Targeting A Genomic approach to Ovarian Cancer Schematic of NF-B signaling Defining the Ovarian Cancer-specific IKK gene signature using IKK inhibitor and IKK shRNA IKK gene signature is coordinately expressed in primary ovarian cancers High IKK activity associates with worse survival in ovarian cancer Intersecting pathways cooperate with NF-κB in ovarian cancer RNAi sensitization screen shRNA library targeting human kinome (500 kinases) Combination with IKK inhibitor (sub-lethal dose) Clinical application: How can we leverage caspase 8? TNF: NF-kB activation or apoptosis? Normal cells: SMAC released from mitochondria, inhibiting cIAP 1 & removing blockade to activated caspase function apoptotic cell death Tumor cells: apoptosis is dysregulated due to low SMAC or upstream blockade e.g overexpression of IAPs SMAC SMAC X
Slide 48 - Ovarian Cancer in the Genomics Era Christina M. Annunziata, MD, PhD Medical Oncology Branch National Cancer Institute Bethesda, MD Ovarian Cancer Stage Description Incidence Survival I Confined to ovaries 20% 90% II Confined to pelvis 5% 65% III Spread IP or nodes 58% 45% IV Distant metastases 17% <5% Ovarian Cancer: Prognostic Factors Stage Extent of Cytoreduction Histology and Grade Performance Status p53 Status Vital Organ Function Physiologic Age Platinum+Taxane Primary Therapy Intraperitoneal therapy Information from Second-Look Surgery Genotype BRCA1/2 VEGF Production Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Chemotherapy Clinical Trials The State of Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Full assessment of abdomen and pelvis Random biopsy of visually negative areas Lymph node dissection (except Stage I) Optimal reductive surgery Chemotherapy Clinical Trials Surgical staging of ovarian cancer The State of Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Stage I, II - Complete removal of all disease Stage III, IV - Residual disease < 1 cm Chemotherapy Clinical Trials Optimal Cytoreduction 0 cm 0-1 cm 1-2 cm >2 cm Time since initial surgery (years) Proportion surviving The State of Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Chemotherapy Platinum = cisplatin or carboplatin AND Taxane = paclitaxel or docetaxel Intraperitoneal if Stage III, optimal reduction Clinical Trials 1960 1970 1980 1990 2000 CISPLATIN/ALKYLATOR COMBINATIONS INTRA- PERITONEAL PACLITAXEL/ CARBOPLATIN ALKYLATORS CISPLATIN 5 YR SURVIVAL ADVANCED DISEASE 40% 35% 15% 5% 0 1960 1970 1980 1990 2000 Timeline of Treatment and Outcome for Advanced Ovarian Cancer Representative Chemotherapy Agents Platinum Paclitaxel Topotecan Gemcitabine Doxil Target: DNA b-tubulin Topo-I RN-reductase, Nucleotide pool Topo-II Mechanism:DNA adduct formation TubulinAggregation Stabilize DNA-TopoDNA synth DNA Schedule:Independent Dependent(toxicity)Dependent(efficacy) Dependent Phosporylation Prolonged clearance Resistance:GSH, tolerance, retention MDR-MRP, tubulin mutations Topo-I, BCRP RN-reductase MDR-MRP Topo-II Platinum Interaction:N/A Platelet Sparing ---- Enhanced Toxicity ---- GOG 172: The new Standard of Care Epithelial Ovarian Cancer, Optimal Stage III, No prior therapy, Well balanced arms 1. Intravenous therapy, Cisplatin 75 mg/m2 Paclitaxel 135 mg/m2 (24 h), 83% completed 6 cycles 2. Intraperitoneal therapy, Cisplatin 100 mg/m2 IP d1 Paclitaxel 135 mg/m2 (24 h) IV d1 Paclitaxel 60 mg/m2 IP d8, 42% completed 6 cycles Open: 23-Mar-98 Closed: 29-Jan-01 Accrual: 416 pts (evaluable) GOG 172: The new Standard of Care Median survival = 49.7 mo Median survival = 65.6 mo Ovarian Cancer in the Genomics Era Preclinical studies Translational Oncology Observation Hypothesis Experiment / Trial Result Analysis Integrated genomic analyses of ovarian carcinoma The Cancer Genome Atlas Research Network* Nature 474: 609-615 Background The Cancer Genome Atlas (TCGA) Clinically annotated HGS-OvCa samples Identify molecular abnormalities that influence pathophysiology, affect outcome and constitute therapeutic targets. Microarray analyses: 489 HGS-OvCa tumours, mRNA expression, microRNA (miRNA) expression, DNA copy number and DNA promoter methylation for and Whole exome DNA sequence: 316 samples. Methods Sample inclusion criteria Newly diagnosed patients ovarian serous adenocarcinoma no prior treatment regardless of surgical stage or histologic grade Each frozen tumor specimen had to have a companion normal tissue specimen, which could be adjacent normal tissue, peripheral lymphocytes, or previously extracted germline DNA. Methods Clinical data collection Clinical data can be accessed and downloaded from the TCGA Data Portal Demographics, histopathologic information treatment details outcome parameters Methods Mutated genes in HGS-OvCa Genome copy number abnormality Copy number profiles of 489 HGS-OvCa, compared with profiles of 197 glioblastoma multiforme (GBM) tumours. Copy number increases (red) and decreases (blue) are plotted as a function of distance along the normal genome (vertical axis, divided into chromosomes). Gene and miRNA patterns: Molecular subtype and outcome prediction Altered pathways in HGS-OvCa Altered pathways in HGS-OvCa Altered pathways in HGS-OvCa Altered pathways in HGS-OvCa TCGA findings TCGA: large-scale integrative view of aberrations in HGS-OvCa Mutational spectrum “surprisingly simple” TP53 predominated = 96% BRCA1 and BRCA2 =22% Seven other significantly mutated genes = 2–6% HGS-OvCa is distinct from other histological subtypes Clear-cell: few TP53; recurrent ARID1A, PIK3CA mutations Endometrioid: frequent CTNNB1, ARID1A and PIK3CA; fewer TP53 Mucinous: prevalent KRAS mutations TCGA findings “Remarkable degree of genomic disarray” “Striking contrast to previous TCGA findings in glioblastoma” Mutations and promoter methylation in putative DNA repair genes (HR) may explain the high prevalence of SCNAs. TCGA – what next? New therapeutic approaches? 50% with HR defects : PARP inhibitors commonly deregulated pathways: RB, RAS/PI3K, FOXM1, NOTCH, provide opportunities for therapeutic treatment Inhibitors exist for 22 genes in regions of recurrent amplification aberrant genes or networks: targeted therapies selected to be effective ... The State of Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Chemotherapy Clinical Trials: targeted therapies Translational Oncology Observation Hypothesis Experiment / Trial Result Analysis Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced ovarian cancer American Society of Clinical Oncology, 2009 Presenter: M William Audeh From genomic aberration to pathway PARP PARP inhibition: BRCA-mutant cancers Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced ovarian cancer Olaparib (AZD2281) novel, orally active PARP inhibitor synthetic lethality in homozygous BRCA-mut cells The primary aim of this study was to test the efficacy of olaparib in confirmed BRCA1/BRCA2 carriers with advanced refractory ovarian cancer Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced ovarian cancer Results: 57 enrolled pts 39 BRCA1 deficient and 18 BRCA2 deficient 33 evaluable at 400 mg bid and 24 at 100 mg bid ORR was 33% at 400 mg bd; 12.5% at 100 mg bd Clinical benefit rate: ORR and/or confirmed ≥50% decline in CA125 57.6% at 400 mg bd and 16.7% at 100 mg bd Median PFS: 5.8 mo (med duration 9.6 mo) Toxicity grade 1/2 nausea (44%); fatigue (35%); anemia (14%) Grade 3 toxicity occurred infrequently, and comprised primarily nausea (7%) and leukopenia (5%). Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced ovarian cancer Audeh, et al. Lancet 376:245 – 251 (2010) Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced ovarian cancer Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced ovarian cancer Conclusions: Oral olaparib is well tolerated and highly active in advanced, chemotherapy-refractory BRCA-deficient ovarian cancer Greater activity seen at the higher dose Toxicity in BRCA1/2 carriers was similar to that seen in non-carriers “Positive proof of the concept of the activity and tolerability of genetically defined targeted therapy with olaparib in BRCA-deficient ovarian cancers.” NF-B: Deregulation and Targeting A Genomic approach to Ovarian Cancer Schematic of NF-B signaling Defining the Ovarian Cancer-specific IKK gene signature using IKK inhibitor and IKK shRNA IKK gene signature is coordinately expressed in primary ovarian cancers High IKK activity associates with worse survival in ovarian cancer Intersecting pathways cooperate with NF-κB in ovarian cancer RNAi sensitization screen shRNA library targeting human kinome (500 kinases) Combination with IKK inhibitor (sub-lethal dose) Clinical application: How can we leverage caspase 8? TNF: NF-kB activation or apoptosis? Normal cells: SMAC released from mitochondria, inhibiting cIAP 1 & removing blockade to activated caspase function apoptotic cell death Tumor cells: apoptosis is dysregulated due to low SMAC or upstream blockade e.g overexpression of IAPs SMAC SMAC X TNF: NF-kB activation or apoptosis? High immunohistochemical expression of TNFα in ovarian tumor & stroma Increased TNF-α serum concentrations reported in patients with endometrial carcinoma TNFα may activate NF-kB in the presence of IAP (Inhibitors of Apoptotic Proteins), but trigger apoptosis in its absence
Slide 49 - Ovarian Cancer in the Genomics Era Christina M. Annunziata, MD, PhD Medical Oncology Branch National Cancer Institute Bethesda, MD Ovarian Cancer Stage Description Incidence Survival I Confined to ovaries 20% 90% II Confined to pelvis 5% 65% III Spread IP or nodes 58% 45% IV Distant metastases 17% <5% Ovarian Cancer: Prognostic Factors Stage Extent of Cytoreduction Histology and Grade Performance Status p53 Status Vital Organ Function Physiologic Age Platinum+Taxane Primary Therapy Intraperitoneal therapy Information from Second-Look Surgery Genotype BRCA1/2 VEGF Production Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Chemotherapy Clinical Trials The State of Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Full assessment of abdomen and pelvis Random biopsy of visually negative areas Lymph node dissection (except Stage I) Optimal reductive surgery Chemotherapy Clinical Trials Surgical staging of ovarian cancer The State of Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Stage I, II - Complete removal of all disease Stage III, IV - Residual disease < 1 cm Chemotherapy Clinical Trials Optimal Cytoreduction 0 cm 0-1 cm 1-2 cm >2 cm Time since initial surgery (years) Proportion surviving The State of Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Chemotherapy Platinum = cisplatin or carboplatin AND Taxane = paclitaxel or docetaxel Intraperitoneal if Stage III, optimal reduction Clinical Trials 1960 1970 1980 1990 2000 CISPLATIN/ALKYLATOR COMBINATIONS INTRA- PERITONEAL PACLITAXEL/ CARBOPLATIN ALKYLATORS CISPLATIN 5 YR SURVIVAL ADVANCED DISEASE 40% 35% 15% 5% 0 1960 1970 1980 1990 2000 Timeline of Treatment and Outcome for Advanced Ovarian Cancer Representative Chemotherapy Agents Platinum Paclitaxel Topotecan Gemcitabine Doxil Target: DNA b-tubulin Topo-I RN-reductase, Nucleotide pool Topo-II Mechanism:DNA adduct formation TubulinAggregation Stabilize DNA-TopoDNA synth DNA Schedule:Independent Dependent(toxicity)Dependent(efficacy) Dependent Phosporylation Prolonged clearance Resistance:GSH, tolerance, retention MDR-MRP, tubulin mutations Topo-I, BCRP RN-reductase MDR-MRP Topo-II Platinum Interaction:N/A Platelet Sparing ---- Enhanced Toxicity ---- GOG 172: The new Standard of Care Epithelial Ovarian Cancer, Optimal Stage III, No prior therapy, Well balanced arms 1. Intravenous therapy, Cisplatin 75 mg/m2 Paclitaxel 135 mg/m2 (24 h), 83% completed 6 cycles 2. Intraperitoneal therapy, Cisplatin 100 mg/m2 IP d1 Paclitaxel 135 mg/m2 (24 h) IV d1 Paclitaxel 60 mg/m2 IP d8, 42% completed 6 cycles Open: 23-Mar-98 Closed: 29-Jan-01 Accrual: 416 pts (evaluable) GOG 172: The new Standard of Care Median survival = 49.7 mo Median survival = 65.6 mo Ovarian Cancer in the Genomics Era Preclinical studies Translational Oncology Observation Hypothesis Experiment / Trial Result Analysis Integrated genomic analyses of ovarian carcinoma The Cancer Genome Atlas Research Network* Nature 474: 609-615 Background The Cancer Genome Atlas (TCGA) Clinically annotated HGS-OvCa samples Identify molecular abnormalities that influence pathophysiology, affect outcome and constitute therapeutic targets. Microarray analyses: 489 HGS-OvCa tumours, mRNA expression, microRNA (miRNA) expression, DNA copy number and DNA promoter methylation for and Whole exome DNA sequence: 316 samples. Methods Sample inclusion criteria Newly diagnosed patients ovarian serous adenocarcinoma no prior treatment regardless of surgical stage or histologic grade Each frozen tumor specimen had to have a companion normal tissue specimen, which could be adjacent normal tissue, peripheral lymphocytes, or previously extracted germline DNA. Methods Clinical data collection Clinical data can be accessed and downloaded from the TCGA Data Portal Demographics, histopathologic information treatment details outcome parameters Methods Mutated genes in HGS-OvCa Genome copy number abnormality Copy number profiles of 489 HGS-OvCa, compared with profiles of 197 glioblastoma multiforme (GBM) tumours. Copy number increases (red) and decreases (blue) are plotted as a function of distance along the normal genome (vertical axis, divided into chromosomes). Gene and miRNA patterns: Molecular subtype and outcome prediction Altered pathways in HGS-OvCa Altered pathways in HGS-OvCa Altered pathways in HGS-OvCa Altered pathways in HGS-OvCa TCGA findings TCGA: large-scale integrative view of aberrations in HGS-OvCa Mutational spectrum “surprisingly simple” TP53 predominated = 96% BRCA1 and BRCA2 =22% Seven other significantly mutated genes = 2–6% HGS-OvCa is distinct from other histological subtypes Clear-cell: few TP53; recurrent ARID1A, PIK3CA mutations Endometrioid: frequent CTNNB1, ARID1A and PIK3CA; fewer TP53 Mucinous: prevalent KRAS mutations TCGA findings “Remarkable degree of genomic disarray” “Striking contrast to previous TCGA findings in glioblastoma” Mutations and promoter methylation in putative DNA repair genes (HR) may explain the high prevalence of SCNAs. TCGA – what next? New therapeutic approaches? 50% with HR defects : PARP inhibitors commonly deregulated pathways: RB, RAS/PI3K, FOXM1, NOTCH, provide opportunities for therapeutic treatment Inhibitors exist for 22 genes in regions of recurrent amplification aberrant genes or networks: targeted therapies selected to be effective ... The State of Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Chemotherapy Clinical Trials: targeted therapies Translational Oncology Observation Hypothesis Experiment / Trial Result Analysis Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced ovarian cancer American Society of Clinical Oncology, 2009 Presenter: M William Audeh From genomic aberration to pathway PARP PARP inhibition: BRCA-mutant cancers Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced ovarian cancer Olaparib (AZD2281) novel, orally active PARP inhibitor synthetic lethality in homozygous BRCA-mut cells The primary aim of this study was to test the efficacy of olaparib in confirmed BRCA1/BRCA2 carriers with advanced refractory ovarian cancer Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced ovarian cancer Results: 57 enrolled pts 39 BRCA1 deficient and 18 BRCA2 deficient 33 evaluable at 400 mg bid and 24 at 100 mg bid ORR was 33% at 400 mg bd; 12.5% at 100 mg bd Clinical benefit rate: ORR and/or confirmed ≥50% decline in CA125 57.6% at 400 mg bd and 16.7% at 100 mg bd Median PFS: 5.8 mo (med duration 9.6 mo) Toxicity grade 1/2 nausea (44%); fatigue (35%); anemia (14%) Grade 3 toxicity occurred infrequently, and comprised primarily nausea (7%) and leukopenia (5%). Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced ovarian cancer Audeh, et al. Lancet 376:245 – 251 (2010) Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced ovarian cancer Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced ovarian cancer Conclusions: Oral olaparib is well tolerated and highly active in advanced, chemotherapy-refractory BRCA-deficient ovarian cancer Greater activity seen at the higher dose Toxicity in BRCA1/2 carriers was similar to that seen in non-carriers “Positive proof of the concept of the activity and tolerability of genetically defined targeted therapy with olaparib in BRCA-deficient ovarian cancers.” NF-B: Deregulation and Targeting A Genomic approach to Ovarian Cancer Schematic of NF-B signaling Defining the Ovarian Cancer-specific IKK gene signature using IKK inhibitor and IKK shRNA IKK gene signature is coordinately expressed in primary ovarian cancers High IKK activity associates with worse survival in ovarian cancer Intersecting pathways cooperate with NF-κB in ovarian cancer RNAi sensitization screen shRNA library targeting human kinome (500 kinases) Combination with IKK inhibitor (sub-lethal dose) Clinical application: How can we leverage caspase 8? TNF: NF-kB activation or apoptosis? Normal cells: SMAC released from mitochondria, inhibiting cIAP 1 & removing blockade to activated caspase function apoptotic cell death Tumor cells: apoptosis is dysregulated due to low SMAC or upstream blockade e.g overexpression of IAPs SMAC SMAC X TNF: NF-kB activation or apoptosis? High immunohistochemical expression of TNFα in ovarian tumor & stroma Increased TNF-α serum concentrations reported in patients with endometrial carcinoma TNFα may activate NF-kB in the presence of IAP (Inhibitors of Apoptotic Proteins), but trigger apoptosis in its absence New Hypothesis: The intersection of the NF-κB and caspase pathways provides a novel point of therapeutic intervention, where pro-survival signals can be switched to pro-apoptotic killing of cancer cells
Slide 50 - Ovarian Cancer in the Genomics Era Christina M. Annunziata, MD, PhD Medical Oncology Branch National Cancer Institute Bethesda, MD Ovarian Cancer Stage Description Incidence Survival I Confined to ovaries 20% 90% II Confined to pelvis 5% 65% III Spread IP or nodes 58% 45% IV Distant metastases 17% <5% Ovarian Cancer: Prognostic Factors Stage Extent of Cytoreduction Histology and Grade Performance Status p53 Status Vital Organ Function Physiologic Age Platinum+Taxane Primary Therapy Intraperitoneal therapy Information from Second-Look Surgery Genotype BRCA1/2 VEGF Production Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Chemotherapy Clinical Trials The State of Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Full assessment of abdomen and pelvis Random biopsy of visually negative areas Lymph node dissection (except Stage I) Optimal reductive surgery Chemotherapy Clinical Trials Surgical staging of ovarian cancer The State of Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Stage I, II - Complete removal of all disease Stage III, IV - Residual disease < 1 cm Chemotherapy Clinical Trials Optimal Cytoreduction 0 cm 0-1 cm 1-2 cm >2 cm Time since initial surgery (years) Proportion surviving The State of Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Chemotherapy Platinum = cisplatin or carboplatin AND Taxane = paclitaxel or docetaxel Intraperitoneal if Stage III, optimal reduction Clinical Trials 1960 1970 1980 1990 2000 CISPLATIN/ALKYLATOR COMBINATIONS INTRA- PERITONEAL PACLITAXEL/ CARBOPLATIN ALKYLATORS CISPLATIN 5 YR SURVIVAL ADVANCED DISEASE 40% 35% 15% 5% 0 1960 1970 1980 1990 2000 Timeline of Treatment and Outcome for Advanced Ovarian Cancer Representative Chemotherapy Agents Platinum Paclitaxel Topotecan Gemcitabine Doxil Target: DNA b-tubulin Topo-I RN-reductase, Nucleotide pool Topo-II Mechanism:DNA adduct formation TubulinAggregation Stabilize DNA-TopoDNA synth DNA Schedule:Independent Dependent(toxicity)Dependent(efficacy) Dependent Phosporylation Prolonged clearance Resistance:GSH, tolerance, retention MDR-MRP, tubulin mutations Topo-I, BCRP RN-reductase MDR-MRP Topo-II Platinum Interaction:N/A Platelet Sparing ---- Enhanced Toxicity ---- GOG 172: The new Standard of Care Epithelial Ovarian Cancer, Optimal Stage III, No prior therapy, Well balanced arms 1. Intravenous therapy, Cisplatin 75 mg/m2 Paclitaxel 135 mg/m2 (24 h), 83% completed 6 cycles 2. Intraperitoneal therapy, Cisplatin 100 mg/m2 IP d1 Paclitaxel 135 mg/m2 (24 h) IV d1 Paclitaxel 60 mg/m2 IP d8, 42% completed 6 cycles Open: 23-Mar-98 Closed: 29-Jan-01 Accrual: 416 pts (evaluable) GOG 172: The new Standard of Care Median survival = 49.7 mo Median survival = 65.6 mo Ovarian Cancer in the Genomics Era Preclinical studies Translational Oncology Observation Hypothesis Experiment / Trial Result Analysis Integrated genomic analyses of ovarian carcinoma The Cancer Genome Atlas Research Network* Nature 474: 609-615 Background The Cancer Genome Atlas (TCGA) Clinically annotated HGS-OvCa samples Identify molecular abnormalities that influence pathophysiology, affect outcome and constitute therapeutic targets. Microarray analyses: 489 HGS-OvCa tumours, mRNA expression, microRNA (miRNA) expression, DNA copy number and DNA promoter methylation for and Whole exome DNA sequence: 316 samples. Methods Sample inclusion criteria Newly diagnosed patients ovarian serous adenocarcinoma no prior treatment regardless of surgical stage or histologic grade Each frozen tumor specimen had to have a companion normal tissue specimen, which could be adjacent normal tissue, peripheral lymphocytes, or previously extracted germline DNA. Methods Clinical data collection Clinical data can be accessed and downloaded from the TCGA Data Portal Demographics, histopathologic information treatment details outcome parameters Methods Mutated genes in HGS-OvCa Genome copy number abnormality Copy number profiles of 489 HGS-OvCa, compared with profiles of 197 glioblastoma multiforme (GBM) tumours. Copy number increases (red) and decreases (blue) are plotted as a function of distance along the normal genome (vertical axis, divided into chromosomes). Gene and miRNA patterns: Molecular subtype and outcome prediction Altered pathways in HGS-OvCa Altered pathways in HGS-OvCa Altered pathways in HGS-OvCa Altered pathways in HGS-OvCa TCGA findings TCGA: large-scale integrative view of aberrations in HGS-OvCa Mutational spectrum “surprisingly simple” TP53 predominated = 96% BRCA1 and BRCA2 =22% Seven other significantly mutated genes = 2–6% HGS-OvCa is distinct from other histological subtypes Clear-cell: few TP53; recurrent ARID1A, PIK3CA mutations Endometrioid: frequent CTNNB1, ARID1A and PIK3CA; fewer TP53 Mucinous: prevalent KRAS mutations TCGA findings “Remarkable degree of genomic disarray” “Striking contrast to previous TCGA findings in glioblastoma” Mutations and promoter methylation in putative DNA repair genes (HR) may explain the high prevalence of SCNAs. TCGA – what next? New therapeutic approaches? 50% with HR defects : PARP inhibitors commonly deregulated pathways: RB, RAS/PI3K, FOXM1, NOTCH, provide opportunities for therapeutic treatment Inhibitors exist for 22 genes in regions of recurrent amplification aberrant genes or networks: targeted therapies selected to be effective ... The State of Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Chemotherapy Clinical Trials: targeted therapies Translational Oncology Observation Hypothesis Experiment / Trial Result Analysis Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced ovarian cancer American Society of Clinical Oncology, 2009 Presenter: M William Audeh From genomic aberration to pathway PARP PARP inhibition: BRCA-mutant cancers Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced ovarian cancer Olaparib (AZD2281) novel, orally active PARP inhibitor synthetic lethality in homozygous BRCA-mut cells The primary aim of this study was to test the efficacy of olaparib in confirmed BRCA1/BRCA2 carriers with advanced refractory ovarian cancer Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced ovarian cancer Results: 57 enrolled pts 39 BRCA1 deficient and 18 BRCA2 deficient 33 evaluable at 400 mg bid and 24 at 100 mg bid ORR was 33% at 400 mg bd; 12.5% at 100 mg bd Clinical benefit rate: ORR and/or confirmed ≥50% decline in CA125 57.6% at 400 mg bd and 16.7% at 100 mg bd Median PFS: 5.8 mo (med duration 9.6 mo) Toxicity grade 1/2 nausea (44%); fatigue (35%); anemia (14%) Grade 3 toxicity occurred infrequently, and comprised primarily nausea (7%) and leukopenia (5%). Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced ovarian cancer Audeh, et al. Lancet 376:245 – 251 (2010) Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced ovarian cancer Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced ovarian cancer Conclusions: Oral olaparib is well tolerated and highly active in advanced, chemotherapy-refractory BRCA-deficient ovarian cancer Greater activity seen at the higher dose Toxicity in BRCA1/2 carriers was similar to that seen in non-carriers “Positive proof of the concept of the activity and tolerability of genetically defined targeted therapy with olaparib in BRCA-deficient ovarian cancers.” NF-B: Deregulation and Targeting A Genomic approach to Ovarian Cancer Schematic of NF-B signaling Defining the Ovarian Cancer-specific IKK gene signature using IKK inhibitor and IKK shRNA IKK gene signature is coordinately expressed in primary ovarian cancers High IKK activity associates with worse survival in ovarian cancer Intersecting pathways cooperate with NF-κB in ovarian cancer RNAi sensitization screen shRNA library targeting human kinome (500 kinases) Combination with IKK inhibitor (sub-lethal dose) Clinical application: How can we leverage caspase 8? TNF: NF-kB activation or apoptosis? Normal cells: SMAC released from mitochondria, inhibiting cIAP 1 & removing blockade to activated caspase function apoptotic cell death Tumor cells: apoptosis is dysregulated due to low SMAC or upstream blockade e.g overexpression of IAPs SMAC SMAC X TNF: NF-kB activation or apoptosis? High immunohistochemical expression of TNFα in ovarian tumor & stroma Increased TNF-α serum concentrations reported in patients with endometrial carcinoma TNFα may activate NF-kB in the presence of IAP (Inhibitors of Apoptotic Proteins), but trigger apoptosis in its absence New Hypothesis: The intersection of the NF-κB and caspase pathways provides a novel point of therapeutic intervention, where pro-survival signals can be switched to pro-apoptotic killing of cancer cells TNFa enhances SMAC mimetic killing
Slide 51 - Ovarian Cancer in the Genomics Era Christina M. Annunziata, MD, PhD Medical Oncology Branch National Cancer Institute Bethesda, MD Ovarian Cancer Stage Description Incidence Survival I Confined to ovaries 20% 90% II Confined to pelvis 5% 65% III Spread IP or nodes 58% 45% IV Distant metastases 17% <5% Ovarian Cancer: Prognostic Factors Stage Extent of Cytoreduction Histology and Grade Performance Status p53 Status Vital Organ Function Physiologic Age Platinum+Taxane Primary Therapy Intraperitoneal therapy Information from Second-Look Surgery Genotype BRCA1/2 VEGF Production Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Chemotherapy Clinical Trials The State of Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Full assessment of abdomen and pelvis Random biopsy of visually negative areas Lymph node dissection (except Stage I) Optimal reductive surgery Chemotherapy Clinical Trials Surgical staging of ovarian cancer The State of Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Stage I, II - Complete removal of all disease Stage III, IV - Residual disease < 1 cm Chemotherapy Clinical Trials Optimal Cytoreduction 0 cm 0-1 cm 1-2 cm >2 cm Time since initial surgery (years) Proportion surviving The State of Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Chemotherapy Platinum = cisplatin or carboplatin AND Taxane = paclitaxel or docetaxel Intraperitoneal if Stage III, optimal reduction Clinical Trials 1960 1970 1980 1990 2000 CISPLATIN/ALKYLATOR COMBINATIONS INTRA- PERITONEAL PACLITAXEL/ CARBOPLATIN ALKYLATORS CISPLATIN 5 YR SURVIVAL ADVANCED DISEASE 40% 35% 15% 5% 0 1960 1970 1980 1990 2000 Timeline of Treatment and Outcome for Advanced Ovarian Cancer Representative Chemotherapy Agents Platinum Paclitaxel Topotecan Gemcitabine Doxil Target: DNA b-tubulin Topo-I RN-reductase, Nucleotide pool Topo-II Mechanism:DNA adduct formation TubulinAggregation Stabilize DNA-TopoDNA synth DNA Schedule:Independent Dependent(toxicity)Dependent(efficacy) Dependent Phosporylation Prolonged clearance Resistance:GSH, tolerance, retention MDR-MRP, tubulin mutations Topo-I, BCRP RN-reductase MDR-MRP Topo-II Platinum Interaction:N/A Platelet Sparing ---- Enhanced Toxicity ---- GOG 172: The new Standard of Care Epithelial Ovarian Cancer, Optimal Stage III, No prior therapy, Well balanced arms 1. Intravenous therapy, Cisplatin 75 mg/m2 Paclitaxel 135 mg/m2 (24 h), 83% completed 6 cycles 2. Intraperitoneal therapy, Cisplatin 100 mg/m2 IP d1 Paclitaxel 135 mg/m2 (24 h) IV d1 Paclitaxel 60 mg/m2 IP d8, 42% completed 6 cycles Open: 23-Mar-98 Closed: 29-Jan-01 Accrual: 416 pts (evaluable) GOG 172: The new Standard of Care Median survival = 49.7 mo Median survival = 65.6 mo Ovarian Cancer in the Genomics Era Preclinical studies Translational Oncology Observation Hypothesis Experiment / Trial Result Analysis Integrated genomic analyses of ovarian carcinoma The Cancer Genome Atlas Research Network* Nature 474: 609-615 Background The Cancer Genome Atlas (TCGA) Clinically annotated HGS-OvCa samples Identify molecular abnormalities that influence pathophysiology, affect outcome and constitute therapeutic targets. Microarray analyses: 489 HGS-OvCa tumours, mRNA expression, microRNA (miRNA) expression, DNA copy number and DNA promoter methylation for and Whole exome DNA sequence: 316 samples. Methods Sample inclusion criteria Newly diagnosed patients ovarian serous adenocarcinoma no prior treatment regardless of surgical stage or histologic grade Each frozen tumor specimen had to have a companion normal tissue specimen, which could be adjacent normal tissue, peripheral lymphocytes, or previously extracted germline DNA. Methods Clinical data collection Clinical data can be accessed and downloaded from the TCGA Data Portal Demographics, histopathologic information treatment details outcome parameters Methods Mutated genes in HGS-OvCa Genome copy number abnormality Copy number profiles of 489 HGS-OvCa, compared with profiles of 197 glioblastoma multiforme (GBM) tumours. Copy number increases (red) and decreases (blue) are plotted as a function of distance along the normal genome (vertical axis, divided into chromosomes). Gene and miRNA patterns: Molecular subtype and outcome prediction Altered pathways in HGS-OvCa Altered pathways in HGS-OvCa Altered pathways in HGS-OvCa Altered pathways in HGS-OvCa TCGA findings TCGA: large-scale integrative view of aberrations in HGS-OvCa Mutational spectrum “surprisingly simple” TP53 predominated = 96% BRCA1 and BRCA2 =22% Seven other significantly mutated genes = 2–6% HGS-OvCa is distinct from other histological subtypes Clear-cell: few TP53; recurrent ARID1A, PIK3CA mutations Endometrioid: frequent CTNNB1, ARID1A and PIK3CA; fewer TP53 Mucinous: prevalent KRAS mutations TCGA findings “Remarkable degree of genomic disarray” “Striking contrast to previous TCGA findings in glioblastoma” Mutations and promoter methylation in putative DNA repair genes (HR) may explain the high prevalence of SCNAs. TCGA – what next? New therapeutic approaches? 50% with HR defects : PARP inhibitors commonly deregulated pathways: RB, RAS/PI3K, FOXM1, NOTCH, provide opportunities for therapeutic treatment Inhibitors exist for 22 genes in regions of recurrent amplification aberrant genes or networks: targeted therapies selected to be effective ... The State of Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Chemotherapy Clinical Trials: targeted therapies Translational Oncology Observation Hypothesis Experiment / Trial Result Analysis Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced ovarian cancer American Society of Clinical Oncology, 2009 Presenter: M William Audeh From genomic aberration to pathway PARP PARP inhibition: BRCA-mutant cancers Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced ovarian cancer Olaparib (AZD2281) novel, orally active PARP inhibitor synthetic lethality in homozygous BRCA-mut cells The primary aim of this study was to test the efficacy of olaparib in confirmed BRCA1/BRCA2 carriers with advanced refractory ovarian cancer Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced ovarian cancer Results: 57 enrolled pts 39 BRCA1 deficient and 18 BRCA2 deficient 33 evaluable at 400 mg bid and 24 at 100 mg bid ORR was 33% at 400 mg bd; 12.5% at 100 mg bd Clinical benefit rate: ORR and/or confirmed ≥50% decline in CA125 57.6% at 400 mg bd and 16.7% at 100 mg bd Median PFS: 5.8 mo (med duration 9.6 mo) Toxicity grade 1/2 nausea (44%); fatigue (35%); anemia (14%) Grade 3 toxicity occurred infrequently, and comprised primarily nausea (7%) and leukopenia (5%). Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced ovarian cancer Audeh, et al. Lancet 376:245 – 251 (2010) Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced ovarian cancer Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced ovarian cancer Conclusions: Oral olaparib is well tolerated and highly active in advanced, chemotherapy-refractory BRCA-deficient ovarian cancer Greater activity seen at the higher dose Toxicity in BRCA1/2 carriers was similar to that seen in non-carriers “Positive proof of the concept of the activity and tolerability of genetically defined targeted therapy with olaparib in BRCA-deficient ovarian cancers.” NF-B: Deregulation and Targeting A Genomic approach to Ovarian Cancer Schematic of NF-B signaling Defining the Ovarian Cancer-specific IKK gene signature using IKK inhibitor and IKK shRNA IKK gene signature is coordinately expressed in primary ovarian cancers High IKK activity associates with worse survival in ovarian cancer Intersecting pathways cooperate with NF-κB in ovarian cancer RNAi sensitization screen shRNA library targeting human kinome (500 kinases) Combination with IKK inhibitor (sub-lethal dose) Clinical application: How can we leverage caspase 8? TNF: NF-kB activation or apoptosis? Normal cells: SMAC released from mitochondria, inhibiting cIAP 1 & removing blockade to activated caspase function apoptotic cell death Tumor cells: apoptosis is dysregulated due to low SMAC or upstream blockade e.g overexpression of IAPs SMAC SMAC X TNF: NF-kB activation or apoptosis? High immunohistochemical expression of TNFα in ovarian tumor & stroma Increased TNF-α serum concentrations reported in patients with endometrial carcinoma TNFα may activate NF-kB in the presence of IAP (Inhibitors of Apoptotic Proteins), but trigger apoptosis in its absence New Hypothesis: The intersection of the NF-κB and caspase pathways provides a novel point of therapeutic intervention, where pro-survival signals can be switched to pro-apoptotic killing of cancer cells TNFa enhances SMAC mimetic killing SMAC mimetic blocks NF-kB and activates caspases
Slide 52 - Ovarian Cancer in the Genomics Era Christina M. Annunziata, MD, PhD Medical Oncology Branch National Cancer Institute Bethesda, MD Ovarian Cancer Stage Description Incidence Survival I Confined to ovaries 20% 90% II Confined to pelvis 5% 65% III Spread IP or nodes 58% 45% IV Distant metastases 17% <5% Ovarian Cancer: Prognostic Factors Stage Extent of Cytoreduction Histology and Grade Performance Status p53 Status Vital Organ Function Physiologic Age Platinum+Taxane Primary Therapy Intraperitoneal therapy Information from Second-Look Surgery Genotype BRCA1/2 VEGF Production Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Chemotherapy Clinical Trials The State of Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Full assessment of abdomen and pelvis Random biopsy of visually negative areas Lymph node dissection (except Stage I) Optimal reductive surgery Chemotherapy Clinical Trials Surgical staging of ovarian cancer The State of Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Stage I, II - Complete removal of all disease Stage III, IV - Residual disease < 1 cm Chemotherapy Clinical Trials Optimal Cytoreduction 0 cm 0-1 cm 1-2 cm >2 cm Time since initial surgery (years) Proportion surviving The State of Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Chemotherapy Platinum = cisplatin or carboplatin AND Taxane = paclitaxel or docetaxel Intraperitoneal if Stage III, optimal reduction Clinical Trials 1960 1970 1980 1990 2000 CISPLATIN/ALKYLATOR COMBINATIONS INTRA- PERITONEAL PACLITAXEL/ CARBOPLATIN ALKYLATORS CISPLATIN 5 YR SURVIVAL ADVANCED DISEASE 40% 35% 15% 5% 0 1960 1970 1980 1990 2000 Timeline of Treatment and Outcome for Advanced Ovarian Cancer Representative Chemotherapy Agents Platinum Paclitaxel Topotecan Gemcitabine Doxil Target: DNA b-tubulin Topo-I RN-reductase, Nucleotide pool Topo-II Mechanism:DNA adduct formation TubulinAggregation Stabilize DNA-TopoDNA synth DNA Schedule:Independent Dependent(toxicity)Dependent(efficacy) Dependent Phosporylation Prolonged clearance Resistance:GSH, tolerance, retention MDR-MRP, tubulin mutations Topo-I, BCRP RN-reductase MDR-MRP Topo-II Platinum Interaction:N/A Platelet Sparing ---- Enhanced Toxicity ---- GOG 172: The new Standard of Care Epithelial Ovarian Cancer, Optimal Stage III, No prior therapy, Well balanced arms 1. Intravenous therapy, Cisplatin 75 mg/m2 Paclitaxel 135 mg/m2 (24 h), 83% completed 6 cycles 2. Intraperitoneal therapy, Cisplatin 100 mg/m2 IP d1 Paclitaxel 135 mg/m2 (24 h) IV d1 Paclitaxel 60 mg/m2 IP d8, 42% completed 6 cycles Open: 23-Mar-98 Closed: 29-Jan-01 Accrual: 416 pts (evaluable) GOG 172: The new Standard of Care Median survival = 49.7 mo Median survival = 65.6 mo Ovarian Cancer in the Genomics Era Preclinical studies Translational Oncology Observation Hypothesis Experiment / Trial Result Analysis Integrated genomic analyses of ovarian carcinoma The Cancer Genome Atlas Research Network* Nature 474: 609-615 Background The Cancer Genome Atlas (TCGA) Clinically annotated HGS-OvCa samples Identify molecular abnormalities that influence pathophysiology, affect outcome and constitute therapeutic targets. Microarray analyses: 489 HGS-OvCa tumours, mRNA expression, microRNA (miRNA) expression, DNA copy number and DNA promoter methylation for and Whole exome DNA sequence: 316 samples. Methods Sample inclusion criteria Newly diagnosed patients ovarian serous adenocarcinoma no prior treatment regardless of surgical stage or histologic grade Each frozen tumor specimen had to have a companion normal tissue specimen, which could be adjacent normal tissue, peripheral lymphocytes, or previously extracted germline DNA. Methods Clinical data collection Clinical data can be accessed and downloaded from the TCGA Data Portal Demographics, histopathologic information treatment details outcome parameters Methods Mutated genes in HGS-OvCa Genome copy number abnormality Copy number profiles of 489 HGS-OvCa, compared with profiles of 197 glioblastoma multiforme (GBM) tumours. Copy number increases (red) and decreases (blue) are plotted as a function of distance along the normal genome (vertical axis, divided into chromosomes). Gene and miRNA patterns: Molecular subtype and outcome prediction Altered pathways in HGS-OvCa Altered pathways in HGS-OvCa Altered pathways in HGS-OvCa Altered pathways in HGS-OvCa TCGA findings TCGA: large-scale integrative view of aberrations in HGS-OvCa Mutational spectrum “surprisingly simple” TP53 predominated = 96% BRCA1 and BRCA2 =22% Seven other significantly mutated genes = 2–6% HGS-OvCa is distinct from other histological subtypes Clear-cell: few TP53; recurrent ARID1A, PIK3CA mutations Endometrioid: frequent CTNNB1, ARID1A and PIK3CA; fewer TP53 Mucinous: prevalent KRAS mutations TCGA findings “Remarkable degree of genomic disarray” “Striking contrast to previous TCGA findings in glioblastoma” Mutations and promoter methylation in putative DNA repair genes (HR) may explain the high prevalence of SCNAs. TCGA – what next? New therapeutic approaches? 50% with HR defects : PARP inhibitors commonly deregulated pathways: RB, RAS/PI3K, FOXM1, NOTCH, provide opportunities for therapeutic treatment Inhibitors exist for 22 genes in regions of recurrent amplification aberrant genes or networks: targeted therapies selected to be effective ... The State of Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Chemotherapy Clinical Trials: targeted therapies Translational Oncology Observation Hypothesis Experiment / Trial Result Analysis Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced ovarian cancer American Society of Clinical Oncology, 2009 Presenter: M William Audeh From genomic aberration to pathway PARP PARP inhibition: BRCA-mutant cancers Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced ovarian cancer Olaparib (AZD2281) novel, orally active PARP inhibitor synthetic lethality in homozygous BRCA-mut cells The primary aim of this study was to test the efficacy of olaparib in confirmed BRCA1/BRCA2 carriers with advanced refractory ovarian cancer Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced ovarian cancer Results: 57 enrolled pts 39 BRCA1 deficient and 18 BRCA2 deficient 33 evaluable at 400 mg bid and 24 at 100 mg bid ORR was 33% at 400 mg bd; 12.5% at 100 mg bd Clinical benefit rate: ORR and/or confirmed ≥50% decline in CA125 57.6% at 400 mg bd and 16.7% at 100 mg bd Median PFS: 5.8 mo (med duration 9.6 mo) Toxicity grade 1/2 nausea (44%); fatigue (35%); anemia (14%) Grade 3 toxicity occurred infrequently, and comprised primarily nausea (7%) and leukopenia (5%). Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced ovarian cancer Audeh, et al. Lancet 376:245 – 251 (2010) Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced ovarian cancer Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced ovarian cancer Conclusions: Oral olaparib is well tolerated and highly active in advanced, chemotherapy-refractory BRCA-deficient ovarian cancer Greater activity seen at the higher dose Toxicity in BRCA1/2 carriers was similar to that seen in non-carriers “Positive proof of the concept of the activity and tolerability of genetically defined targeted therapy with olaparib in BRCA-deficient ovarian cancers.” NF-B: Deregulation and Targeting A Genomic approach to Ovarian Cancer Schematic of NF-B signaling Defining the Ovarian Cancer-specific IKK gene signature using IKK inhibitor and IKK shRNA IKK gene signature is coordinately expressed in primary ovarian cancers High IKK activity associates with worse survival in ovarian cancer Intersecting pathways cooperate with NF-κB in ovarian cancer RNAi sensitization screen shRNA library targeting human kinome (500 kinases) Combination with IKK inhibitor (sub-lethal dose) Clinical application: How can we leverage caspase 8? TNF: NF-kB activation or apoptosis? Normal cells: SMAC released from mitochondria, inhibiting cIAP 1 & removing blockade to activated caspase function apoptotic cell death Tumor cells: apoptosis is dysregulated due to low SMAC or upstream blockade e.g overexpression of IAPs SMAC SMAC X TNF: NF-kB activation or apoptosis? High immunohistochemical expression of TNFα in ovarian tumor & stroma Increased TNF-α serum concentrations reported in patients with endometrial carcinoma TNFα may activate NF-kB in the presence of IAP (Inhibitors of Apoptotic Proteins), but trigger apoptosis in its absence New Hypothesis: The intersection of the NF-κB and caspase pathways provides a novel point of therapeutic intervention, where pro-survival signals can be switched to pro-apoptotic killing of cancer cells TNFa enhances SMAC mimetic killing SMAC mimetic blocks NF-kB and activates caspases The State of Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Chemotherapy Clinical Trials
Slide 53 - Ovarian Cancer in the Genomics Era Christina M. Annunziata, MD, PhD Medical Oncology Branch National Cancer Institute Bethesda, MD Ovarian Cancer Stage Description Incidence Survival I Confined to ovaries 20% 90% II Confined to pelvis 5% 65% III Spread IP or nodes 58% 45% IV Distant metastases 17% <5% Ovarian Cancer: Prognostic Factors Stage Extent of Cytoreduction Histology and Grade Performance Status p53 Status Vital Organ Function Physiologic Age Platinum+Taxane Primary Therapy Intraperitoneal therapy Information from Second-Look Surgery Genotype BRCA1/2 VEGF Production Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Chemotherapy Clinical Trials The State of Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Full assessment of abdomen and pelvis Random biopsy of visually negative areas Lymph node dissection (except Stage I) Optimal reductive surgery Chemotherapy Clinical Trials Surgical staging of ovarian cancer The State of Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Stage I, II - Complete removal of all disease Stage III, IV - Residual disease < 1 cm Chemotherapy Clinical Trials Optimal Cytoreduction 0 cm 0-1 cm 1-2 cm >2 cm Time since initial surgery (years) Proportion surviving The State of Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Chemotherapy Platinum = cisplatin or carboplatin AND Taxane = paclitaxel or docetaxel Intraperitoneal if Stage III, optimal reduction Clinical Trials 1960 1970 1980 1990 2000 CISPLATIN/ALKYLATOR COMBINATIONS INTRA- PERITONEAL PACLITAXEL/ CARBOPLATIN ALKYLATORS CISPLATIN 5 YR SURVIVAL ADVANCED DISEASE 40% 35% 15% 5% 0 1960 1970 1980 1990 2000 Timeline of Treatment and Outcome for Advanced Ovarian Cancer Representative Chemotherapy Agents Platinum Paclitaxel Topotecan Gemcitabine Doxil Target: DNA b-tubulin Topo-I RN-reductase, Nucleotide pool Topo-II Mechanism:DNA adduct formation TubulinAggregation Stabilize DNA-TopoDNA synth DNA Schedule:Independent Dependent(toxicity)Dependent(efficacy) Dependent Phosporylation Prolonged clearance Resistance:GSH, tolerance, retention MDR-MRP, tubulin mutations Topo-I, BCRP RN-reductase MDR-MRP Topo-II Platinum Interaction:N/A Platelet Sparing ---- Enhanced Toxicity ---- GOG 172: The new Standard of Care Epithelial Ovarian Cancer, Optimal Stage III, No prior therapy, Well balanced arms 1. Intravenous therapy, Cisplatin 75 mg/m2 Paclitaxel 135 mg/m2 (24 h), 83% completed 6 cycles 2. Intraperitoneal therapy, Cisplatin 100 mg/m2 IP d1 Paclitaxel 135 mg/m2 (24 h) IV d1 Paclitaxel 60 mg/m2 IP d8, 42% completed 6 cycles Open: 23-Mar-98 Closed: 29-Jan-01 Accrual: 416 pts (evaluable) GOG 172: The new Standard of Care Median survival = 49.7 mo Median survival = 65.6 mo Ovarian Cancer in the Genomics Era Preclinical studies Translational Oncology Observation Hypothesis Experiment / Trial Result Analysis Integrated genomic analyses of ovarian carcinoma The Cancer Genome Atlas Research Network* Nature 474: 609-615 Background The Cancer Genome Atlas (TCGA) Clinically annotated HGS-OvCa samples Identify molecular abnormalities that influence pathophysiology, affect outcome and constitute therapeutic targets. Microarray analyses: 489 HGS-OvCa tumours, mRNA expression, microRNA (miRNA) expression, DNA copy number and DNA promoter methylation for and Whole exome DNA sequence: 316 samples. Methods Sample inclusion criteria Newly diagnosed patients ovarian serous adenocarcinoma no prior treatment regardless of surgical stage or histologic grade Each frozen tumor specimen had to have a companion normal tissue specimen, which could be adjacent normal tissue, peripheral lymphocytes, or previously extracted germline DNA. Methods Clinical data collection Clinical data can be accessed and downloaded from the TCGA Data Portal Demographics, histopathologic information treatment details outcome parameters Methods Mutated genes in HGS-OvCa Genome copy number abnormality Copy number profiles of 489 HGS-OvCa, compared with profiles of 197 glioblastoma multiforme (GBM) tumours. Copy number increases (red) and decreases (blue) are plotted as a function of distance along the normal genome (vertical axis, divided into chromosomes). Gene and miRNA patterns: Molecular subtype and outcome prediction Altered pathways in HGS-OvCa Altered pathways in HGS-OvCa Altered pathways in HGS-OvCa Altered pathways in HGS-OvCa TCGA findings TCGA: large-scale integrative view of aberrations in HGS-OvCa Mutational spectrum “surprisingly simple” TP53 predominated = 96% BRCA1 and BRCA2 =22% Seven other significantly mutated genes = 2–6% HGS-OvCa is distinct from other histological subtypes Clear-cell: few TP53; recurrent ARID1A, PIK3CA mutations Endometrioid: frequent CTNNB1, ARID1A and PIK3CA; fewer TP53 Mucinous: prevalent KRAS mutations TCGA findings “Remarkable degree of genomic disarray” “Striking contrast to previous TCGA findings in glioblastoma” Mutations and promoter methylation in putative DNA repair genes (HR) may explain the high prevalence of SCNAs. TCGA – what next? New therapeutic approaches? 50% with HR defects : PARP inhibitors commonly deregulated pathways: RB, RAS/PI3K, FOXM1, NOTCH, provide opportunities for therapeutic treatment Inhibitors exist for 22 genes in regions of recurrent amplification aberrant genes or networks: targeted therapies selected to be effective ... The State of Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Chemotherapy Clinical Trials: targeted therapies Translational Oncology Observation Hypothesis Experiment / Trial Result Analysis Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced ovarian cancer American Society of Clinical Oncology, 2009 Presenter: M William Audeh From genomic aberration to pathway PARP PARP inhibition: BRCA-mutant cancers Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced ovarian cancer Olaparib (AZD2281) novel, orally active PARP inhibitor synthetic lethality in homozygous BRCA-mut cells The primary aim of this study was to test the efficacy of olaparib in confirmed BRCA1/BRCA2 carriers with advanced refractory ovarian cancer Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced ovarian cancer Results: 57 enrolled pts 39 BRCA1 deficient and 18 BRCA2 deficient 33 evaluable at 400 mg bid and 24 at 100 mg bid ORR was 33% at 400 mg bd; 12.5% at 100 mg bd Clinical benefit rate: ORR and/or confirmed ≥50% decline in CA125 57.6% at 400 mg bd and 16.7% at 100 mg bd Median PFS: 5.8 mo (med duration 9.6 mo) Toxicity grade 1/2 nausea (44%); fatigue (35%); anemia (14%) Grade 3 toxicity occurred infrequently, and comprised primarily nausea (7%) and leukopenia (5%). Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced ovarian cancer Audeh, et al. Lancet 376:245 – 251 (2010) Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced ovarian cancer Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced ovarian cancer Conclusions: Oral olaparib is well tolerated and highly active in advanced, chemotherapy-refractory BRCA-deficient ovarian cancer Greater activity seen at the higher dose Toxicity in BRCA1/2 carriers was similar to that seen in non-carriers “Positive proof of the concept of the activity and tolerability of genetically defined targeted therapy with olaparib in BRCA-deficient ovarian cancers.” NF-B: Deregulation and Targeting A Genomic approach to Ovarian Cancer Schematic of NF-B signaling Defining the Ovarian Cancer-specific IKK gene signature using IKK inhibitor and IKK shRNA IKK gene signature is coordinately expressed in primary ovarian cancers High IKK activity associates with worse survival in ovarian cancer Intersecting pathways cooperate with NF-κB in ovarian cancer RNAi sensitization screen shRNA library targeting human kinome (500 kinases) Combination with IKK inhibitor (sub-lethal dose) Clinical application: How can we leverage caspase 8? TNF: NF-kB activation or apoptosis? Normal cells: SMAC released from mitochondria, inhibiting cIAP 1 & removing blockade to activated caspase function apoptotic cell death Tumor cells: apoptosis is dysregulated due to low SMAC or upstream blockade e.g overexpression of IAPs SMAC SMAC X TNF: NF-kB activation or apoptosis? High immunohistochemical expression of TNFα in ovarian tumor & stroma Increased TNF-α serum concentrations reported in patients with endometrial carcinoma TNFα may activate NF-kB in the presence of IAP (Inhibitors of Apoptotic Proteins), but trigger apoptosis in its absence New Hypothesis: The intersection of the NF-κB and caspase pathways provides a novel point of therapeutic intervention, where pro-survival signals can be switched to pro-apoptotic killing of cancer cells TNFa enhances SMAC mimetic killing SMAC mimetic blocks NF-kB and activates caspases The State of Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Chemotherapy Clinical Trials Phase 2 study of SMAC-mimetic for relapsed ovarian cancer SMAC mimetic administered IV on days 1, 8, 15 of 28 day cycle 18g needle biopsy prior to start, and after 2 cycles CT scan restaging every 2 cycles
Slide 54 - Ovarian Cancer in the Genomics Era Christina M. Annunziata, MD, PhD Medical Oncology Branch National Cancer Institute Bethesda, MD Ovarian Cancer Stage Description Incidence Survival I Confined to ovaries 20% 90% II Confined to pelvis 5% 65% III Spread IP or nodes 58% 45% IV Distant metastases 17% <5% Ovarian Cancer: Prognostic Factors Stage Extent of Cytoreduction Histology and Grade Performance Status p53 Status Vital Organ Function Physiologic Age Platinum+Taxane Primary Therapy Intraperitoneal therapy Information from Second-Look Surgery Genotype BRCA1/2 VEGF Production Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Chemotherapy Clinical Trials The State of Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Full assessment of abdomen and pelvis Random biopsy of visually negative areas Lymph node dissection (except Stage I) Optimal reductive surgery Chemotherapy Clinical Trials Surgical staging of ovarian cancer The State of Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Stage I, II - Complete removal of all disease Stage III, IV - Residual disease < 1 cm Chemotherapy Clinical Trials Optimal Cytoreduction 0 cm 0-1 cm 1-2 cm >2 cm Time since initial surgery (years) Proportion surviving The State of Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Chemotherapy Platinum = cisplatin or carboplatin AND Taxane = paclitaxel or docetaxel Intraperitoneal if Stage III, optimal reduction Clinical Trials 1960 1970 1980 1990 2000 CISPLATIN/ALKYLATOR COMBINATIONS INTRA- PERITONEAL PACLITAXEL/ CARBOPLATIN ALKYLATORS CISPLATIN 5 YR SURVIVAL ADVANCED DISEASE 40% 35% 15% 5% 0 1960 1970 1980 1990 2000 Timeline of Treatment and Outcome for Advanced Ovarian Cancer Representative Chemotherapy Agents Platinum Paclitaxel Topotecan Gemcitabine Doxil Target: DNA b-tubulin Topo-I RN-reductase, Nucleotide pool Topo-II Mechanism:DNA adduct formation TubulinAggregation Stabilize DNA-TopoDNA synth DNA Schedule:Independent Dependent(toxicity)Dependent(efficacy) Dependent Phosporylation Prolonged clearance Resistance:GSH, tolerance, retention MDR-MRP, tubulin mutations Topo-I, BCRP RN-reductase MDR-MRP Topo-II Platinum Interaction:N/A Platelet Sparing ---- Enhanced Toxicity ---- GOG 172: The new Standard of Care Epithelial Ovarian Cancer, Optimal Stage III, No prior therapy, Well balanced arms 1. Intravenous therapy, Cisplatin 75 mg/m2 Paclitaxel 135 mg/m2 (24 h), 83% completed 6 cycles 2. Intraperitoneal therapy, Cisplatin 100 mg/m2 IP d1 Paclitaxel 135 mg/m2 (24 h) IV d1 Paclitaxel 60 mg/m2 IP d8, 42% completed 6 cycles Open: 23-Mar-98 Closed: 29-Jan-01 Accrual: 416 pts (evaluable) GOG 172: The new Standard of Care Median survival = 49.7 mo Median survival = 65.6 mo Ovarian Cancer in the Genomics Era Preclinical studies Translational Oncology Observation Hypothesis Experiment / Trial Result Analysis Integrated genomic analyses of ovarian carcinoma The Cancer Genome Atlas Research Network* Nature 474: 609-615 Background The Cancer Genome Atlas (TCGA) Clinically annotated HGS-OvCa samples Identify molecular abnormalities that influence pathophysiology, affect outcome and constitute therapeutic targets. Microarray analyses: 489 HGS-OvCa tumours, mRNA expression, microRNA (miRNA) expression, DNA copy number and DNA promoter methylation for and Whole exome DNA sequence: 316 samples. Methods Sample inclusion criteria Newly diagnosed patients ovarian serous adenocarcinoma no prior treatment regardless of surgical stage or histologic grade Each frozen tumor specimen had to have a companion normal tissue specimen, which could be adjacent normal tissue, peripheral lymphocytes, or previously extracted germline DNA. Methods Clinical data collection Clinical data can be accessed and downloaded from the TCGA Data Portal Demographics, histopathologic information treatment details outcome parameters Methods Mutated genes in HGS-OvCa Genome copy number abnormality Copy number profiles of 489 HGS-OvCa, compared with profiles of 197 glioblastoma multiforme (GBM) tumours. Copy number increases (red) and decreases (blue) are plotted as a function of distance along the normal genome (vertical axis, divided into chromosomes). Gene and miRNA patterns: Molecular subtype and outcome prediction Altered pathways in HGS-OvCa Altered pathways in HGS-OvCa Altered pathways in HGS-OvCa Altered pathways in HGS-OvCa TCGA findings TCGA: large-scale integrative view of aberrations in HGS-OvCa Mutational spectrum “surprisingly simple” TP53 predominated = 96% BRCA1 and BRCA2 =22% Seven other significantly mutated genes = 2–6% HGS-OvCa is distinct from other histological subtypes Clear-cell: few TP53; recurrent ARID1A, PIK3CA mutations Endometrioid: frequent CTNNB1, ARID1A and PIK3CA; fewer TP53 Mucinous: prevalent KRAS mutations TCGA findings “Remarkable degree of genomic disarray” “Striking contrast to previous TCGA findings in glioblastoma” Mutations and promoter methylation in putative DNA repair genes (HR) may explain the high prevalence of SCNAs. TCGA – what next? New therapeutic approaches? 50% with HR defects : PARP inhibitors commonly deregulated pathways: RB, RAS/PI3K, FOXM1, NOTCH, provide opportunities for therapeutic treatment Inhibitors exist for 22 genes in regions of recurrent amplification aberrant genes or networks: targeted therapies selected to be effective ... The State of Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Chemotherapy Clinical Trials: targeted therapies Translational Oncology Observation Hypothesis Experiment / Trial Result Analysis Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced ovarian cancer American Society of Clinical Oncology, 2009 Presenter: M William Audeh From genomic aberration to pathway PARP PARP inhibition: BRCA-mutant cancers Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced ovarian cancer Olaparib (AZD2281) novel, orally active PARP inhibitor synthetic lethality in homozygous BRCA-mut cells The primary aim of this study was to test the efficacy of olaparib in confirmed BRCA1/BRCA2 carriers with advanced refractory ovarian cancer Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced ovarian cancer Results: 57 enrolled pts 39 BRCA1 deficient and 18 BRCA2 deficient 33 evaluable at 400 mg bid and 24 at 100 mg bid ORR was 33% at 400 mg bd; 12.5% at 100 mg bd Clinical benefit rate: ORR and/or confirmed ≥50% decline in CA125 57.6% at 400 mg bd and 16.7% at 100 mg bd Median PFS: 5.8 mo (med duration 9.6 mo) Toxicity grade 1/2 nausea (44%); fatigue (35%); anemia (14%) Grade 3 toxicity occurred infrequently, and comprised primarily nausea (7%) and leukopenia (5%). Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced ovarian cancer Audeh, et al. Lancet 376:245 – 251 (2010) Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced ovarian cancer Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced ovarian cancer Conclusions: Oral olaparib is well tolerated and highly active in advanced, chemotherapy-refractory BRCA-deficient ovarian cancer Greater activity seen at the higher dose Toxicity in BRCA1/2 carriers was similar to that seen in non-carriers “Positive proof of the concept of the activity and tolerability of genetically defined targeted therapy with olaparib in BRCA-deficient ovarian cancers.” NF-B: Deregulation and Targeting A Genomic approach to Ovarian Cancer Schematic of NF-B signaling Defining the Ovarian Cancer-specific IKK gene signature using IKK inhibitor and IKK shRNA IKK gene signature is coordinately expressed in primary ovarian cancers High IKK activity associates with worse survival in ovarian cancer Intersecting pathways cooperate with NF-κB in ovarian cancer RNAi sensitization screen shRNA library targeting human kinome (500 kinases) Combination with IKK inhibitor (sub-lethal dose) Clinical application: How can we leverage caspase 8? TNF: NF-kB activation or apoptosis? Normal cells: SMAC released from mitochondria, inhibiting cIAP 1 & removing blockade to activated caspase function apoptotic cell death Tumor cells: apoptosis is dysregulated due to low SMAC or upstream blockade e.g overexpression of IAPs SMAC SMAC X TNF: NF-kB activation or apoptosis? High immunohistochemical expression of TNFα in ovarian tumor & stroma Increased TNF-α serum concentrations reported in patients with endometrial carcinoma TNFα may activate NF-kB in the presence of IAP (Inhibitors of Apoptotic Proteins), but trigger apoptosis in its absence New Hypothesis: The intersection of the NF-κB and caspase pathways provides a novel point of therapeutic intervention, where pro-survival signals can be switched to pro-apoptotic killing of cancer cells TNFa enhances SMAC mimetic killing SMAC mimetic blocks NF-kB and activates caspases The State of Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Chemotherapy Clinical Trials Phase 2 study of SMAC-mimetic for relapsed ovarian cancer SMAC mimetic administered IV on days 1, 8, 15 of 28 day cycle 18g needle biopsy prior to start, and after 2 cycles CT scan restaging every 2 cycles Primary Objectives Dual endpoint efficacy (GOG criteria): objective response (confirmed complete response [CR] of any duration or confirmed partial response [PR] of any duration defined by RECIST version 1.1 criteria) progression-free survival lasting greater than 6 months, in patients with relapsed platinum refractory or resistant ovarian cancer, primary peritoneal cancer, fallopian tube cancer treated with TL32711 at 47mg/m2
Slide 55 - Ovarian Cancer in the Genomics Era Christina M. Annunziata, MD, PhD Medical Oncology Branch National Cancer Institute Bethesda, MD Ovarian Cancer Stage Description Incidence Survival I Confined to ovaries 20% 90% II Confined to pelvis 5% 65% III Spread IP or nodes 58% 45% IV Distant metastases 17% <5% Ovarian Cancer: Prognostic Factors Stage Extent of Cytoreduction Histology and Grade Performance Status p53 Status Vital Organ Function Physiologic Age Platinum+Taxane Primary Therapy Intraperitoneal therapy Information from Second-Look Surgery Genotype BRCA1/2 VEGF Production Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Chemotherapy Clinical Trials The State of Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Full assessment of abdomen and pelvis Random biopsy of visually negative areas Lymph node dissection (except Stage I) Optimal reductive surgery Chemotherapy Clinical Trials Surgical staging of ovarian cancer The State of Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Stage I, II - Complete removal of all disease Stage III, IV - Residual disease < 1 cm Chemotherapy Clinical Trials Optimal Cytoreduction 0 cm 0-1 cm 1-2 cm >2 cm Time since initial surgery (years) Proportion surviving The State of Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Chemotherapy Platinum = cisplatin or carboplatin AND Taxane = paclitaxel or docetaxel Intraperitoneal if Stage III, optimal reduction Clinical Trials 1960 1970 1980 1990 2000 CISPLATIN/ALKYLATOR COMBINATIONS INTRA- PERITONEAL PACLITAXEL/ CARBOPLATIN ALKYLATORS CISPLATIN 5 YR SURVIVAL ADVANCED DISEASE 40% 35% 15% 5% 0 1960 1970 1980 1990 2000 Timeline of Treatment and Outcome for Advanced Ovarian Cancer Representative Chemotherapy Agents Platinum Paclitaxel Topotecan Gemcitabine Doxil Target: DNA b-tubulin Topo-I RN-reductase, Nucleotide pool Topo-II Mechanism:DNA adduct formation TubulinAggregation Stabilize DNA-TopoDNA synth DNA Schedule:Independent Dependent(toxicity)Dependent(efficacy) Dependent Phosporylation Prolonged clearance Resistance:GSH, tolerance, retention MDR-MRP, tubulin mutations Topo-I, BCRP RN-reductase MDR-MRP Topo-II Platinum Interaction:N/A Platelet Sparing ---- Enhanced Toxicity ---- GOG 172: The new Standard of Care Epithelial Ovarian Cancer, Optimal Stage III, No prior therapy, Well balanced arms 1. Intravenous therapy, Cisplatin 75 mg/m2 Paclitaxel 135 mg/m2 (24 h), 83% completed 6 cycles 2. Intraperitoneal therapy, Cisplatin 100 mg/m2 IP d1 Paclitaxel 135 mg/m2 (24 h) IV d1 Paclitaxel 60 mg/m2 IP d8, 42% completed 6 cycles Open: 23-Mar-98 Closed: 29-Jan-01 Accrual: 416 pts (evaluable) GOG 172: The new Standard of Care Median survival = 49.7 mo Median survival = 65.6 mo Ovarian Cancer in the Genomics Era Preclinical studies Translational Oncology Observation Hypothesis Experiment / Trial Result Analysis Integrated genomic analyses of ovarian carcinoma The Cancer Genome Atlas Research Network* Nature 474: 609-615 Background The Cancer Genome Atlas (TCGA) Clinically annotated HGS-OvCa samples Identify molecular abnormalities that influence pathophysiology, affect outcome and constitute therapeutic targets. Microarray analyses: 489 HGS-OvCa tumours, mRNA expression, microRNA (miRNA) expression, DNA copy number and DNA promoter methylation for and Whole exome DNA sequence: 316 samples. Methods Sample inclusion criteria Newly diagnosed patients ovarian serous adenocarcinoma no prior treatment regardless of surgical stage or histologic grade Each frozen tumor specimen had to have a companion normal tissue specimen, which could be adjacent normal tissue, peripheral lymphocytes, or previously extracted germline DNA. Methods Clinical data collection Clinical data can be accessed and downloaded from the TCGA Data Portal Demographics, histopathologic information treatment details outcome parameters Methods Mutated genes in HGS-OvCa Genome copy number abnormality Copy number profiles of 489 HGS-OvCa, compared with profiles of 197 glioblastoma multiforme (GBM) tumours. Copy number increases (red) and decreases (blue) are plotted as a function of distance along the normal genome (vertical axis, divided into chromosomes). Gene and miRNA patterns: Molecular subtype and outcome prediction Altered pathways in HGS-OvCa Altered pathways in HGS-OvCa Altered pathways in HGS-OvCa Altered pathways in HGS-OvCa TCGA findings TCGA: large-scale integrative view of aberrations in HGS-OvCa Mutational spectrum “surprisingly simple” TP53 predominated = 96% BRCA1 and BRCA2 =22% Seven other significantly mutated genes = 2–6% HGS-OvCa is distinct from other histological subtypes Clear-cell: few TP53; recurrent ARID1A, PIK3CA mutations Endometrioid: frequent CTNNB1, ARID1A and PIK3CA; fewer TP53 Mucinous: prevalent KRAS mutations TCGA findings “Remarkable degree of genomic disarray” “Striking contrast to previous TCGA findings in glioblastoma” Mutations and promoter methylation in putative DNA repair genes (HR) may explain the high prevalence of SCNAs. TCGA – what next? New therapeutic approaches? 50% with HR defects : PARP inhibitors commonly deregulated pathways: RB, RAS/PI3K, FOXM1, NOTCH, provide opportunities for therapeutic treatment Inhibitors exist for 22 genes in regions of recurrent amplification aberrant genes or networks: targeted therapies selected to be effective ... The State of Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Chemotherapy Clinical Trials: targeted therapies Translational Oncology Observation Hypothesis Experiment / Trial Result Analysis Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced ovarian cancer American Society of Clinical Oncology, 2009 Presenter: M William Audeh From genomic aberration to pathway PARP PARP inhibition: BRCA-mutant cancers Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced ovarian cancer Olaparib (AZD2281) novel, orally active PARP inhibitor synthetic lethality in homozygous BRCA-mut cells The primary aim of this study was to test the efficacy of olaparib in confirmed BRCA1/BRCA2 carriers with advanced refractory ovarian cancer Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced ovarian cancer Results: 57 enrolled pts 39 BRCA1 deficient and 18 BRCA2 deficient 33 evaluable at 400 mg bid and 24 at 100 mg bid ORR was 33% at 400 mg bd; 12.5% at 100 mg bd Clinical benefit rate: ORR and/or confirmed ≥50% decline in CA125 57.6% at 400 mg bd and 16.7% at 100 mg bd Median PFS: 5.8 mo (med duration 9.6 mo) Toxicity grade 1/2 nausea (44%); fatigue (35%); anemia (14%) Grade 3 toxicity occurred infrequently, and comprised primarily nausea (7%) and leukopenia (5%). Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced ovarian cancer Audeh, et al. Lancet 376:245 – 251 (2010) Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced ovarian cancer Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced ovarian cancer Conclusions: Oral olaparib is well tolerated and highly active in advanced, chemotherapy-refractory BRCA-deficient ovarian cancer Greater activity seen at the higher dose Toxicity in BRCA1/2 carriers was similar to that seen in non-carriers “Positive proof of the concept of the activity and tolerability of genetically defined targeted therapy with olaparib in BRCA-deficient ovarian cancers.” NF-B: Deregulation and Targeting A Genomic approach to Ovarian Cancer Schematic of NF-B signaling Defining the Ovarian Cancer-specific IKK gene signature using IKK inhibitor and IKK shRNA IKK gene signature is coordinately expressed in primary ovarian cancers High IKK activity associates with worse survival in ovarian cancer Intersecting pathways cooperate with NF-κB in ovarian cancer RNAi sensitization screen shRNA library targeting human kinome (500 kinases) Combination with IKK inhibitor (sub-lethal dose) Clinical application: How can we leverage caspase 8? TNF: NF-kB activation or apoptosis? Normal cells: SMAC released from mitochondria, inhibiting cIAP 1 & removing blockade to activated caspase function apoptotic cell death Tumor cells: apoptosis is dysregulated due to low SMAC or upstream blockade e.g overexpression of IAPs SMAC SMAC X TNF: NF-kB activation or apoptosis? High immunohistochemical expression of TNFα in ovarian tumor & stroma Increased TNF-α serum concentrations reported in patients with endometrial carcinoma TNFα may activate NF-kB in the presence of IAP (Inhibitors of Apoptotic Proteins), but trigger apoptosis in its absence New Hypothesis: The intersection of the NF-κB and caspase pathways provides a novel point of therapeutic intervention, where pro-survival signals can be switched to pro-apoptotic killing of cancer cells TNFa enhances SMAC mimetic killing SMAC mimetic blocks NF-kB and activates caspases The State of Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Chemotherapy Clinical Trials Phase 2 study of SMAC-mimetic for relapsed ovarian cancer SMAC mimetic administered IV on days 1, 8, 15 of 28 day cycle 18g needle biopsy prior to start, and after 2 cycles CT scan restaging every 2 cycles Primary Objectives Dual endpoint efficacy (GOG criteria): objective response (confirmed complete response [CR] of any duration or confirmed partial response [PR] of any duration defined by RECIST version 1.1 criteria) progression-free survival lasting greater than 6 months, in patients with relapsed platinum refractory or resistant ovarian cancer, primary peritoneal cancer, fallopian tube cancer treated with TL32711 at 47mg/m2 Correlative Studies on paired pre- and post-treatment tumor biopsies & on archival tissue. Immunohistochemistry for measurement of TNF alpha and TRAIL (NIH Core Facility) Gene expression profiling of NF-kappaB signature (Annunziata lab) Apoptosis gene signature (TetraLogic Pharmaceuticals) Response biomarkers: cIAP1 & cIAP2 (immediate targets of TL37211), with degradation of cIAP1 & 2 protein post-treatment activated caspase-8 – a measure of extrinsic pathway PARP cleavage – a measure of activated caspase-3 and ultimate apoptosis pathway activation (both extrinsic and intrinsic pathways).
Slide 56 - Ovarian Cancer in the Genomics Era Christina M. Annunziata, MD, PhD Medical Oncology Branch National Cancer Institute Bethesda, MD Ovarian Cancer Stage Description Incidence Survival I Confined to ovaries 20% 90% II Confined to pelvis 5% 65% III Spread IP or nodes 58% 45% IV Distant metastases 17% <5% Ovarian Cancer: Prognostic Factors Stage Extent of Cytoreduction Histology and Grade Performance Status p53 Status Vital Organ Function Physiologic Age Platinum+Taxane Primary Therapy Intraperitoneal therapy Information from Second-Look Surgery Genotype BRCA1/2 VEGF Production Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Chemotherapy Clinical Trials The State of Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Full assessment of abdomen and pelvis Random biopsy of visually negative areas Lymph node dissection (except Stage I) Optimal reductive surgery Chemotherapy Clinical Trials Surgical staging of ovarian cancer The State of Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Stage I, II - Complete removal of all disease Stage III, IV - Residual disease < 1 cm Chemotherapy Clinical Trials Optimal Cytoreduction 0 cm 0-1 cm 1-2 cm >2 cm Time since initial surgery (years) Proportion surviving The State of Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Chemotherapy Platinum = cisplatin or carboplatin AND Taxane = paclitaxel or docetaxel Intraperitoneal if Stage III, optimal reduction Clinical Trials 1960 1970 1980 1990 2000 CISPLATIN/ALKYLATOR COMBINATIONS INTRA- PERITONEAL PACLITAXEL/ CARBOPLATIN ALKYLATORS CISPLATIN 5 YR SURVIVAL ADVANCED DISEASE 40% 35% 15% 5% 0 1960 1970 1980 1990 2000 Timeline of Treatment and Outcome for Advanced Ovarian Cancer Representative Chemotherapy Agents Platinum Paclitaxel Topotecan Gemcitabine Doxil Target: DNA b-tubulin Topo-I RN-reductase, Nucleotide pool Topo-II Mechanism:DNA adduct formation TubulinAggregation Stabilize DNA-TopoDNA synth DNA Schedule:Independent Dependent(toxicity)Dependent(efficacy) Dependent Phosporylation Prolonged clearance Resistance:GSH, tolerance, retention MDR-MRP, tubulin mutations Topo-I, BCRP RN-reductase MDR-MRP Topo-II Platinum Interaction:N/A Platelet Sparing ---- Enhanced Toxicity ---- GOG 172: The new Standard of Care Epithelial Ovarian Cancer, Optimal Stage III, No prior therapy, Well balanced arms 1. Intravenous therapy, Cisplatin 75 mg/m2 Paclitaxel 135 mg/m2 (24 h), 83% completed 6 cycles 2. Intraperitoneal therapy, Cisplatin 100 mg/m2 IP d1 Paclitaxel 135 mg/m2 (24 h) IV d1 Paclitaxel 60 mg/m2 IP d8, 42% completed 6 cycles Open: 23-Mar-98 Closed: 29-Jan-01 Accrual: 416 pts (evaluable) GOG 172: The new Standard of Care Median survival = 49.7 mo Median survival = 65.6 mo Ovarian Cancer in the Genomics Era Preclinical studies Translational Oncology Observation Hypothesis Experiment / Trial Result Analysis Integrated genomic analyses of ovarian carcinoma The Cancer Genome Atlas Research Network* Nature 474: 609-615 Background The Cancer Genome Atlas (TCGA) Clinically annotated HGS-OvCa samples Identify molecular abnormalities that influence pathophysiology, affect outcome and constitute therapeutic targets. Microarray analyses: 489 HGS-OvCa tumours, mRNA expression, microRNA (miRNA) expression, DNA copy number and DNA promoter methylation for and Whole exome DNA sequence: 316 samples. Methods Sample inclusion criteria Newly diagnosed patients ovarian serous adenocarcinoma no prior treatment regardless of surgical stage or histologic grade Each frozen tumor specimen had to have a companion normal tissue specimen, which could be adjacent normal tissue, peripheral lymphocytes, or previously extracted germline DNA. Methods Clinical data collection Clinical data can be accessed and downloaded from the TCGA Data Portal Demographics, histopathologic information treatment details outcome parameters Methods Mutated genes in HGS-OvCa Genome copy number abnormality Copy number profiles of 489 HGS-OvCa, compared with profiles of 197 glioblastoma multiforme (GBM) tumours. Copy number increases (red) and decreases (blue) are plotted as a function of distance along the normal genome (vertical axis, divided into chromosomes). Gene and miRNA patterns: Molecular subtype and outcome prediction Altered pathways in HGS-OvCa Altered pathways in HGS-OvCa Altered pathways in HGS-OvCa Altered pathways in HGS-OvCa TCGA findings TCGA: large-scale integrative view of aberrations in HGS-OvCa Mutational spectrum “surprisingly simple” TP53 predominated = 96% BRCA1 and BRCA2 =22% Seven other significantly mutated genes = 2–6% HGS-OvCa is distinct from other histological subtypes Clear-cell: few TP53; recurrent ARID1A, PIK3CA mutations Endometrioid: frequent CTNNB1, ARID1A and PIK3CA; fewer TP53 Mucinous: prevalent KRAS mutations TCGA findings “Remarkable degree of genomic disarray” “Striking contrast to previous TCGA findings in glioblastoma” Mutations and promoter methylation in putative DNA repair genes (HR) may explain the high prevalence of SCNAs. TCGA – what next? New therapeutic approaches? 50% with HR defects : PARP inhibitors commonly deregulated pathways: RB, RAS/PI3K, FOXM1, NOTCH, provide opportunities for therapeutic treatment Inhibitors exist for 22 genes in regions of recurrent amplification aberrant genes or networks: targeted therapies selected to be effective ... The State of Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Chemotherapy Clinical Trials: targeted therapies Translational Oncology Observation Hypothesis Experiment / Trial Result Analysis Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced ovarian cancer American Society of Clinical Oncology, 2009 Presenter: M William Audeh From genomic aberration to pathway PARP PARP inhibition: BRCA-mutant cancers Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced ovarian cancer Olaparib (AZD2281) novel, orally active PARP inhibitor synthetic lethality in homozygous BRCA-mut cells The primary aim of this study was to test the efficacy of olaparib in confirmed BRCA1/BRCA2 carriers with advanced refractory ovarian cancer Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced ovarian cancer Results: 57 enrolled pts 39 BRCA1 deficient and 18 BRCA2 deficient 33 evaluable at 400 mg bid and 24 at 100 mg bid ORR was 33% at 400 mg bd; 12.5% at 100 mg bd Clinical benefit rate: ORR and/or confirmed ≥50% decline in CA125 57.6% at 400 mg bd and 16.7% at 100 mg bd Median PFS: 5.8 mo (med duration 9.6 mo) Toxicity grade 1/2 nausea (44%); fatigue (35%); anemia (14%) Grade 3 toxicity occurred infrequently, and comprised primarily nausea (7%) and leukopenia (5%). Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced ovarian cancer Audeh, et al. Lancet 376:245 – 251 (2010) Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced ovarian cancer Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced ovarian cancer Conclusions: Oral olaparib is well tolerated and highly active in advanced, chemotherapy-refractory BRCA-deficient ovarian cancer Greater activity seen at the higher dose Toxicity in BRCA1/2 carriers was similar to that seen in non-carriers “Positive proof of the concept of the activity and tolerability of genetically defined targeted therapy with olaparib in BRCA-deficient ovarian cancers.” NF-B: Deregulation and Targeting A Genomic approach to Ovarian Cancer Schematic of NF-B signaling Defining the Ovarian Cancer-specific IKK gene signature using IKK inhibitor and IKK shRNA IKK gene signature is coordinately expressed in primary ovarian cancers High IKK activity associates with worse survival in ovarian cancer Intersecting pathways cooperate with NF-κB in ovarian cancer RNAi sensitization screen shRNA library targeting human kinome (500 kinases) Combination with IKK inhibitor (sub-lethal dose) Clinical application: How can we leverage caspase 8? TNF: NF-kB activation or apoptosis? Normal cells: SMAC released from mitochondria, inhibiting cIAP 1 & removing blockade to activated caspase function apoptotic cell death Tumor cells: apoptosis is dysregulated due to low SMAC or upstream blockade e.g overexpression of IAPs SMAC SMAC X TNF: NF-kB activation or apoptosis? High immunohistochemical expression of TNFα in ovarian tumor & stroma Increased TNF-α serum concentrations reported in patients with endometrial carcinoma TNFα may activate NF-kB in the presence of IAP (Inhibitors of Apoptotic Proteins), but trigger apoptosis in its absence New Hypothesis: The intersection of the NF-κB and caspase pathways provides a novel point of therapeutic intervention, where pro-survival signals can be switched to pro-apoptotic killing of cancer cells TNFa enhances SMAC mimetic killing SMAC mimetic blocks NF-kB and activates caspases The State of Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Chemotherapy Clinical Trials Phase 2 study of SMAC-mimetic for relapsed ovarian cancer SMAC mimetic administered IV on days 1, 8, 15 of 28 day cycle 18g needle biopsy prior to start, and after 2 cycles CT scan restaging every 2 cycles Primary Objectives Dual endpoint efficacy (GOG criteria): objective response (confirmed complete response [CR] of any duration or confirmed partial response [PR] of any duration defined by RECIST version 1.1 criteria) progression-free survival lasting greater than 6 months, in patients with relapsed platinum refractory or resistant ovarian cancer, primary peritoneal cancer, fallopian tube cancer treated with TL32711 at 47mg/m2 Correlative Studies on paired pre- and post-treatment tumor biopsies & on archival tissue. Immunohistochemistry for measurement of TNF alpha and TRAIL (NIH Core Facility) Gene expression profiling of NF-kappaB signature (Annunziata lab) Apoptosis gene signature (TetraLogic Pharmaceuticals) Response biomarkers: cIAP1 & cIAP2 (immediate targets of TL37211), with degradation of cIAP1 & 2 protein post-treatment activated caspase-8 – a measure of extrinsic pathway PARP cleavage – a measure of activated caspase-3 and ultimate apoptosis pathway activation (both extrinsic and intrinsic pathways). Correlative Studies on blood specimens PBMC Cleaved caspase 3/7 levels in PBMCs Cleaved PARP levels in PBMCs cIAP1/2 levels in PBMCs Plasma TNF alpha, TRAIL IL-6, IL-8
Slide 57 - Ovarian Cancer in the Genomics Era Christina M. Annunziata, MD, PhD Medical Oncology Branch National Cancer Institute Bethesda, MD Ovarian Cancer Stage Description Incidence Survival I Confined to ovaries 20% 90% II Confined to pelvis 5% 65% III Spread IP or nodes 58% 45% IV Distant metastases 17% <5% Ovarian Cancer: Prognostic Factors Stage Extent of Cytoreduction Histology and Grade Performance Status p53 Status Vital Organ Function Physiologic Age Platinum+Taxane Primary Therapy Intraperitoneal therapy Information from Second-Look Surgery Genotype BRCA1/2 VEGF Production Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Chemotherapy Clinical Trials The State of Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Full assessment of abdomen and pelvis Random biopsy of visually negative areas Lymph node dissection (except Stage I) Optimal reductive surgery Chemotherapy Clinical Trials Surgical staging of ovarian cancer The State of Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Stage I, II - Complete removal of all disease Stage III, IV - Residual disease < 1 cm Chemotherapy Clinical Trials Optimal Cytoreduction 0 cm 0-1 cm 1-2 cm >2 cm Time since initial surgery (years) Proportion surviving The State of Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Chemotherapy Platinum = cisplatin or carboplatin AND Taxane = paclitaxel or docetaxel Intraperitoneal if Stage III, optimal reduction Clinical Trials 1960 1970 1980 1990 2000 CISPLATIN/ALKYLATOR COMBINATIONS INTRA- PERITONEAL PACLITAXEL/ CARBOPLATIN ALKYLATORS CISPLATIN 5 YR SURVIVAL ADVANCED DISEASE 40% 35% 15% 5% 0 1960 1970 1980 1990 2000 Timeline of Treatment and Outcome for Advanced Ovarian Cancer Representative Chemotherapy Agents Platinum Paclitaxel Topotecan Gemcitabine Doxil Target: DNA b-tubulin Topo-I RN-reductase, Nucleotide pool Topo-II Mechanism:DNA adduct formation TubulinAggregation Stabilize DNA-TopoDNA synth DNA Schedule:Independent Dependent(toxicity)Dependent(efficacy) Dependent Phosporylation Prolonged clearance Resistance:GSH, tolerance, retention MDR-MRP, tubulin mutations Topo-I, BCRP RN-reductase MDR-MRP Topo-II Platinum Interaction:N/A Platelet Sparing ---- Enhanced Toxicity ---- GOG 172: The new Standard of Care Epithelial Ovarian Cancer, Optimal Stage III, No prior therapy, Well balanced arms 1. Intravenous therapy, Cisplatin 75 mg/m2 Paclitaxel 135 mg/m2 (24 h), 83% completed 6 cycles 2. Intraperitoneal therapy, Cisplatin 100 mg/m2 IP d1 Paclitaxel 135 mg/m2 (24 h) IV d1 Paclitaxel 60 mg/m2 IP d8, 42% completed 6 cycles Open: 23-Mar-98 Closed: 29-Jan-01 Accrual: 416 pts (evaluable) GOG 172: The new Standard of Care Median survival = 49.7 mo Median survival = 65.6 mo Ovarian Cancer in the Genomics Era Preclinical studies Translational Oncology Observation Hypothesis Experiment / Trial Result Analysis Integrated genomic analyses of ovarian carcinoma The Cancer Genome Atlas Research Network* Nature 474: 609-615 Background The Cancer Genome Atlas (TCGA) Clinically annotated HGS-OvCa samples Identify molecular abnormalities that influence pathophysiology, affect outcome and constitute therapeutic targets. Microarray analyses: 489 HGS-OvCa tumours, mRNA expression, microRNA (miRNA) expression, DNA copy number and DNA promoter methylation for and Whole exome DNA sequence: 316 samples. Methods Sample inclusion criteria Newly diagnosed patients ovarian serous adenocarcinoma no prior treatment regardless of surgical stage or histologic grade Each frozen tumor specimen had to have a companion normal tissue specimen, which could be adjacent normal tissue, peripheral lymphocytes, or previously extracted germline DNA. Methods Clinical data collection Clinical data can be accessed and downloaded from the TCGA Data Portal Demographics, histopathologic information treatment details outcome parameters Methods Mutated genes in HGS-OvCa Genome copy number abnormality Copy number profiles of 489 HGS-OvCa, compared with profiles of 197 glioblastoma multiforme (GBM) tumours. Copy number increases (red) and decreases (blue) are plotted as a function of distance along the normal genome (vertical axis, divided into chromosomes). Gene and miRNA patterns: Molecular subtype and outcome prediction Altered pathways in HGS-OvCa Altered pathways in HGS-OvCa Altered pathways in HGS-OvCa Altered pathways in HGS-OvCa TCGA findings TCGA: large-scale integrative view of aberrations in HGS-OvCa Mutational spectrum “surprisingly simple” TP53 predominated = 96% BRCA1 and BRCA2 =22% Seven other significantly mutated genes = 2–6% HGS-OvCa is distinct from other histological subtypes Clear-cell: few TP53; recurrent ARID1A, PIK3CA mutations Endometrioid: frequent CTNNB1, ARID1A and PIK3CA; fewer TP53 Mucinous: prevalent KRAS mutations TCGA findings “Remarkable degree of genomic disarray” “Striking contrast to previous TCGA findings in glioblastoma” Mutations and promoter methylation in putative DNA repair genes (HR) may explain the high prevalence of SCNAs. TCGA – what next? New therapeutic approaches? 50% with HR defects : PARP inhibitors commonly deregulated pathways: RB, RAS/PI3K, FOXM1, NOTCH, provide opportunities for therapeutic treatment Inhibitors exist for 22 genes in regions of recurrent amplification aberrant genes or networks: targeted therapies selected to be effective ... The State of Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Chemotherapy Clinical Trials: targeted therapies Translational Oncology Observation Hypothesis Experiment / Trial Result Analysis Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced ovarian cancer American Society of Clinical Oncology, 2009 Presenter: M William Audeh From genomic aberration to pathway PARP PARP inhibition: BRCA-mutant cancers Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced ovarian cancer Olaparib (AZD2281) novel, orally active PARP inhibitor synthetic lethality in homozygous BRCA-mut cells The primary aim of this study was to test the efficacy of olaparib in confirmed BRCA1/BRCA2 carriers with advanced refractory ovarian cancer Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced ovarian cancer Results: 57 enrolled pts 39 BRCA1 deficient and 18 BRCA2 deficient 33 evaluable at 400 mg bid and 24 at 100 mg bid ORR was 33% at 400 mg bd; 12.5% at 100 mg bd Clinical benefit rate: ORR and/or confirmed ≥50% decline in CA125 57.6% at 400 mg bd and 16.7% at 100 mg bd Median PFS: 5.8 mo (med duration 9.6 mo) Toxicity grade 1/2 nausea (44%); fatigue (35%); anemia (14%) Grade 3 toxicity occurred infrequently, and comprised primarily nausea (7%) and leukopenia (5%). Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced ovarian cancer Audeh, et al. Lancet 376:245 – 251 (2010) Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced ovarian cancer Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced ovarian cancer Conclusions: Oral olaparib is well tolerated and highly active in advanced, chemotherapy-refractory BRCA-deficient ovarian cancer Greater activity seen at the higher dose Toxicity in BRCA1/2 carriers was similar to that seen in non-carriers “Positive proof of the concept of the activity and tolerability of genetically defined targeted therapy with olaparib in BRCA-deficient ovarian cancers.” NF-B: Deregulation and Targeting A Genomic approach to Ovarian Cancer Schematic of NF-B signaling Defining the Ovarian Cancer-specific IKK gene signature using IKK inhibitor and IKK shRNA IKK gene signature is coordinately expressed in primary ovarian cancers High IKK activity associates with worse survival in ovarian cancer Intersecting pathways cooperate with NF-κB in ovarian cancer RNAi sensitization screen shRNA library targeting human kinome (500 kinases) Combination with IKK inhibitor (sub-lethal dose) Clinical application: How can we leverage caspase 8? TNF: NF-kB activation or apoptosis? Normal cells: SMAC released from mitochondria, inhibiting cIAP 1 & removing blockade to activated caspase function apoptotic cell death Tumor cells: apoptosis is dysregulated due to low SMAC or upstream blockade e.g overexpression of IAPs SMAC SMAC X TNF: NF-kB activation or apoptosis? High immunohistochemical expression of TNFα in ovarian tumor & stroma Increased TNF-α serum concentrations reported in patients with endometrial carcinoma TNFα may activate NF-kB in the presence of IAP (Inhibitors of Apoptotic Proteins), but trigger apoptosis in its absence New Hypothesis: The intersection of the NF-κB and caspase pathways provides a novel point of therapeutic intervention, where pro-survival signals can be switched to pro-apoptotic killing of cancer cells TNFa enhances SMAC mimetic killing SMAC mimetic blocks NF-kB and activates caspases The State of Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Chemotherapy Clinical Trials Phase 2 study of SMAC-mimetic for relapsed ovarian cancer SMAC mimetic administered IV on days 1, 8, 15 of 28 day cycle 18g needle biopsy prior to start, and after 2 cycles CT scan restaging every 2 cycles Primary Objectives Dual endpoint efficacy (GOG criteria): objective response (confirmed complete response [CR] of any duration or confirmed partial response [PR] of any duration defined by RECIST version 1.1 criteria) progression-free survival lasting greater than 6 months, in patients with relapsed platinum refractory or resistant ovarian cancer, primary peritoneal cancer, fallopian tube cancer treated with TL32711 at 47mg/m2 Correlative Studies on paired pre- and post-treatment tumor biopsies & on archival tissue. Immunohistochemistry for measurement of TNF alpha and TRAIL (NIH Core Facility) Gene expression profiling of NF-kappaB signature (Annunziata lab) Apoptosis gene signature (TetraLogic Pharmaceuticals) Response biomarkers: cIAP1 & cIAP2 (immediate targets of TL37211), with degradation of cIAP1 & 2 protein post-treatment activated caspase-8 – a measure of extrinsic pathway PARP cleavage – a measure of activated caspase-3 and ultimate apoptosis pathway activation (both extrinsic and intrinsic pathways). Correlative Studies on blood specimens PBMC Cleaved caspase 3/7 levels in PBMCs Cleaved PARP levels in PBMCs cIAP1/2 levels in PBMCs Plasma TNF alpha, TRAIL IL-6, IL-8 Translational Oncology Observation Hypothesis Experiment / Trial Result Analysis
Slide 58 - Ovarian Cancer in the Genomics Era Christina M. Annunziata, MD, PhD Medical Oncology Branch National Cancer Institute Bethesda, MD Ovarian Cancer Stage Description Incidence Survival I Confined to ovaries 20% 90% II Confined to pelvis 5% 65% III Spread IP or nodes 58% 45% IV Distant metastases 17% <5% Ovarian Cancer: Prognostic Factors Stage Extent of Cytoreduction Histology and Grade Performance Status p53 Status Vital Organ Function Physiologic Age Platinum+Taxane Primary Therapy Intraperitoneal therapy Information from Second-Look Surgery Genotype BRCA1/2 VEGF Production Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Chemotherapy Clinical Trials The State of Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Full assessment of abdomen and pelvis Random biopsy of visually negative areas Lymph node dissection (except Stage I) Optimal reductive surgery Chemotherapy Clinical Trials Surgical staging of ovarian cancer The State of Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Stage I, II - Complete removal of all disease Stage III, IV - Residual disease < 1 cm Chemotherapy Clinical Trials Optimal Cytoreduction 0 cm 0-1 cm 1-2 cm >2 cm Time since initial surgery (years) Proportion surviving The State of Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Chemotherapy Platinum = cisplatin or carboplatin AND Taxane = paclitaxel or docetaxel Intraperitoneal if Stage III, optimal reduction Clinical Trials 1960 1970 1980 1990 2000 CISPLATIN/ALKYLATOR COMBINATIONS INTRA- PERITONEAL PACLITAXEL/ CARBOPLATIN ALKYLATORS CISPLATIN 5 YR SURVIVAL ADVANCED DISEASE 40% 35% 15% 5% 0 1960 1970 1980 1990 2000 Timeline of Treatment and Outcome for Advanced Ovarian Cancer Representative Chemotherapy Agents Platinum Paclitaxel Topotecan Gemcitabine Doxil Target: DNA b-tubulin Topo-I RN-reductase, Nucleotide pool Topo-II Mechanism:DNA adduct formation TubulinAggregation Stabilize DNA-TopoDNA synth DNA Schedule:Independent Dependent(toxicity)Dependent(efficacy) Dependent Phosporylation Prolonged clearance Resistance:GSH, tolerance, retention MDR-MRP, tubulin mutations Topo-I, BCRP RN-reductase MDR-MRP Topo-II Platinum Interaction:N/A Platelet Sparing ---- Enhanced Toxicity ---- GOG 172: The new Standard of Care Epithelial Ovarian Cancer, Optimal Stage III, No prior therapy, Well balanced arms 1. Intravenous therapy, Cisplatin 75 mg/m2 Paclitaxel 135 mg/m2 (24 h), 83% completed 6 cycles 2. Intraperitoneal therapy, Cisplatin 100 mg/m2 IP d1 Paclitaxel 135 mg/m2 (24 h) IV d1 Paclitaxel 60 mg/m2 IP d8, 42% completed 6 cycles Open: 23-Mar-98 Closed: 29-Jan-01 Accrual: 416 pts (evaluable) GOG 172: The new Standard of Care Median survival = 49.7 mo Median survival = 65.6 mo Ovarian Cancer in the Genomics Era Preclinical studies Translational Oncology Observation Hypothesis Experiment / Trial Result Analysis Integrated genomic analyses of ovarian carcinoma The Cancer Genome Atlas Research Network* Nature 474: 609-615 Background The Cancer Genome Atlas (TCGA) Clinically annotated HGS-OvCa samples Identify molecular abnormalities that influence pathophysiology, affect outcome and constitute therapeutic targets. Microarray analyses: 489 HGS-OvCa tumours, mRNA expression, microRNA (miRNA) expression, DNA copy number and DNA promoter methylation for and Whole exome DNA sequence: 316 samples. Methods Sample inclusion criteria Newly diagnosed patients ovarian serous adenocarcinoma no prior treatment regardless of surgical stage or histologic grade Each frozen tumor specimen had to have a companion normal tissue specimen, which could be adjacent normal tissue, peripheral lymphocytes, or previously extracted germline DNA. Methods Clinical data collection Clinical data can be accessed and downloaded from the TCGA Data Portal Demographics, histopathologic information treatment details outcome parameters Methods Mutated genes in HGS-OvCa Genome copy number abnormality Copy number profiles of 489 HGS-OvCa, compared with profiles of 197 glioblastoma multiforme (GBM) tumours. Copy number increases (red) and decreases (blue) are plotted as a function of distance along the normal genome (vertical axis, divided into chromosomes). Gene and miRNA patterns: Molecular subtype and outcome prediction Altered pathways in HGS-OvCa Altered pathways in HGS-OvCa Altered pathways in HGS-OvCa Altered pathways in HGS-OvCa TCGA findings TCGA: large-scale integrative view of aberrations in HGS-OvCa Mutational spectrum “surprisingly simple” TP53 predominated = 96% BRCA1 and BRCA2 =22% Seven other significantly mutated genes = 2–6% HGS-OvCa is distinct from other histological subtypes Clear-cell: few TP53; recurrent ARID1A, PIK3CA mutations Endometrioid: frequent CTNNB1, ARID1A and PIK3CA; fewer TP53 Mucinous: prevalent KRAS mutations TCGA findings “Remarkable degree of genomic disarray” “Striking contrast to previous TCGA findings in glioblastoma” Mutations and promoter methylation in putative DNA repair genes (HR) may explain the high prevalence of SCNAs. TCGA – what next? New therapeutic approaches? 50% with HR defects : PARP inhibitors commonly deregulated pathways: RB, RAS/PI3K, FOXM1, NOTCH, provide opportunities for therapeutic treatment Inhibitors exist for 22 genes in regions of recurrent amplification aberrant genes or networks: targeted therapies selected to be effective ... The State of Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Chemotherapy Clinical Trials: targeted therapies Translational Oncology Observation Hypothesis Experiment / Trial Result Analysis Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced ovarian cancer American Society of Clinical Oncology, 2009 Presenter: M William Audeh From genomic aberration to pathway PARP PARP inhibition: BRCA-mutant cancers Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced ovarian cancer Olaparib (AZD2281) novel, orally active PARP inhibitor synthetic lethality in homozygous BRCA-mut cells The primary aim of this study was to test the efficacy of olaparib in confirmed BRCA1/BRCA2 carriers with advanced refractory ovarian cancer Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced ovarian cancer Results: 57 enrolled pts 39 BRCA1 deficient and 18 BRCA2 deficient 33 evaluable at 400 mg bid and 24 at 100 mg bid ORR was 33% at 400 mg bd; 12.5% at 100 mg bd Clinical benefit rate: ORR and/or confirmed ≥50% decline in CA125 57.6% at 400 mg bd and 16.7% at 100 mg bd Median PFS: 5.8 mo (med duration 9.6 mo) Toxicity grade 1/2 nausea (44%); fatigue (35%); anemia (14%) Grade 3 toxicity occurred infrequently, and comprised primarily nausea (7%) and leukopenia (5%). Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced ovarian cancer Audeh, et al. Lancet 376:245 – 251 (2010) Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced ovarian cancer Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced ovarian cancer Conclusions: Oral olaparib is well tolerated and highly active in advanced, chemotherapy-refractory BRCA-deficient ovarian cancer Greater activity seen at the higher dose Toxicity in BRCA1/2 carriers was similar to that seen in non-carriers “Positive proof of the concept of the activity and tolerability of genetically defined targeted therapy with olaparib in BRCA-deficient ovarian cancers.” NF-B: Deregulation and Targeting A Genomic approach to Ovarian Cancer Schematic of NF-B signaling Defining the Ovarian Cancer-specific IKK gene signature using IKK inhibitor and IKK shRNA IKK gene signature is coordinately expressed in primary ovarian cancers High IKK activity associates with worse survival in ovarian cancer Intersecting pathways cooperate with NF-κB in ovarian cancer RNAi sensitization screen shRNA library targeting human kinome (500 kinases) Combination with IKK inhibitor (sub-lethal dose) Clinical application: How can we leverage caspase 8? TNF: NF-kB activation or apoptosis? Normal cells: SMAC released from mitochondria, inhibiting cIAP 1 & removing blockade to activated caspase function apoptotic cell death Tumor cells: apoptosis is dysregulated due to low SMAC or upstream blockade e.g overexpression of IAPs SMAC SMAC X TNF: NF-kB activation or apoptosis? High immunohistochemical expression of TNFα in ovarian tumor & stroma Increased TNF-α serum concentrations reported in patients with endometrial carcinoma TNFα may activate NF-kB in the presence of IAP (Inhibitors of Apoptotic Proteins), but trigger apoptosis in its absence New Hypothesis: The intersection of the NF-κB and caspase pathways provides a novel point of therapeutic intervention, where pro-survival signals can be switched to pro-apoptotic killing of cancer cells TNFa enhances SMAC mimetic killing SMAC mimetic blocks NF-kB and activates caspases The State of Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Chemotherapy Clinical Trials Phase 2 study of SMAC-mimetic for relapsed ovarian cancer SMAC mimetic administered IV on days 1, 8, 15 of 28 day cycle 18g needle biopsy prior to start, and after 2 cycles CT scan restaging every 2 cycles Primary Objectives Dual endpoint efficacy (GOG criteria): objective response (confirmed complete response [CR] of any duration or confirmed partial response [PR] of any duration defined by RECIST version 1.1 criteria) progression-free survival lasting greater than 6 months, in patients with relapsed platinum refractory or resistant ovarian cancer, primary peritoneal cancer, fallopian tube cancer treated with TL32711 at 47mg/m2 Correlative Studies on paired pre- and post-treatment tumor biopsies & on archival tissue. Immunohistochemistry for measurement of TNF alpha and TRAIL (NIH Core Facility) Gene expression profiling of NF-kappaB signature (Annunziata lab) Apoptosis gene signature (TetraLogic Pharmaceuticals) Response biomarkers: cIAP1 & cIAP2 (immediate targets of TL37211), with degradation of cIAP1 & 2 protein post-treatment activated caspase-8 – a measure of extrinsic pathway PARP cleavage – a measure of activated caspase-3 and ultimate apoptosis pathway activation (both extrinsic and intrinsic pathways). Correlative Studies on blood specimens PBMC Cleaved caspase 3/7 levels in PBMCs Cleaved PARP levels in PBMCs cIAP1/2 levels in PBMCs Plasma TNF alpha, TRAIL IL-6, IL-8 Translational Oncology Observation Hypothesis Experiment / Trial Result Analysis Future directions (…back to bench)
Slide 59 - Ovarian Cancer in the Genomics Era Christina M. Annunziata, MD, PhD Medical Oncology Branch National Cancer Institute Bethesda, MD Ovarian Cancer Stage Description Incidence Survival I Confined to ovaries 20% 90% II Confined to pelvis 5% 65% III Spread IP or nodes 58% 45% IV Distant metastases 17% <5% Ovarian Cancer: Prognostic Factors Stage Extent of Cytoreduction Histology and Grade Performance Status p53 Status Vital Organ Function Physiologic Age Platinum+Taxane Primary Therapy Intraperitoneal therapy Information from Second-Look Surgery Genotype BRCA1/2 VEGF Production Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Chemotherapy Clinical Trials The State of Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Full assessment of abdomen and pelvis Random biopsy of visually negative areas Lymph node dissection (except Stage I) Optimal reductive surgery Chemotherapy Clinical Trials Surgical staging of ovarian cancer The State of Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Stage I, II - Complete removal of all disease Stage III, IV - Residual disease < 1 cm Chemotherapy Clinical Trials Optimal Cytoreduction 0 cm 0-1 cm 1-2 cm >2 cm Time since initial surgery (years) Proportion surviving The State of Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Chemotherapy Platinum = cisplatin or carboplatin AND Taxane = paclitaxel or docetaxel Intraperitoneal if Stage III, optimal reduction Clinical Trials 1960 1970 1980 1990 2000 CISPLATIN/ALKYLATOR COMBINATIONS INTRA- PERITONEAL PACLITAXEL/ CARBOPLATIN ALKYLATORS CISPLATIN 5 YR SURVIVAL ADVANCED DISEASE 40% 35% 15% 5% 0 1960 1970 1980 1990 2000 Timeline of Treatment and Outcome for Advanced Ovarian Cancer Representative Chemotherapy Agents Platinum Paclitaxel Topotecan Gemcitabine Doxil Target: DNA b-tubulin Topo-I RN-reductase, Nucleotide pool Topo-II Mechanism:DNA adduct formation TubulinAggregation Stabilize DNA-TopoDNA synth DNA Schedule:Independent Dependent(toxicity)Dependent(efficacy) Dependent Phosporylation Prolonged clearance Resistance:GSH, tolerance, retention MDR-MRP, tubulin mutations Topo-I, BCRP RN-reductase MDR-MRP Topo-II Platinum Interaction:N/A Platelet Sparing ---- Enhanced Toxicity ---- GOG 172: The new Standard of Care Epithelial Ovarian Cancer, Optimal Stage III, No prior therapy, Well balanced arms 1. Intravenous therapy, Cisplatin 75 mg/m2 Paclitaxel 135 mg/m2 (24 h), 83% completed 6 cycles 2. Intraperitoneal therapy, Cisplatin 100 mg/m2 IP d1 Paclitaxel 135 mg/m2 (24 h) IV d1 Paclitaxel 60 mg/m2 IP d8, 42% completed 6 cycles Open: 23-Mar-98 Closed: 29-Jan-01 Accrual: 416 pts (evaluable) GOG 172: The new Standard of Care Median survival = 49.7 mo Median survival = 65.6 mo Ovarian Cancer in the Genomics Era Preclinical studies Translational Oncology Observation Hypothesis Experiment / Trial Result Analysis Integrated genomic analyses of ovarian carcinoma The Cancer Genome Atlas Research Network* Nature 474: 609-615 Background The Cancer Genome Atlas (TCGA) Clinically annotated HGS-OvCa samples Identify molecular abnormalities that influence pathophysiology, affect outcome and constitute therapeutic targets. Microarray analyses: 489 HGS-OvCa tumours, mRNA expression, microRNA (miRNA) expression, DNA copy number and DNA promoter methylation for and Whole exome DNA sequence: 316 samples. Methods Sample inclusion criteria Newly diagnosed patients ovarian serous adenocarcinoma no prior treatment regardless of surgical stage or histologic grade Each frozen tumor specimen had to have a companion normal tissue specimen, which could be adjacent normal tissue, peripheral lymphocytes, or previously extracted germline DNA. Methods Clinical data collection Clinical data can be accessed and downloaded from the TCGA Data Portal Demographics, histopathologic information treatment details outcome parameters Methods Mutated genes in HGS-OvCa Genome copy number abnormality Copy number profiles of 489 HGS-OvCa, compared with profiles of 197 glioblastoma multiforme (GBM) tumours. Copy number increases (red) and decreases (blue) are plotted as a function of distance along the normal genome (vertical axis, divided into chromosomes). Gene and miRNA patterns: Molecular subtype and outcome prediction Altered pathways in HGS-OvCa Altered pathways in HGS-OvCa Altered pathways in HGS-OvCa Altered pathways in HGS-OvCa TCGA findings TCGA: large-scale integrative view of aberrations in HGS-OvCa Mutational spectrum “surprisingly simple” TP53 predominated = 96% BRCA1 and BRCA2 =22% Seven other significantly mutated genes = 2–6% HGS-OvCa is distinct from other histological subtypes Clear-cell: few TP53; recurrent ARID1A, PIK3CA mutations Endometrioid: frequent CTNNB1, ARID1A and PIK3CA; fewer TP53 Mucinous: prevalent KRAS mutations TCGA findings “Remarkable degree of genomic disarray” “Striking contrast to previous TCGA findings in glioblastoma” Mutations and promoter methylation in putative DNA repair genes (HR) may explain the high prevalence of SCNAs. TCGA – what next? New therapeutic approaches? 50% with HR defects : PARP inhibitors commonly deregulated pathways: RB, RAS/PI3K, FOXM1, NOTCH, provide opportunities for therapeutic treatment Inhibitors exist for 22 genes in regions of recurrent amplification aberrant genes or networks: targeted therapies selected to be effective ... The State of Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Chemotherapy Clinical Trials: targeted therapies Translational Oncology Observation Hypothesis Experiment / Trial Result Analysis Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced ovarian cancer American Society of Clinical Oncology, 2009 Presenter: M William Audeh From genomic aberration to pathway PARP PARP inhibition: BRCA-mutant cancers Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced ovarian cancer Olaparib (AZD2281) novel, orally active PARP inhibitor synthetic lethality in homozygous BRCA-mut cells The primary aim of this study was to test the efficacy of olaparib in confirmed BRCA1/BRCA2 carriers with advanced refractory ovarian cancer Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced ovarian cancer Results: 57 enrolled pts 39 BRCA1 deficient and 18 BRCA2 deficient 33 evaluable at 400 mg bid and 24 at 100 mg bid ORR was 33% at 400 mg bd; 12.5% at 100 mg bd Clinical benefit rate: ORR and/or confirmed ≥50% decline in CA125 57.6% at 400 mg bd and 16.7% at 100 mg bd Median PFS: 5.8 mo (med duration 9.6 mo) Toxicity grade 1/2 nausea (44%); fatigue (35%); anemia (14%) Grade 3 toxicity occurred infrequently, and comprised primarily nausea (7%) and leukopenia (5%). Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced ovarian cancer Audeh, et al. Lancet 376:245 – 251 (2010) Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced ovarian cancer Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced ovarian cancer Conclusions: Oral olaparib is well tolerated and highly active in advanced, chemotherapy-refractory BRCA-deficient ovarian cancer Greater activity seen at the higher dose Toxicity in BRCA1/2 carriers was similar to that seen in non-carriers “Positive proof of the concept of the activity and tolerability of genetically defined targeted therapy with olaparib in BRCA-deficient ovarian cancers.” NF-B: Deregulation and Targeting A Genomic approach to Ovarian Cancer Schematic of NF-B signaling Defining the Ovarian Cancer-specific IKK gene signature using IKK inhibitor and IKK shRNA IKK gene signature is coordinately expressed in primary ovarian cancers High IKK activity associates with worse survival in ovarian cancer Intersecting pathways cooperate with NF-κB in ovarian cancer RNAi sensitization screen shRNA library targeting human kinome (500 kinases) Combination with IKK inhibitor (sub-lethal dose) Clinical application: How can we leverage caspase 8? TNF: NF-kB activation or apoptosis? Normal cells: SMAC released from mitochondria, inhibiting cIAP 1 & removing blockade to activated caspase function apoptotic cell death Tumor cells: apoptosis is dysregulated due to low SMAC or upstream blockade e.g overexpression of IAPs SMAC SMAC X TNF: NF-kB activation or apoptosis? High immunohistochemical expression of TNFα in ovarian tumor & stroma Increased TNF-α serum concentrations reported in patients with endometrial carcinoma TNFα may activate NF-kB in the presence of IAP (Inhibitors of Apoptotic Proteins), but trigger apoptosis in its absence New Hypothesis: The intersection of the NF-κB and caspase pathways provides a novel point of therapeutic intervention, where pro-survival signals can be switched to pro-apoptotic killing of cancer cells TNFa enhances SMAC mimetic killing SMAC mimetic blocks NF-kB and activates caspases The State of Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Chemotherapy Clinical Trials Phase 2 study of SMAC-mimetic for relapsed ovarian cancer SMAC mimetic administered IV on days 1, 8, 15 of 28 day cycle 18g needle biopsy prior to start, and after 2 cycles CT scan restaging every 2 cycles Primary Objectives Dual endpoint efficacy (GOG criteria): objective response (confirmed complete response [CR] of any duration or confirmed partial response [PR] of any duration defined by RECIST version 1.1 criteria) progression-free survival lasting greater than 6 months, in patients with relapsed platinum refractory or resistant ovarian cancer, primary peritoneal cancer, fallopian tube cancer treated with TL32711 at 47mg/m2 Correlative Studies on paired pre- and post-treatment tumor biopsies & on archival tissue. Immunohistochemistry for measurement of TNF alpha and TRAIL (NIH Core Facility) Gene expression profiling of NF-kappaB signature (Annunziata lab) Apoptosis gene signature (TetraLogic Pharmaceuticals) Response biomarkers: cIAP1 & cIAP2 (immediate targets of TL37211), with degradation of cIAP1 & 2 protein post-treatment activated caspase-8 – a measure of extrinsic pathway PARP cleavage – a measure of activated caspase-3 and ultimate apoptosis pathway activation (both extrinsic and intrinsic pathways). Correlative Studies on blood specimens PBMC Cleaved caspase 3/7 levels in PBMCs Cleaved PARP levels in PBMCs cIAP1/2 levels in PBMCs Plasma TNF alpha, TRAIL IL-6, IL-8 Translational Oncology Observation Hypothesis Experiment / Trial Result Analysis Future directions (…back to bench) What sequence of SMAC mimetic in combination achieves maximal tumor cell death and correlates with proteomic changes in apoptosis and NF-kB pathways Biomarkers will be used in future clinical trials Future directions (…back to bench)
Slide 60 - Ovarian Cancer in the Genomics Era Christina M. Annunziata, MD, PhD Medical Oncology Branch National Cancer Institute Bethesda, MD Ovarian Cancer Stage Description Incidence Survival I Confined to ovaries 20% 90% II Confined to pelvis 5% 65% III Spread IP or nodes 58% 45% IV Distant metastases 17% <5% Ovarian Cancer: Prognostic Factors Stage Extent of Cytoreduction Histology and Grade Performance Status p53 Status Vital Organ Function Physiologic Age Platinum+Taxane Primary Therapy Intraperitoneal therapy Information from Second-Look Surgery Genotype BRCA1/2 VEGF Production Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Chemotherapy Clinical Trials The State of Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Full assessment of abdomen and pelvis Random biopsy of visually negative areas Lymph node dissection (except Stage I) Optimal reductive surgery Chemotherapy Clinical Trials Surgical staging of ovarian cancer The State of Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Stage I, II - Complete removal of all disease Stage III, IV - Residual disease < 1 cm Chemotherapy Clinical Trials Optimal Cytoreduction 0 cm 0-1 cm 1-2 cm >2 cm Time since initial surgery (years) Proportion surviving The State of Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Chemotherapy Platinum = cisplatin or carboplatin AND Taxane = paclitaxel or docetaxel Intraperitoneal if Stage III, optimal reduction Clinical Trials 1960 1970 1980 1990 2000 CISPLATIN/ALKYLATOR COMBINATIONS INTRA- PERITONEAL PACLITAXEL/ CARBOPLATIN ALKYLATORS CISPLATIN 5 YR SURVIVAL ADVANCED DISEASE 40% 35% 15% 5% 0 1960 1970 1980 1990 2000 Timeline of Treatment and Outcome for Advanced Ovarian Cancer Representative Chemotherapy Agents Platinum Paclitaxel Topotecan Gemcitabine Doxil Target: DNA b-tubulin Topo-I RN-reductase, Nucleotide pool Topo-II Mechanism:DNA adduct formation TubulinAggregation Stabilize DNA-TopoDNA synth DNA Schedule:Independent Dependent(toxicity)Dependent(efficacy) Dependent Phosporylation Prolonged clearance Resistance:GSH, tolerance, retention MDR-MRP, tubulin mutations Topo-I, BCRP RN-reductase MDR-MRP Topo-II Platinum Interaction:N/A Platelet Sparing ---- Enhanced Toxicity ---- GOG 172: The new Standard of Care Epithelial Ovarian Cancer, Optimal Stage III, No prior therapy, Well balanced arms 1. Intravenous therapy, Cisplatin 75 mg/m2 Paclitaxel 135 mg/m2 (24 h), 83% completed 6 cycles 2. Intraperitoneal therapy, Cisplatin 100 mg/m2 IP d1 Paclitaxel 135 mg/m2 (24 h) IV d1 Paclitaxel 60 mg/m2 IP d8, 42% completed 6 cycles Open: 23-Mar-98 Closed: 29-Jan-01 Accrual: 416 pts (evaluable) GOG 172: The new Standard of Care Median survival = 49.7 mo Median survival = 65.6 mo Ovarian Cancer in the Genomics Era Preclinical studies Translational Oncology Observation Hypothesis Experiment / Trial Result Analysis Integrated genomic analyses of ovarian carcinoma The Cancer Genome Atlas Research Network* Nature 474: 609-615 Background The Cancer Genome Atlas (TCGA) Clinically annotated HGS-OvCa samples Identify molecular abnormalities that influence pathophysiology, affect outcome and constitute therapeutic targets. Microarray analyses: 489 HGS-OvCa tumours, mRNA expression, microRNA (miRNA) expression, DNA copy number and DNA promoter methylation for and Whole exome DNA sequence: 316 samples. Methods Sample inclusion criteria Newly diagnosed patients ovarian serous adenocarcinoma no prior treatment regardless of surgical stage or histologic grade Each frozen tumor specimen had to have a companion normal tissue specimen, which could be adjacent normal tissue, peripheral lymphocytes, or previously extracted germline DNA. Methods Clinical data collection Clinical data can be accessed and downloaded from the TCGA Data Portal Demographics, histopathologic information treatment details outcome parameters Methods Mutated genes in HGS-OvCa Genome copy number abnormality Copy number profiles of 489 HGS-OvCa, compared with profiles of 197 glioblastoma multiforme (GBM) tumours. Copy number increases (red) and decreases (blue) are plotted as a function of distance along the normal genome (vertical axis, divided into chromosomes). Gene and miRNA patterns: Molecular subtype and outcome prediction Altered pathways in HGS-OvCa Altered pathways in HGS-OvCa Altered pathways in HGS-OvCa Altered pathways in HGS-OvCa TCGA findings TCGA: large-scale integrative view of aberrations in HGS-OvCa Mutational spectrum “surprisingly simple” TP53 predominated = 96% BRCA1 and BRCA2 =22% Seven other significantly mutated genes = 2–6% HGS-OvCa is distinct from other histological subtypes Clear-cell: few TP53; recurrent ARID1A, PIK3CA mutations Endometrioid: frequent CTNNB1, ARID1A and PIK3CA; fewer TP53 Mucinous: prevalent KRAS mutations TCGA findings “Remarkable degree of genomic disarray” “Striking contrast to previous TCGA findings in glioblastoma” Mutations and promoter methylation in putative DNA repair genes (HR) may explain the high prevalence of SCNAs. TCGA – what next? New therapeutic approaches? 50% with HR defects : PARP inhibitors commonly deregulated pathways: RB, RAS/PI3K, FOXM1, NOTCH, provide opportunities for therapeutic treatment Inhibitors exist for 22 genes in regions of recurrent amplification aberrant genes or networks: targeted therapies selected to be effective ... The State of Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Chemotherapy Clinical Trials: targeted therapies Translational Oncology Observation Hypothesis Experiment / Trial Result Analysis Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced ovarian cancer American Society of Clinical Oncology, 2009 Presenter: M William Audeh From genomic aberration to pathway PARP PARP inhibition: BRCA-mutant cancers Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced ovarian cancer Olaparib (AZD2281) novel, orally active PARP inhibitor synthetic lethality in homozygous BRCA-mut cells The primary aim of this study was to test the efficacy of olaparib in confirmed BRCA1/BRCA2 carriers with advanced refractory ovarian cancer Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced ovarian cancer Results: 57 enrolled pts 39 BRCA1 deficient and 18 BRCA2 deficient 33 evaluable at 400 mg bid and 24 at 100 mg bid ORR was 33% at 400 mg bd; 12.5% at 100 mg bd Clinical benefit rate: ORR and/or confirmed ≥50% decline in CA125 57.6% at 400 mg bd and 16.7% at 100 mg bd Median PFS: 5.8 mo (med duration 9.6 mo) Toxicity grade 1/2 nausea (44%); fatigue (35%); anemia (14%) Grade 3 toxicity occurred infrequently, and comprised primarily nausea (7%) and leukopenia (5%). Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced ovarian cancer Audeh, et al. Lancet 376:245 – 251 (2010) Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced ovarian cancer Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced ovarian cancer Conclusions: Oral olaparib is well tolerated and highly active in advanced, chemotherapy-refractory BRCA-deficient ovarian cancer Greater activity seen at the higher dose Toxicity in BRCA1/2 carriers was similar to that seen in non-carriers “Positive proof of the concept of the activity and tolerability of genetically defined targeted therapy with olaparib in BRCA-deficient ovarian cancers.” NF-B: Deregulation and Targeting A Genomic approach to Ovarian Cancer Schematic of NF-B signaling Defining the Ovarian Cancer-specific IKK gene signature using IKK inhibitor and IKK shRNA IKK gene signature is coordinately expressed in primary ovarian cancers High IKK activity associates with worse survival in ovarian cancer Intersecting pathways cooperate with NF-κB in ovarian cancer RNAi sensitization screen shRNA library targeting human kinome (500 kinases) Combination with IKK inhibitor (sub-lethal dose) Clinical application: How can we leverage caspase 8? TNF: NF-kB activation or apoptosis? Normal cells: SMAC released from mitochondria, inhibiting cIAP 1 & removing blockade to activated caspase function apoptotic cell death Tumor cells: apoptosis is dysregulated due to low SMAC or upstream blockade e.g overexpression of IAPs SMAC SMAC X TNF: NF-kB activation or apoptosis? High immunohistochemical expression of TNFα in ovarian tumor & stroma Increased TNF-α serum concentrations reported in patients with endometrial carcinoma TNFα may activate NF-kB in the presence of IAP (Inhibitors of Apoptotic Proteins), but trigger apoptosis in its absence New Hypothesis: The intersection of the NF-κB and caspase pathways provides a novel point of therapeutic intervention, where pro-survival signals can be switched to pro-apoptotic killing of cancer cells TNFa enhances SMAC mimetic killing SMAC mimetic blocks NF-kB and activates caspases The State of Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Chemotherapy Clinical Trials Phase 2 study of SMAC-mimetic for relapsed ovarian cancer SMAC mimetic administered IV on days 1, 8, 15 of 28 day cycle 18g needle biopsy prior to start, and after 2 cycles CT scan restaging every 2 cycles Primary Objectives Dual endpoint efficacy (GOG criteria): objective response (confirmed complete response [CR] of any duration or confirmed partial response [PR] of any duration defined by RECIST version 1.1 criteria) progression-free survival lasting greater than 6 months, in patients with relapsed platinum refractory or resistant ovarian cancer, primary peritoneal cancer, fallopian tube cancer treated with TL32711 at 47mg/m2 Correlative Studies on paired pre- and post-treatment tumor biopsies & on archival tissue. Immunohistochemistry for measurement of TNF alpha and TRAIL (NIH Core Facility) Gene expression profiling of NF-kappaB signature (Annunziata lab) Apoptosis gene signature (TetraLogic Pharmaceuticals) Response biomarkers: cIAP1 & cIAP2 (immediate targets of TL37211), with degradation of cIAP1 & 2 protein post-treatment activated caspase-8 – a measure of extrinsic pathway PARP cleavage – a measure of activated caspase-3 and ultimate apoptosis pathway activation (both extrinsic and intrinsic pathways). Correlative Studies on blood specimens PBMC Cleaved caspase 3/7 levels in PBMCs Cleaved PARP levels in PBMCs cIAP1/2 levels in PBMCs Plasma TNF alpha, TRAIL IL-6, IL-8 Translational Oncology Observation Hypothesis Experiment / Trial Result Analysis Future directions (…back to bench) What sequence of SMAC mimetic in combination achieves maximal tumor cell death and correlates with proteomic changes in apoptosis and NF-kB pathways Biomarkers will be used in future clinical trials Future directions (…back to bench) Clinical application: Indvidualized therapy Therapeutic agents targeting each critical pathway can be tested for their ability to overcome molecularly defined cancers Ultimately, the benefit of signature-directed therapy will be assessed by prospectively profiling individual patients and allocating therapy based on the molecular defects identified at the bench
Slide 61 - Ovarian Cancer in the Genomics Era Christina M. Annunziata, MD, PhD Medical Oncology Branch National Cancer Institute Bethesda, MD Ovarian Cancer Stage Description Incidence Survival I Confined to ovaries 20% 90% II Confined to pelvis 5% 65% III Spread IP or nodes 58% 45% IV Distant metastases 17% <5% Ovarian Cancer: Prognostic Factors Stage Extent of Cytoreduction Histology and Grade Performance Status p53 Status Vital Organ Function Physiologic Age Platinum+Taxane Primary Therapy Intraperitoneal therapy Information from Second-Look Surgery Genotype BRCA1/2 VEGF Production Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Chemotherapy Clinical Trials The State of Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Full assessment of abdomen and pelvis Random biopsy of visually negative areas Lymph node dissection (except Stage I) Optimal reductive surgery Chemotherapy Clinical Trials Surgical staging of ovarian cancer The State of Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Stage I, II - Complete removal of all disease Stage III, IV - Residual disease < 1 cm Chemotherapy Clinical Trials Optimal Cytoreduction 0 cm 0-1 cm 1-2 cm >2 cm Time since initial surgery (years) Proportion surviving The State of Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Chemotherapy Platinum = cisplatin or carboplatin AND Taxane = paclitaxel or docetaxel Intraperitoneal if Stage III, optimal reduction Clinical Trials 1960 1970 1980 1990 2000 CISPLATIN/ALKYLATOR COMBINATIONS INTRA- PERITONEAL PACLITAXEL/ CARBOPLATIN ALKYLATORS CISPLATIN 5 YR SURVIVAL ADVANCED DISEASE 40% 35% 15% 5% 0 1960 1970 1980 1990 2000 Timeline of Treatment and Outcome for Advanced Ovarian Cancer Representative Chemotherapy Agents Platinum Paclitaxel Topotecan Gemcitabine Doxil Target: DNA b-tubulin Topo-I RN-reductase, Nucleotide pool Topo-II Mechanism:DNA adduct formation TubulinAggregation Stabilize DNA-TopoDNA synth DNA Schedule:Independent Dependent(toxicity)Dependent(efficacy) Dependent Phosporylation Prolonged clearance Resistance:GSH, tolerance, retention MDR-MRP, tubulin mutations Topo-I, BCRP RN-reductase MDR-MRP Topo-II Platinum Interaction:N/A Platelet Sparing ---- Enhanced Toxicity ---- GOG 172: The new Standard of Care Epithelial Ovarian Cancer, Optimal Stage III, No prior therapy, Well balanced arms 1. Intravenous therapy, Cisplatin 75 mg/m2 Paclitaxel 135 mg/m2 (24 h), 83% completed 6 cycles 2. Intraperitoneal therapy, Cisplatin 100 mg/m2 IP d1 Paclitaxel 135 mg/m2 (24 h) IV d1 Paclitaxel 60 mg/m2 IP d8, 42% completed 6 cycles Open: 23-Mar-98 Closed: 29-Jan-01 Accrual: 416 pts (evaluable) GOG 172: The new Standard of Care Median survival = 49.7 mo Median survival = 65.6 mo Ovarian Cancer in the Genomics Era Preclinical studies Translational Oncology Observation Hypothesis Experiment / Trial Result Analysis Integrated genomic analyses of ovarian carcinoma The Cancer Genome Atlas Research Network* Nature 474: 609-615 Background The Cancer Genome Atlas (TCGA) Clinically annotated HGS-OvCa samples Identify molecular abnormalities that influence pathophysiology, affect outcome and constitute therapeutic targets. Microarray analyses: 489 HGS-OvCa tumours, mRNA expression, microRNA (miRNA) expression, DNA copy number and DNA promoter methylation for and Whole exome DNA sequence: 316 samples. Methods Sample inclusion criteria Newly diagnosed patients ovarian serous adenocarcinoma no prior treatment regardless of surgical stage or histologic grade Each frozen tumor specimen had to have a companion normal tissue specimen, which could be adjacent normal tissue, peripheral lymphocytes, or previously extracted germline DNA. Methods Clinical data collection Clinical data can be accessed and downloaded from the TCGA Data Portal Demographics, histopathologic information treatment details outcome parameters Methods Mutated genes in HGS-OvCa Genome copy number abnormality Copy number profiles of 489 HGS-OvCa, compared with profiles of 197 glioblastoma multiforme (GBM) tumours. Copy number increases (red) and decreases (blue) are plotted as a function of distance along the normal genome (vertical axis, divided into chromosomes). Gene and miRNA patterns: Molecular subtype and outcome prediction Altered pathways in HGS-OvCa Altered pathways in HGS-OvCa Altered pathways in HGS-OvCa Altered pathways in HGS-OvCa TCGA findings TCGA: large-scale integrative view of aberrations in HGS-OvCa Mutational spectrum “surprisingly simple” TP53 predominated = 96% BRCA1 and BRCA2 =22% Seven other significantly mutated genes = 2–6% HGS-OvCa is distinct from other histological subtypes Clear-cell: few TP53; recurrent ARID1A, PIK3CA mutations Endometrioid: frequent CTNNB1, ARID1A and PIK3CA; fewer TP53 Mucinous: prevalent KRAS mutations TCGA findings “Remarkable degree of genomic disarray” “Striking contrast to previous TCGA findings in glioblastoma” Mutations and promoter methylation in putative DNA repair genes (HR) may explain the high prevalence of SCNAs. TCGA – what next? New therapeutic approaches? 50% with HR defects : PARP inhibitors commonly deregulated pathways: RB, RAS/PI3K, FOXM1, NOTCH, provide opportunities for therapeutic treatment Inhibitors exist for 22 genes in regions of recurrent amplification aberrant genes or networks: targeted therapies selected to be effective ... The State of Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Chemotherapy Clinical Trials: targeted therapies Translational Oncology Observation Hypothesis Experiment / Trial Result Analysis Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced ovarian cancer American Society of Clinical Oncology, 2009 Presenter: M William Audeh From genomic aberration to pathway PARP PARP inhibition: BRCA-mutant cancers Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced ovarian cancer Olaparib (AZD2281) novel, orally active PARP inhibitor synthetic lethality in homozygous BRCA-mut cells The primary aim of this study was to test the efficacy of olaparib in confirmed BRCA1/BRCA2 carriers with advanced refractory ovarian cancer Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced ovarian cancer Results: 57 enrolled pts 39 BRCA1 deficient and 18 BRCA2 deficient 33 evaluable at 400 mg bid and 24 at 100 mg bid ORR was 33% at 400 mg bd; 12.5% at 100 mg bd Clinical benefit rate: ORR and/or confirmed ≥50% decline in CA125 57.6% at 400 mg bd and 16.7% at 100 mg bd Median PFS: 5.8 mo (med duration 9.6 mo) Toxicity grade 1/2 nausea (44%); fatigue (35%); anemia (14%) Grade 3 toxicity occurred infrequently, and comprised primarily nausea (7%) and leukopenia (5%). Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced ovarian cancer Audeh, et al. Lancet 376:245 – 251 (2010) Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced ovarian cancer Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced ovarian cancer Conclusions: Oral olaparib is well tolerated and highly active in advanced, chemotherapy-refractory BRCA-deficient ovarian cancer Greater activity seen at the higher dose Toxicity in BRCA1/2 carriers was similar to that seen in non-carriers “Positive proof of the concept of the activity and tolerability of genetically defined targeted therapy with olaparib in BRCA-deficient ovarian cancers.” NF-B: Deregulation and Targeting A Genomic approach to Ovarian Cancer Schematic of NF-B signaling Defining the Ovarian Cancer-specific IKK gene signature using IKK inhibitor and IKK shRNA IKK gene signature is coordinately expressed in primary ovarian cancers High IKK activity associates with worse survival in ovarian cancer Intersecting pathways cooperate with NF-κB in ovarian cancer RNAi sensitization screen shRNA library targeting human kinome (500 kinases) Combination with IKK inhibitor (sub-lethal dose) Clinical application: How can we leverage caspase 8? TNF: NF-kB activation or apoptosis? Normal cells: SMAC released from mitochondria, inhibiting cIAP 1 & removing blockade to activated caspase function apoptotic cell death Tumor cells: apoptosis is dysregulated due to low SMAC or upstream blockade e.g overexpression of IAPs SMAC SMAC X TNF: NF-kB activation or apoptosis? High immunohistochemical expression of TNFα in ovarian tumor & stroma Increased TNF-α serum concentrations reported in patients with endometrial carcinoma TNFα may activate NF-kB in the presence of IAP (Inhibitors of Apoptotic Proteins), but trigger apoptosis in its absence New Hypothesis: The intersection of the NF-κB and caspase pathways provides a novel point of therapeutic intervention, where pro-survival signals can be switched to pro-apoptotic killing of cancer cells TNFa enhances SMAC mimetic killing SMAC mimetic blocks NF-kB and activates caspases The State of Treatment for Newly Diagnosed Ovarian Cancer Complete surgical staging Optimal reductive surgery Chemotherapy Clinical Trials Phase 2 study of SMAC-mimetic for relapsed ovarian cancer SMAC mimetic administered IV on days 1, 8, 15 of 28 day cycle 18g needle biopsy prior to start, and after 2 cycles CT scan restaging every 2 cycles Primary Objectives Dual endpoint efficacy (GOG criteria): objective response (confirmed complete response [CR] of any duration or confirmed partial response [PR] of any duration defined by RECIST version 1.1 criteria) progression-free survival lasting greater than 6 months, in patients with relapsed platinum refractory or resistant ovarian cancer, primary peritoneal cancer, fallopian tube cancer treated with TL32711 at 47mg/m2 Correlative Studies on paired pre- and post-treatment tumor biopsies & on archival tissue. Immunohistochemistry for measurement of TNF alpha and TRAIL (NIH Core Facility) Gene expression profiling of NF-kappaB signature (Annunziata lab) Apoptosis gene signature (TetraLogic Pharmaceuticals) Response biomarkers: cIAP1 & cIAP2 (immediate targets of TL37211), with degradation of cIAP1 & 2 protein post-treatment activated caspase-8 – a measure of extrinsic pathway PARP cleavage – a measure of activated caspase-3 and ultimate apoptosis pathway activation (both extrinsic and intrinsic pathways). Correlative Studies on blood specimens PBMC Cleaved caspase 3/7 levels in PBMCs Cleaved PARP levels in PBMCs cIAP1/2 levels in PBMCs Plasma TNF alpha, TRAIL IL-6, IL-8 Translational Oncology Observation Hypothesis Experiment / Trial Result Analysis Future directions (…back to bench) What sequence of SMAC mimetic in combination achieves maximal tumor cell death and correlates with proteomic changes in apoptosis and NF-kB pathways Biomarkers will be used in future clinical trials Future directions (…back to bench) Clinical application: Indvidualized therapy Therapeutic agents targeting each critical pathway can be tested for their ability to overcome molecularly defined cancers Ultimately, the benefit of signature-directed therapy will be assessed by prospectively profiling individual patients and allocating therapy based on the molecular defects identified at the bench Medical Ovarian Cancer Team Anne Noonan, MD Elise C. Kohn, MD Jung-Min Lee, MD Nicole Houston, RN Jessica Hearn, RN MOB Fellows and Nursing Staff Translational scientists: Lidia Hernandez, MS Marianne Kim, PhD Carrie House, PhD Ethan Sagher Bridget Hill